Ticker,Drug,Stage,Catalyst
SPPI,ZEVALIN  Non-Hodgkin’s lymphoma,CRL,"07/05/2009  CRL received July 5, 2009."
ZGNX,Sumavel  Migraine,Approved,"07/16/2009  Approved July 16, 2009."
ARDM,Sumavel  Migraine,Approved,"07/16/2009  Approval granted July 16, 2009."
SPPI,ZEVALIN  Non-Hodgkin’s lymphoma,CRL,"09/04/2009  Approved September 4, 2009."
SPPI,FUSILEV  Colorectal cancer,Approved,"10/09/2009  CRL received October 9, 2009."
PRTK,Intermezzo  Insomnia,Approved,"11/02/2009  CRL issued November 2, 2009."
GTXI,Toremifene  Reduce fractures in men with prostate cancer,CRL,"11/02/2009  CRL issued November 2, 2009."
HEB,Ampligen  CFS,CRL,"12/01/2009  CRL issued December 1, 2009."
FCSC,Laviv  Wrinkles,Approved,"12/18/2009  CRL issued December 18, 2009."
ACOR,Ampyra  Improve walking in patients with multiple sclerosis,-,"01/22/2010  Approved January 22, 2010."
ALKS,BYDUREON  Type 2 diabetes,Approved,"01/27/2010  Approved January 27, 2010."
MNKD,AFREZZA Type 1/2 diabetes,Approved,"03/15/2010  CRL issued March 15, 2010."
ALKS,BYDUREON  Type 2 diabetes,Approved,"03/15/2010  CRL received March 15, 2010."
HRTX,APF530 - Sustol  Prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV),Approved,"03/19/2010  CRL issued March 19, 2010."
CTIC,PIXUVRI - PIX306 Trial  B-cell non-Hodgkin lymphoma,Phase 3,"04/09/2010  CRL received April 9, 2010."
ARLZ,VIMOVO  Gastric ulcers,Approved,"04/30/2010  Approved April 30, 2010."
JAZZ,JZP-6  Fibromyalgia,Approved,"10/11/2010  CRL received October 11, 2010."
VVUS,Qnexa  Obesity,Approved,"10/28/2010  October 28, 2010."
MNKD,AFREZZA Type 1/2 diabetes,Approved,"01/19/2011  CRL received January 19, 2011."
DEPO,GRALISE  Postherpetic neuralgia - shingles,Approved,"01/28/2011  Approved January 28, 2011."
PLX,Taliglucerase alfa  Gaucher disease,Approved,"02/25/2011  CRL issued February 25, 2011."
SPPI,FUSILEV  Colorectal cancer,Approved,"04/29/2011  Approved April 29, 2011."
FCSC,Laviv  Wrinkles,Approved,"06/22/2011  Approved June 22, 2011."
DRRX,Remoxy  Chronic pain,CRL,"06/24/2011  CRL received June 24, 2011."
PTIE,Remoxy  Chronic pain,CRL,"06/24/2011  CRL received June 24, 2011."
SGEN,ADCETRIS  Hodgkin lymphoma and Anaplastic large cell lymphoma,Approved,"08/19/2011  Approval announced August 19, 2011."
PCRX,EXPAREL  Postsurgical pain,Approved,"10/31/2011  Approved October 31, 2011."
ALIM,Iluvien  Diabetic macular edema,Approved,11/11/2011  CRL November 2011.
INCY,Jakafi  Myelofibrosis,Approved,"11/16/2011  Approved November 16, 2011."
PRTK,Intermezzo  Insomnia,Approved,"11/23/2011  Approved November 23, 2011."
ATRS,Anturol  Overactive bladder,Approved,"12/08/2011  Approved December 8, 2011."
INSY,SUBSYS  Cancer pain,Approved,"01/05/2012  Approved January 5, 2012."
CRIS,Vismodegib  Basal Cell Carcinoma,Approved,"01/30/2012  Approved January 30, 2012."
CORT,Corlux - Korlym  Cushing's Syndrome,Approved,"02/17/2012  Approved February 17, 2012."
VVUS,Avanafil  Erectile dysfunction,Approved,"04/27/2012  Approved April 27, 2012."
PLX,Taliglucerase alfa  Gaucher disease,Approved,"05/01/2012  Approved May 1, 2012."
EBS,BioThrax  Anthrax Vaccine,Approved,"05/17/2012  Approved May 17, 2012."
RGEN,RG1068  Detection of pancreatic duct abnormalities,CRL,"06/22/2012  CRL received June 22, 2012."
ARNA,Lorcaserin  Obesity,Approved,"06/27/2012  Approved June 27, 2012."
VVUS,Qnexa  Obesity,Approved,"07/17/2012  Approved July 17, 2012."
AMRN,Vascepa REDUCE-IT outcomes trial  High Triglycerides With Mixed Dyslipidemia,Phase 3,"07/26/2012  Approved July 26, 2012."
HALO,HYQVIA  Subcutaneous treatment for patients with primary immunodeficiency (PI),Approved,"08/01/2012  CRL issued August 1, 2012."
NAVB,Lymphoseek  Lymphatic-tissue tracing agent,Approved,"09/10/2012  CRL issued September 10, 2012."
SUPN,Oxtellar  Epilepsy,Approved,"10/22/2012  Approved October 22, 2012."
EXEL,Cabozantinib  Medullary thyroid cancer,Approved,"11/29/2012  Approved November 29, 2012."
HEB,Ampligen  CFS,CRL,"02/04/2013  CRL February 4, 2013."
IMGN,Kadcyla  2nd-line HER2+ Metastatic Breast Cancer,Approved,"02/22/2013  Approved February 22, 2013 - under priority review."
DVAX,HEPLISAV-B Hepatitis B,Approved,"02/25/2013  CRL issued February 25, 2013."
NAVB,Lymphoseek  Lymphatic-tissue tracing agent,Approved,"03/13/2013  Approved March 13, 2013."
HRTX,APF530 - Sustol  Prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV),Approved,"03/28/2013  CRL March, 28 2013."
TTNP,Probuphine  Opioid dependence,Approved,"04/30/2013  CRL issued April 30, 2013."
ENDP,AVEED (testosterone undecanoate) intramuscular injection  Men diagnosed with hypogonadism,Approved,"05/30/2013  CRL issued September 5, 2013."
DEPO,SEFELSA  Hot flashes,CRL,"05/31/2013  CRL issued May 31, 2013."
AVDL,Bloxiverz (neostigmine methylsulfate)  Reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery,Approved,"06/03/2013  Approved June 3, 2013."
AVEO,TIVO-3 - tivozanib Third line treatment of patients with renal cell cancer,Phase 3,"06/10/2013  CRL issued June 10, 2013."
TBPH,VIBATIV (telavancin hydrochloride) for injection  Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP),Approved,"06/21/2013  Approved June 21, 2013."
SUPN,Trokendi Epilepsy,Approved,"08/19/2013  Approved Aug 19, 2013."
ATRS,OTREXUP  Rheumatoid arthritis (RA),Approved,"10/14/2013  Approved Oct 14, 2013."
ALIM,Iluvien  Diabetic macular edema,Approved,"10/17/2013  Second CRL October 17, 2013."
ZGNX,Zohydro ER  Moderate to severe pain,Approved,"10/25/2013  Approved October 25, 2013."
ABBV,Ibrutinib  Relapsed or refractory MCL mantle cell lymphoma,Approved,"11/13/2013  Approved November 13, 2013."
AMAG,Feraheme  Adults with iron deficiency anemia (IDA),Approved,"01/22/2014  CRL issued January 22, 2014."
AMAG,Feraheme  Adults with iron deficiency anemia (IDA),PDUFA,"01/22/2014  CRL issued January 22, 2014."
VNDA,HETLIOZ (tasimelteon)  Insomnia,Approved,"01/31/2014  Approved January 31, 2014."
DRRX,Posidur  Post-operative pain relief,CRL,"02/12/2014  CRL issued February 12, 2014."
ABBV,Imbruvica  Cancer - Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy,Approved,"02/12/2014  Approved February 12, 2014."
BMRN,Vimizim (GALNS)  (MPS IVA) Morquio A Syndrome,Approved,"02/14/2014  Approved February 14, 2014."
ENDP,AVEED (testosterone undecanoate) intramuscular injection  Men diagnosed with hypogonadism,Approved,"03/06/2014  Approved March 6, 2014."
ARLZ,YOSPRALA (PA32540/PA8140) Secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers,Approved,"04/25/2014  CRL issued April 25, 2014."
MDCO,Cangrelor  Reduction of thrombotic cardiovascular events including stent thrombosis in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI),Approved,04/30/2014  CRL April 30 2014.
OMER,Omidria  Cataract surgery,Approved,"06/02/2014  Approved June 2, 2014."
BDSI,BEMA Buprenorphine/Naloxone (BNX) - BUNAVAIL  Opioid dependence,Approved,"06/06/2014  Approved June 6, 2014."
NAVB,Lymphoseek  Head and Neck Cancer,Approved,"06/13/2014  Approved June 13, 2014."
MNKD,AFREZZA Type 1/2 diabetes,Approved,"06/27/2014  Approved June 27, 2014."
AVDL,VAZCULEP (phenylephrine hydrochloride)  Clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia,Approved,"06/30/2014  Approved June 30, 2014."
EGRX,EP-3101 (bendamustine RTD) Chronic lymphocytic leukemia; Indolent non-Hodgkin's lymphoma - cancer,Approved,"07/02/2014  Tentative approval July 2 2014. Teva has also received orphan drug and related pediatric exclusivity expiring in September 2015 and May 2016 for the CLL and NHL indications, respectively."
SPPI,Belinostat  Peripheral T-Cell Lymphoma cancer,Approved,"07/07/2014  Approved July 7, 2014."
ABBV,Imbruvica  Deletion 17p,Approved,"07/19/2014  Approved July 19, 2014."
EGRX,Ryanodex  Malignant hyperthermia - cancer,Approved,"07/23/2014  Approved July 23, 2014 under priority review."
ACRX,Zalviso  Post-operative pain following open abdominal surgery and hip or knee replacement surgery,Phase 3,07/25/2014  CRL issued July 25 2014.
MDCO,Oritavancin  ABSSSI,Approved,"08/06/2014  Approved August 6, 2014 under priority review"
KERX,Auryxia  Hyperphosphatemia,Approved,"09/05/2014  Approved Sept 5, 2014."
HALO,HYQVIA  Subcutaneous treatment for patients with primary immunodeficiency (PI),Approved,"09/12/2014  Approved September 12, 2014."
NKTR,MOVANTIK (Naloxegol)  Opioid-induced constipation (OIC),Approved,"09/16/2014  Approved September 16, 2014."
ALIM,Iluvien  Diabetic macular edema,Approved,"09/26/2014  Approved September 26, 2014,"
PGNX,Subcutaneous RELISTOR  Chronic pain,Approved,"09/29/2014  Approved September 29, 2014."
AEZS,Macimorelin Acetate - Macrilen  Adult Growth Deficiency,Approved,"11/06/2014  CRL issued November 6, 2014."
INCY,Jakafi (ruxolitinib) (RESPONSE)  Polycythemia Vera,Approved,"12/04/2014  Approved December 4, 2014."
ARLZ,YOSPRALA (PA32540/PA8140) Secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers,Approved,"12/17/2014  CRL issued December 17, 2014."
ABBV,VIEKIRA PAK  HCV - genotype 1,Approved,"12/19/2014  Approved December 19, 2014."
BCRX,RAPIVAB (peramivir)  INFLUENZA ACUTE,Approved,"12/22/2014  Approved December 22, 2014."
ADMS,Namzaric  Moderate to severe dementia of the Alzheimer's type.,Approved,"12/24/2014  Approved December, 24 2014."
VRTX,KALYDECO  Cystic fibrosis (CF) ages 6 and older who have the R117H mutation,Approved,"12/29/2014  Approved December 29, 2014."
NBIX,Elagolix Endometriosis,Approved,"01/08/2015  First Phase 3 trial met both co-primary endpoints - January 8, 2015."
ABBV,Elagolix Endometriosis,Approved,"01/08/2015  First Phase 3 trial met both co-primary endpoints - January 8, 2015."
RMTI,Soluble Ferric Pyrophosphate  Iron deficiency,Approved,"01/26/2015  Approved January 26, 2015."
ABBV,IMBRUVICA  Waldenström’s Macroglobulinemia,Approved,"01/29/2015  Approved January 29, 2015 - PCYC"
ZGNX,Abuse deterrent formulations of Zohydro ER  Moderate to severe pain,Approved,"01/30/2015  Approved January 30, 2015."
PCRX,EXPAREL  Post surgical pain,Approved,"03/02/2015  CRL March 2, 2015."
PCRX,EXPAREL  Post surgical pain,PDUFA,"03/02/2015  CRL March 2, 2015."
NKTR,Etirinotecan pegol NKTR-102 (BEACON)  Cancer - Metastatic Breast Cancer,Phase 3,"03/17/2015  Phase 3 topline data mid March 17, 2015 did not reach primary endpoint."
VRTX,KALYDECO (ivacaftor)  Children ages 2 to 5 with cystic fibrosis who have the G551D or one of the eight additional gating mutations,Approved,"03/17/2015  Approved March 17, 2015."
ADMP,Epinephrine Pre-filled Syringe (PFS) Emergency treatment of anaphylaxis.,Approved,03/25/2015  CRL issued March 27 2015.
EBS,Anthrax Immune Globulin Intravenous (Human) [AIGIV] Anthrax,Approved,"03/25/2015  Approved March 25, 2015."
AMGN,Corlanor  Chronic Heart Failure,Approved,"04/15/2015  Approved April 15, 2015."
MNTA,Generic Copaxone  Multiple sclerosis,Approved,04/16/2015  Approved April 16 2015.
MNK,RAPLIXA  Hemostasis,Approved,"04/30/2015  Approved April 30, 2015."
TBPH,BREO ELLIPTA  Asthma,Approved,"04/30/2015  Approved April 30, 2015."
PTX,TREXIMET  Adolescent migraine patients,Approved,"05/15/2015  Approved May 15, 2015."
VRTX,Lumacaftor and ivacaftor  Cystic fibrosis (CF) ages 12 and older who have two copies of the F508del mutation,Approved,"07/02/2015  Approved July 2, 2015."
NYMX,NX-1207 Fexapotide BPH,Phase 3,07/27/2015  Phase 3 endpoints met in extension trial July 2015.
SGEN,ADCETRIS - AETHERA  Post-transplant Hodgkin lymphoma (HL) cancer,Approved,"08/17/2015  Approved August 17, 2015 under priority review."
VTL,"VTI-308  Alcohol-induced liver decompensation, or AILD",Phase 3,"08/21/2015  Phase 3 VTI-208 trial did not meet endpoints - August 21, 2015."
TTPH,Eravacycline (TP-434) - IGNITE3  cUTI - complicated urinary tract infections,Phase 3,"09/08/2015  Phase 3 trial did not meet endpoints September 8, 2015."
IMGN,Kadcyla GATSBY trial  Cancer - metastatic HER2+ gastric cancer,Phase 3,"10/22/2015  Phase 3 endpoint not met - October 22, 2015."
MACK,ONIVYDE  Cancer - second line pancreatic,Approved,"10/22/2015  Approved October 22, 2015."
SPPI,EVOMELA (melphalan) for Injection  Conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma,Approved,"10/23/2015  CRL issued October 23, 2015."
BDSI,BEMA Buprenorphine  Pain,Approved,"10/25/2015  Approved October 26, 2015."
ENDP,"BEMA Buprenorphine  Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatment options are inadequate",Approved,"10/26/2015  Approved October 26, 2015."
GWPH,Sativex  Cancer pain,Phase 3,10/27/2015  Phase 3 trials did not meet endpoints.
LPTX,CureXcell  Diabetic Foot Ulcers,Phase 3,10/27/2015  Phase 3 trial did not meet primary endpoint.
SPHS,Topsalysin (PRX302)  Benign prostatic hyperplasia,Phase 3,"11/10/2015  Phase 3 primary endpoints met - November 10, 2015."
EXEL,Vemurafenib  BRAF V600 Mutation-Positive Advanced Melanoma - Cancer,Approved,"11/10/2015  Approved November 10, 2015."
NKTR,ADYNOVATE  Hemophilia A,Approved,"11/16/2015  Approved November 16, 2015."
EBS,BioThrax Anthrax Vaccine Adsorbed,Approved,"11/24/2015  Approved November 24, 2015."
OTIC,OTIPRIO (ciprofloxacin otic suspension) Ear Tube Placement Surgery,Approved,"12/11/2015  Approved December 11, 2015."
ADMS,ADS-5102  Levodopa-Induced Dyskinesia,Approved,"12/23/2015  Phase 3 data released December 23, 2015."
EGRX,"Docetaxel Injection  Breast, non-small cell lung, prostate gastric adenocarcinoma, and head and neck cancer",Approved,"12/24/2015  Approved December 24, 2015."
CHRS,CHS-0214  Rheumatoid arthritis,Phase 3,"01/11/2016  Phase 3 data released January 2016. Endpoints met. However, commercialization not possible in US before 2029 due to patent issues"
BMRN,Kyndrisa  Duchenne Muscular Dystrophy (DMD),CRL,01/14/2016  CRL issued January 14 2016.
ZFGN,Beloranib  Prader-Willi Syndrome (PWS),Phase 3,01/20/2016  Phase 3 co-primary endpoints met.
NEOS,Adzenys XR-ODT  Attention deficit hyperactivity disorder (ADHD),Approved,"01/27/2016  Approved January 27, 2016."
VRTX,KALYDECO (ivacaftor)  Cystic fibrosis (CF) ages 2 and older who have one of 23 residual function mutations.,CRL,"02/05/2016  CRL issued February 5, 2016."
NBIX,Elagolix Endometriosis,Approved,02/10/2016  First Phase 3 trial met both co-primary endpoints - Jan 2015. Data from second Phase 3 released February 2016 also met endpoints.
ABBV,Elagolix Endometriosis,Approved,02/10/2016  First Phase 3 trial met both co-primary endpoints - Jan 2015. Data from second Phase 3 released February 2016 also met endpoints.
RDHL,RHB-105 - ERADICATE Hp 2  H. pylori,Phase 3,"03/08/2016  Phase 3 final data released March 8, 2016."
GWPH,Epidiolex  Dravet Syndrome and Lennox-Gastaut syndrome,Approved,"03/14/2016  Top line Phase 3 data released March 14, 2016 met primary endpoint."
SPPI,EVOMELA (melphalan) for Injection  Conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma,Approved,03/15/2016  Approved March 15 2016.
EGRX,KANGIO (bivalirudin injection)  Percutaneous Coronary Intervention (PCI) and Percutaneous Transluminal Coronary Angioplasty (PTCA),CRL,03/18/2016  CRL March 18 2016. FDA requested further characterization of bivalirudin-related substances in the drug product.
PTLA,Bevyxxa (betrixaban)  Venous thromboembolism (VTE) Prevention,Approved,"03/24/2016  Phase 3 data released March 24, 2016 did not meet primary endpoint."
OPK,RAYALDEE  Secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) and vitamin D insufficiency - Stage 3 and 4,Approved,"03/30/2016  CRL issued March 30, 2016."
CHMA,Mycapssa  Acromegaly,CRL,"04/15/2016  CRL April 15, 2016."
EXEL,CABOMETYX (cabozantinib)  Metastatic renal cell cancer (RCC),Approved,"04/25/2016  Approved April 25, 2016."
ACAD,Pimavanserin  Parkinson’s disease psychosis (PDP),Approved,"04/29/2016  Approved April 29, 2016."
AVDL,Akovaz  Hypotension,Approved,"05/02/2016  Approved May 2, 2016."
NLNK,HyperAcute Pancreas - IMPRESS  Surgically resected pancreatic cancer,Phase 3,"05/09/2016  Phase 3 failed to meet primary endpoint - May 9, 2016."
AZN,Lokelma (ZS-9)  Hyperkalaemia,Approved,"05/26/2016  CRL issued May 26, 2016."
TTNP,Probuphine  Opioid dependence,Approved,"05/26/2016  CRL issued April 30, 2013. Approved May 26, 2016."
VNDA,Fanapt Supplemental New Drug Application (sNDA) as a maintenance treatment of schizophrenia in adults.,Approved,"05/26/2016  Approved May 26, 2016."
ICPT,Obeticholic acid (Ocaliva)  Primary biliary cirrhosis (PBC) - POISE,Approved,05/27/2016  Approved May 27 2016.
OCUL,DEXTENZA  Allergic conjunctivitis,Phase 3,"06/06/2016  Phase 3 trial did not meet primary endpoint - June 6, 2016."
ADMP,Epinephrine Pre-filled Syringe (PFS) Emergency treatment of anaphylaxis.,Approved,"06/06/2016  CRL issued March 27 2015. CRL issued again June 6, 2016."
MRNS,Ganaxolone  Focal onset seizures,Phase 3,"06/13/2016  Phase 3 data did not meet endpoints - June 13, 2016"
RVNC,RT001 - REALISE 1  Lateral Canthal (Crow’s Feet) Lines,Phase 3,"06/13/2016  Phase 3 endpoints not met June 13, 2016."
KMPH,Apadaz (KP201/APAP)  Acute pain,PDUFA,"06/13/2016  CRL issued June 13, 2016."
PRTK,Omadacycline  Acute bacterial skin and skin structure infections (ABSSSI),Approved,"06/16/2016  Phase 3 top-line data met endpoints - June 16, 2016"
OPK,RAYALDEE  Secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) and vitamin D insufficiency - Stage 3 and 4,Approved,"06/21/2016  Announced FDA Approval June 21, 2016."
MDCO,Meropenem-vaborbactam  Complicated urinary tract infections (cUTI),Approved,"06/27/2016  Phase 3 data met endpoints June 27, 2016."
CLVS,Rociletinib Mutant EGFR T790M-positive lung cancer,CRL,"06/28/2016  CRL June 28, 2016. Phase 3 TIGER-3 also terminated."
LPCN,LPCN 1021  Men with low testosterone (Low T),-,"06/29/2016  CRL issued June 29, 2016."
TSRO,Niraparib - NOVA (Niraparib Ovarian) Cancer - ovarian,Approved,06/29/2016  Phase 3 data met endpoints - June 2016.
AMPE,Ampion  Osteoarthritis of the Knee,Phase 3,06/30/2016  STRIDE study mid April 2015 did not meet endpoint. Second Phase 3 trial also did not meet primary endpoint - June 2016
INSY,Dronabinol Oral Solution  AIDS-related anorexia,Approved,"07/05/2016  Announced approval July 5, 2016."
CYTR,Aldoxorubicin with doxorubicin  Soft tissue sarcomas refractory cancer,Phase 3,"07/11/2016  Phase 3 PFS data released July 2016 showed no significant improvement in PFS. Second analysis released November 29, 2016 showed improvement in population with leiomyosarcoma and liposarcoma."
RARE,MEPSEVII (vestronidase alfa)  Mucopolysaccharidosis 7 (MPS 7),Approved,07/14/2016  Phase 3 data released July 2016. Primary endpoint hit. Secondary missed.
PGNX,Oral RELISTOR  Chronic pain,Approved,07/19/2016  Approved July 19 2016.
OCUL,DEXTENZA  Ocular inflammation and pain following cataract surgery,PDUFA,07/25/2016  CRL July 25 2016 - due to manufacturing deficiencies.
MCRB,SER-109 - ECOSPOR III  Recurrent C. Difficile infection,Phase 3,07/29/2016  Phase 2 interim data did not meet primary endpoint.
ADMA,RI-002  Primary Immune Deficiency Diseases,PDUFA,07/29/2016  CRL issued July 29 2016. Third-party manufacturing issues cited.
IONS,SPINRAZA - Nusinersen  Spinal muscular atrophy (SMA),Approved,"08/01/2016  Phase 3 ENDEAR trial met primary endpoint August 1, 2016."
HRTX,APF530 - Sustol  Prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV),Approved,"08/10/2016  CRL Mar 28 2013. Approved August 10, 2016."
VTVT,TTP399 - AGATA  Type 2 Diabetes,Phase 2b,"08/10/2016  Phase 2 data released August 10, 2016. Primary endpoint met."
AUPH,Voclosporin - AURORA  Lupus,Phase 3,08/15/2016  Phase 2b data released August 2016. Primary endpoint met but with high number of deaths.
ACRX,DSUVIA (ARX-04)  Moderate-to-severe acute pain following a surgical procedure,Approved,"08/15/2016  Phase 3 data released August 15, 2016."
PTLA,Andexxa  Factor Xa inhibitor reversal agent,PDUFA,08/17/2016  CRL August 17 2016.
ACRS,A-101 THWART-1 and THWART-2  Common warts (verruca vulgaris),Phase 3,08/18/2016  Phase 2 data released August 2016.
EARS,AM-101 (Keyzilen) - TACTT2  Acute inner ear tinnitus,Phase 3,08/18/2016  Phase 3 trial did not meet primary endpoints.
LPTX,CureXcell  Venous Leg Ulcers,Phase 3,"08/19/2016  Phase 3 endpoint not expected to be met - August 19, 2015."
RIGL,Tavalissetm (Fostamatinib)  Immune Thrombocytopenic Purpura (ITP),PDUFA,08/30/2016  Phase 3 data from the first trial released August 30 2016. Primary endpoint met.
KMDA,Inhaled formulation of AAT  AATD - Alpha-1 Antitrypsin deficiency,Phase 2,"08/30/2016  Top-line data released August 30, 2016. Primary endpoint met"
RIGL,Tavalissetm (Fostamatinib)  Immune Thrombocytopenic Purpura (ITP),Approved,08/30/2016  Phase 3 data from the first trial released August 30 2016. Primary endpoint met.
RIGL,Tavalissetm (Fostamatinib)  Immune Thrombocytopenic Purpura (ITP),Approved,08/30/2016  Phase 3 data from the first trial released August 30 2016. Primary endpoint met.
OPK,"Rolapitant  Prevention of chemotherapy induced nausea and vomiting, or CINV",Approved,"09/02/2016  Approved September 2, 2015."
TSRO,"Rolapitant  Prevention of chemotherapy induced nausea and vomiting, or CINV in HEC patients",Approved,"09/02/2016  Approved September 2, 2015."
TNXP,TNX-102 SL Fibromyalgia,Phase 3,"09/06/2016  Phase 3 data released September 6, 2016. Primary endpoint not met. Program discontinued"
KPTI,Selinexor  Quadruple Refractory Multiple Myeloma,PDUFA priority review,"09/06/2016  Phase 2 positive top-line data released September 6, 2016"
AERI,Roclatan  Glaucoma,PDUFA,"09/14/2016  Phase 3 Mercury 1 data released September 14, 2016. Primary endpoint met."
NVAX,RSV vaccine - Resolve trial  Respiratory Syncytial Virus (RSV) in older adults,Phase 3,"09/15/2016  Phase 3 released September 15, 2016 did not demonstrate efficacy."
ARLZ,YOSPRALA (PA32540/PA8140) Secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers,Approved,"09/15/2016  Approval announced September 15, 2016."
VICL,ASP0113 Vaccine  Kidney transplant recipients,Phase 2,"09/19/2016  Phase 2 data released September 19, 2016 - did not meet primary endpoint."
SRPT,Eteplirsen - Exon 51  Duchenne muscular dystrophy,Approved,"09/19/2016  Approved September 19, 2016."
DRRX,Remoxy  Chronic pain,CRL,"09/26/2016  CRL received September 26, 2016."
PTIE,Remoxy  Chronic pain,CRL,"09/26/2016  CRL received September 26, 2016."
GILD,Yescarta (axicabtagene ciloleucel)  Refractory Non-Hodgkin's Lymphoma (NHL) - cancer,Phase 2,"09/26/2016  Phase 2 pivotal top-line data released September 26, 2016. Primary analysis due 1Q 2017. BLA filing due late 2016."
ITCI,Lumateperone  Schizophrenia,NDA Filing,"09/28/2016  Phase 3 trial failed - September 28, 2016."
GNCA,GEN-003  Genital herpes,-,09/29/2016  Phase 2b virologic efficacy data released September 2016.
ABUS,ARB-1467  Hepatitis B (HBV),Phase 2,09/29/2016  Phase 2 single dose data released September 2016.
MLNT,Solithromycin  NASH,Phase 2,"09/30/2016  Phase 2 interim data released September 30, 2016."
TENX,Levosimendan  Septic shock,Phase 2b,10/05/2016  Phase 2b trial did not meet primary endpoint.
ALNY,Revusiran ENDEAVOUR  ATTR in patients with familial amyloidotic cardiomyopathy (FAC),Phase 3,10/05/2016  Phase 3 trial discontinued October 2016.
ALKS,ALKS 5461  Major depressive disorder,PDUFA,"10/20/2016  Phase 3 data from first two trials did not meet their endpoints. FORWARD-5 data, the third of three trials did meet endpoints - October 2016."
PLXP,Locilex  Mild infections of diabetic foot ulcers,Phase 3,"10/25/2016  Phase 3 top-line data did not meet endpoints - October 25, 2016 - TICKER CHANGED FROM DPRX FOLLOWING MERGER"
RIGL,Tavalissetm (Fostamatinib)  Immune Thrombocytopenic Purpura (ITP),PDUFA,10/30/2016  Phase 3 data from second trial did not meet the primary endpoint.
RIGL,Tavalissetm (Fostamatinib)  Immune Thrombocytopenic Purpura (ITP),Approved,10/30/2016  Phase 3 data from second trial did not meet the primary endpoint.
AMAG,Rekynda (Bremelanotide)  Female sexual dysfunction (FSD),PDUFA,"11/01/2016  Phase 3 data released November 1, 2016."
PTN,Rekynda (Bremelanotide)  Female sexual dysfunction (FSD),PDUFA,"11/01/2016  Phase 3 data released November 1, 2016."
IONS,SPINRAZA - Nusinersen  Spinal muscular atrophy (SMA),Approved,"11/07/2016  Phase 3 CHERISH data met primary endpoint - November 7, 2016."
ANTH,Blisibimod  Lupus,Phase 3,"11/10/2016  Phase 3 trial did not meet endpoints - November 10, 2016."
DVAX,HEPLISAV-B Hepatitis B,Approved,"11/14/2016  CRL November 14, 2016"
ALNY,Inclisiran - ORION-9  Hypercholesterolemia,Phase 3,"11/15/2016  Phase 2 Day 180 data presented at AHA Scientific Sessions on November 15, 2016."
MDCO,Inclisiran - ORION-9  Hypercholesterolemia,Phase 3,"11/15/2016  Phase 2 Day 180 data presented at AHA Scientific Sessions on November 15, 2016."
ACRS,ESKATA (hydrogen peroxide)  Seborrheic keratosis (SK),Approved,"11/15/2016  Phase 3 trial met endpoints - November 15, 2016."
BSTC,XIAFLEX (collagenase clostridium histolyticum) - RELEASE  Edematous fibrosclerotic panniculopathy (“cellulite”),Phase 3,"11/17/2016  Phase 2b data released November 17, 2016. Met endpoints"
ENDP,XIAFLEX (collagenase clostridium histolyticum) - RELEASE  Edematous fibrosclerotic panniculopathy (“cellulite”),Phase 3,"11/17/2016  Phase 2b data released November 17, 2016. Met endpoints"
SPPI,QAPZOLA - Apaziquone  Bladder cancer,Phase 3,"11/17/2016  Failed to meet primary endpoint in Phase 3 trial - Apr 2012. PDUFA date December 11 2016. Advisory Committee Meeting September 14 2016 voted 14 - 0 against approval. CRL issued November 17, 2016. Considering further trials."
ACOR,Dalfampridine  Post stroke deficits,Phase 3,"11/21/2016  Phase 3 data released November 21, 2016 - failed to show efficacy, development to be discontinued."
REPH,Intravenous (IV) meloxicam Acute pain following bunionectomy surgery,PDUFA,"11/28/2016  Phase 3 data from second trial released November 28, 2016. Primary endpoint met."
NOVN,SB206  Human papillomavirus (HPV),Phase 2,"11/29/2016  Phase 2 data released November 29, 2016. Primary endpoint met."
CERC,CERC-301  Major depressive disorder (MDD),Phase 2,"11/29/2016  Phase 2 top-line data released November 29, 2016 failed to meet primary endpoint."
HTBX,HS-410  Bladder cancer,Phase 2,"11/30/2016  Phase 2 trial did not meet primary endpoint - November 30, 2016."
ARDM,Linhaliq (Pulmaquin)  Non-cystic fibrosis bronchiectasis (non-CF BE).,CRL,"12/01/2016  Phase 3 data released December 1, 2016. One of two trials met primary endpoint."
ARDM,Linhaliq (Pulmaquin)  Non-cystic fibrosis bronchiectasis (non-CF BE).,PDUFA priority review,"12/01/2016  Phase 3 data released December 1, 2016. One of two trials met primary endpoint."
LXRX,Sotagliflozin  Type 1 Diabetes,Phase 2,12/05/2016  Phase 2 trial did not meet primary endpoint.
HZNP,ACTIMMUNE  Friedreich's Ataxia (FA),Phase 3,"12/08/2016  Phase 3 data released December 8, 2016 - primary endpoint not met"
SGYP,Trulance (plecanatide)  Constipation-predominant irritable bowel syndrome (IBS-C),PDUFA,"12/09/2016  Phase 3 data from first trial met primary endpoint - December 9, 2016."
SGYP,Trulance (plecanatide)  Constipation-predominant irritable bowel syndrome (IBS-C),Approved,"12/09/2016  Phase 3 data from first trial met primary endpoint - December 9, 2016."
AKAO,Plazomicin  Complicated urinary tract infections (cUTI),Approved,"12/12/2016  Phase 3 data released December 12, 2016 - primary endpoint met."
OPHT,Fovista  Wet age-related macular degeneration (Wet-AMD),Phase 3,"12/12/2016  Phase 3 data released December 12, 2016 - primary endpoint not met."
ABUS,ARB-1467  Hepatitis B (HBV),Phase 2,"12/12/2016  Phase 2 single dose data released September 2016, multiple dose data released December 12, 2016."
LIFE,Resolaris  Limb girdle muscular dystrophy (LGMD) 2B / Adult patients with facioscapulohumeral muscular dystrophy (FSHD),Phase 1/2,"12/13/2016  Phase 1b/2 data released December 13, 2016."
PRTO,Vonapanitase (PRT-201) PATENCY-1 Chronic kidney disease (CKD) patients undergoing surgical placement of an arteriovenous fistula (AVF),Phase 3,"12/13/2016  Phase 3 data released December 13, 2016 - primary endpoint not met."
VCEL,MACI Focal chondral cartilage defects in the knee.,Approved,"12/13/2016  FDA Approval announced December 13, 2016 ahead of PDUFA date of January 3 2017."
BDSI,Clonidine gel  Painful diabetic neuropathy (PDN),Phase 2b,"12/13/2016  Phase 2b data released December 13, 2016 - primary endpoints not met."
VTVT,TTP273 - LOGRA  Type 2 Diabetes,Phase 2,"12/14/2016  Phase 2 primary endpoint met - December 14, 2016."
CLVS,Rucaparib ARIEL2  Cancer - ovarian second line,Approved,"12/19/2016  Approved December 19, 2016. Original PDUFA date under priority review was February 23, 2017."
ACAD,Pimavanserin - Harmony  Alzheimer’s disease psychosis,Phase 3,"12/20/2016  Phase 2 top-line data released December 20, 2016. Primary endpoint met. Key secondary endpoint missed."
MACK,MM-302 HERMIONE  Cancer - HER2-positive locally advanced or metastatic breast cancer,Phase 2,"12/21/2016  Phase 2 trial discontinued December 21, 2016 due to poor efficacy."
NVS,Lutathera  Inoperable progressive midgut NETs,PDUFA,"12/21/2016  PDUFA date under priority review was December 28, 2016. CRL issued December 21, 2016."
NVS,Lutathera  Inoperable progressive midgut NETs,Approved,"12/21/2016  PDUFA date under priority review was December 28, 2016. CRL issued December 21, 2016."
LXRX,Sotagliflozin  Type 1 Diabetes,PDUFA,"12/21/2016  Phase 3 data from second trial released December 21, 2016 - primary endpoint met."
SNY,Sotagliflozin  Type 1 Diabetes,PDUFA,"12/21/2016  Phase 3 data from second trial released December 21, 2016 - primary endpoint met."
SGYP,Trulance (plecanatide)  Constipation-predominant irritable bowel syndrome (IBS-C),PDUFA,"12/22/2016  Phase 3 data from second trial met primary endpoints - December 9 and 22, 2016."
SGYP,Trulance (plecanatide)  Constipation-predominant irritable bowel syndrome (IBS-C),Approved,"12/22/2016  Phase 3 data from second trial met primary endpoints - December 9 and 22, 2016."
IRWD,Linaclotide  Irritable Bowel Syndrome with Constipation (IBS-C),Phase 3,"12/22/2016  Phase 2b data released December 22, 2016."
IONS,SPINRAZA - Nusinersen  Spinal muscular atrophy (SMA),Approved,"12/23/2016  Approved December 23, 2016."
AMPH,Primatene Mist (epinephrine inhalation aerosol)  Asthma,CRL,"12/27/2016  CRL issued December 27, 2016."
ANTH,Sollpura (liprotamase)  Cystic fibrosis who suffer from exocrine pancreatic insufficiency,Phase 3,"12/28/2016  Top-line data released December 27, 2016 - missed primary endpoint."
MLNT,Solithera - intravenous  Community-acquired bacterial pneumonia (CABP),CRL,"12/29/2016  CRL announced December 29, 2016. Further trials required."
OPK,hGH-CTP  Adults - growth hormone deficiency,Phase 3,"12/30/2016  Phase 3 data released December 30, 2016 - primary endpoint not met."
AGRX,Twirla  Contraceptive patch,CRL,"01/03/2017  CRL issued 2013. Phase 3 top-line data released January 3, 2017 - poor data but intends to reflile NDA 1H 2017."
PLX,AIR DNase (PRX-110)  Cystic Fibrosis,Phase 2,"01/03/2017  Phase 2 interim data released January 3, 2017."
AEZS,Macimorelin Acetate - Macrilen  Adult Growth Deficiency,Approved,"01/04/2017  Phase 3 data released January 4, 2017 - trial failed."
GNCA,GEN-003  Genital herpes,-,"01/05/2017  Phase 2b data released January 5, 2017."
OTIC,OTIPRIO  Acute otitis externa,PDUFA,"01/05/2017  Phase 3 trial met primary endpoint - January 5, 2017."
OTIC,OTIPRIO  Acute otitis externa,Approved,"01/05/2017  Phase 3 trial met primary endpoint - January 5, 2017."
HALO,PEGPH20 - HALO-301  Pancreatic cancer,Phase 3,01/05/2017  Primary endpoint met.
EGLT,ARYMO ER  Abuse-Deterrent Morphine,Approved,"01/09/2017  Approved January 9, 2017."
CHRS,CHS-1420  Psoriasis,Phase 3,"01/10/2017  Phase 3 top-line data met endpoints August 2016. Full data due released January 10, 2016."
TSRO,"Rolapitant - intravenous (IV)  Prevention of chemotherapy induced nausea and vomiting, or CINV in HEC patients",Approved,01/11/2017  CRL issued January 11 2017.
FGEN,Pamrevlumab (FG-3019)  Pancreatic cancer,Phase 1/2,"01/17/2017  Phase 2 abstract released January 17, 2017."
NBIX,INGREZZA  Tourette syndrome - adults,Phase 2,"01/18/2017  Phase 2 data released January 18, 2017 did not meet primary endpoint."
AGN,ESMYA (ulipristal acetate)  Uterine Fibroids,CRL,"01/18/2017  Phase 3 data released January 18, 2017 - endpoints met."
AGN,Oxymetazoline HCl cream 1.0%  Facial Erythema (Redness) Associated with Rosacea,Approved,"01/19/2017  Approved January 19, 2017."
ABBV,Imbruvica  Marginal zone lymphoma,Approved,"01/19/2017  sNDA filing under priority review approved January 19, 2017."
SGYP,Trulance (plecanatide)  Chronic idiopathic constipation (CIC),Approved,"01/19/2017  Approved January 19, 2017."
MRNS,Ganaxolone  CDKL5 disorder,Phase 3,"01/23/2017  Phase 2 preliminary CDKL5 cohort data released January 23, 2017."
VRTX,VX-150  Osteoarthritis,Phase 2,"01/25/2017  Phase 2 primary endpoint met - January 25, 2017."
AGN,Linaclotide 72 mcg dose for use in the treatment of adults  Chronic idiopathic constipation (CIC),Approved,"01/26/2017  sNDA approval announced January 26, 2017."
PFE,PF-06425090  C. difficile Infection,Phase 2,"01/26/2017  Phase 2 positive data released January 26, 2017."
NOVN,SB204 Acne vulgaris,Phase 3,"01/27/2017  Phase 3 top-line data released January 27, 2017. Met one of three co-primary endpoints in NI-AC301 trial. Met all endpoints in NI-AC302 trial."
AGN,AVYCAZ (ceftazidime and avibactam)  Complicated Urinary Tract Infections (cUTI),Approved,"01/30/2017  sNDA approval announced January 30, 2017."
GEMP,Gemcabene - COBALT-1  Homozygous Familial Hypercholesterolemia (HoFH),Phase 2b,"01/30/2017  Phase 2b interim data released January 30, 2017."
CATB,Edasalonexent (CAT-1004)  Duchenne muscular dystrophy (DMD),Phase 3,01/31/2017  Phase 1/2 top-line data released January 31 - primary endpoint not met.
TENX,Levosimendan  Reduce the incidence of low cardiac output syndrome during cardiac surgery,Phase 3,"01/31/2017  Phase 3 top line data released January 31, 2017 - primary endpoints not met."
AMGN,Parsabiv  Secondary hyperparathyroidism (SHPT),Approved,"02/07/2017  Approved February 7, 2017."
GWPH,Sativex  Spasticity due multiple sclerosis,Phase 2,"02/07/2017  Phase 2 trial did not meet primary endpoint - noted February 7, 2017."
JNJ,XARELTO (rivaroxaban)  Coronary Artery Disease or Peripheral Artery Disease,Phase 3,"02/08/2017  Phase 3 trial stopped early due to positive efficacy - February 8, 2017."
ACOR,INBRIJA (CVT-301)  OFF episodes of Parkinson’s disease (PD),PDUFA,"02/09/2017  Phase 3 data released February 9, 2017 - primary endpoint met."
TCON,TRC105 and Avastin  Glioblastoma - cancer,Phase 2,"02/09/2017  Phase 2 data released February 9, 2017 - primary endpoint not met."
ZSAN,M207  Migraine,Phase 3,"02/13/2017  Phase 3 trial data due released February 13, 2017 - primary endpoints met."
SAGE,SAGE-217  Major Depressive Disorder (MDD),Phase 3,"02/13/2017  Phase 2 top-line data from open-label trial released February 13, 2017"
AXON,Nelotanserin Visual hallucinations in subjects with Lewy body dementia,Phase 2,"02/13/2017  Phase 2 preliminary data released February 13, 2017. Primary endpoint hit, secondary endpoints missed. Full study to be completed mid-2017. Phase 3 trial to be initiated 2H 2017."
MRK,MK-8931 (017) - Verubecestat  Mild-to-moderate Alzheimer's,Phase 3,"02/14/2017  Phase 3 trial stopped due to lack of efficacy - February 14, 2017."
ARDX,Tenapanor  Hyperphosphatemia in end-stage renal disease (ESRD) patients,Phase 3,"02/15/2017  Phase 3 released February 15, 2017 - primary endpoint met."
BHC,Brodalumab  Psoriasis,Approved,"02/15/2017  Approved February 15, 2017."
ALKS,ALKS 6428 Opioid dependence,Phase 3,02/15/2017  Phase 3 trial did not meet endpoint - February 2017 (exact date unsure).
XBIT,MABp1  Hidradenitis Suppurativa (HS),Phase 2,"02/16/2017  Phase 2 data released February 16, 2017."
AZN,Lynparza  Breast cancer,Approved,"02/17/2017  Phase 3 data released February 17, 2016 - primary endpoint met."
MRK,Lynparza  Breast cancer,Approved,"02/17/2017  Phase 3 data released February 17, 2016 - primary endpoint met."
AMPH,Naloxone Intranasal  Opioid overdose,CRL,"02/21/2017  CRL announced February 21, 2017."
TRVN,Oliceridine (TRV130)  Moderate to severe acute pain,CRL,"02/21/2017  Phase 3 APOLLO-1 and APOLLO-2 data released February 21, 2017 - primary endpoints met but commercial doubts raised."
XBIT,Xilonix  Colorectal cancer,Phase 3,"02/21/2017  Phase 3 interim analysis announced February 21, 2017 - trial to continue as planned."
CDTX,CD101 Topical - RADIANT  Vulvovaginal candidiasis (VVC),Phase 2,"02/21/2017  Phase 2 data released February 21, 2017 - efficacy not evident, Development to be discontinued."
CMRX,Brincidofovir - Advise trial  Adenovirus Infection,Phase 3,"02/22/2017  Phase 3 interim analysis released May 2016. Final data released February 22, 2017."
CELG,REVLIMID Multiple myeloma (MM) - autologous stem cell transplant (ASCT),Approved,"02/22/2017  Approved February 22, 2017."
MLNT,Taksta - Fusidic acid  Acute bacterial skin and skin structure infections (ABSSSI),Phase 3,"02/24/2017  Phase 3 data released February 24, 2017 - endpoints met."
BCRX,BCX7353 - APeX-2  Reduce or eliminate attacks in HAE patients,Phase 3,"02/27/2017  Phase 2 interim data released February 27, 2017."
LJPC,GiaprezaTM (angiotensin II)  Increase blood pressure in adults with septic or other distributive shock,Approved,"02/27/2017  Phase 3 data released February 27, 2016 - primary endpoint hit. Secondary endpoints not mentioned. NDA filing due 2H 2017."
AZN,Saxagliptin and dapagliflozin  Type-2 diabetes,Approved,"02/28/2017  Approval announced February 28, 2017."
LXRX,Telotristat etiprate (XERMELO)  Carcinoid Syndrome,Approved,"02/28/2017  Approved February 28, 2017."
GILD,Yescarta (axicabtagene ciloleucel)  Refractory Non-Hodgkin's Lymphoma (NHL) - cancer,Phase 2,"02/28/2017  Phase 2 primary analysis released February 28, 2017 showed trial met primary endpoint. 31% CR for DLBCL."
MLNT,Solithromycin  NASH,Phase 2,"02/28/2017  Noted February 28, 2017 that development has been suspended due to lack of efficacy."
AUPH,Voclosporin - AURORA  Lupus,Phase 3,"03/01/2017  Phase 2b data released August 2016. Primary endpoint met but with high number of deaths. Further data released March 1, 2017 - no additional deaths and endpoints met."
MRK,Odactra (MK-8237)  House dust mite allergies,Approved,"03/01/2017  Approved March 1, 2017."
KPTI,Selinexor SOPRA  Cancer - Relapsed/Refractory Acute Myeloid Leukemia (AML),Phase 2,"03/02/2017  Data Safety Monitoring Board (DSMB) noted March 2, 2017 that trial will not meet primary endpoint."
PTCT,Translarna  Nonsense mutation cystic fibrosis,Phase 3,"03/02/2017  Phase 3 data released March 2, 2017 - endpoints not met. Development to be discontinued."
PBYI,Roche (RHHBY) - Perjeta + Herceptin (APHINITY)  Adjuvant HER2+ breast cancer,Phase 3,"03/02/2017  Note this trial is conducted by competitor Roche (RHHBY), NOT by Puma. The event was likely to have a significant impact on the share price of Puma (e.g. positive data would likely have a negative impact on Puma and vice versa). Data were released March 2, 2017 - primary endpoint was met."
SCYX,Intravenous SCY-078  Invasive candidiasis,Phase 2,"03/02/2017  Clinical hold placed on the initiation of intravenous (IV) SCY-078 until the FDA completes a review of all data. Clinical hold follows three mild-to-moderate thrombotic events in healthy volunteers - announced March 2, 2017."
GALT,GR-MD-02  Plaque psoriasis,Phase 2a,"03/06/2017  Phase 2 data released March 6, 2017."
IONS,Volanesorsen - APPROACH  Familial chylomicronemia syndrome (FCS),CRL,"03/06/2017  Phase 3 data released March 6, 2017 - primary endpoint met. Relative safety concerns noted."
AKCA,Volanesorsen - APPROACH  Familial chylomicronemia syndrome (FCS),CRL,"03/06/2017  Phase 3 data released March 6, 2017 - primary endpoint met. Relative safety concerns noted."
TGTX,TG-1101 and IMBRUVICA (GENUINE trial)  Chronic Lymphocytic Leukemia (CLL) cancer,Phase 3,"03/06/2017  Phase 3 trial met primary endpoint - March 6, 2017, meeting with FDA in 2H 2017."
KURA,Tipifarnib  Head and neck squamous cell carcinomas (HNSCC),Phase 2,"03/06/2017  Phase 2 ongoing data released March 6, 2017 - further data due 2H 2017."
ACOR,Ampyra  Improve walking in patients with multiple sclerosis,-,"03/09/2017  Decision on Inter Partes Review (IPR) released March 10, 2017 - patents upheld."
NVS,LEE011  HR+/HER2- advanced breast cancer,Approved,"03/13/2017  Priority review granted November 1, 2016. Approval announced March 13, 2017."
ENDP,OPANA ER  Management of pain,-,"03/14/2017  Advisory Committee Meeting March 14, 2017 voted 18 to eight that the benefits of reformulated OPANA ER no longer outweigh its risks."
MRK,KEYTRUDA  Relapsed or Refractory Classical Hodgkin Lymphoma,Approved,"03/14/2017  Approval announced March 14, 2017."
AZN,Lynparza - SOLO 2  Second-line ovarian cancer,Approved,"03/14/2017  Data presented March 14, 2017 showed significant PFS benefit."
CPRX,Firdapse MuSK-antibody positive myasthenia gravis (MuSK-MG),Phase 2,"03/15/2017  Phase 2 top-line data met endpoints - March 15, 2017. Pivotal trial planned."
AMGN,Repatha  Cardiovascular disease,Approved,"03/17/2017  Phase 3 cardiovascular outcomes study data released March 17, 2017 - endpoints met but down on expectations."
AZN,Lokelma (ZS-9)  Hyperkalaemia,Approved,"03/17/2017  Second CRL issued March 17, 2017."
BLRX,BL-8040 GENESIS  Stem-cell mobilization for autologous transplantation,Phase 3,"03/20/2017  Phase 2 trial initiated March 2016. Partial data released March 20, 2017."
GNMX,NFC-1 - SAGA  mGluR mutation positive ADHD,Phase 2/3,"03/20/2017  Phase 2/3 data released March 20, 2017 - primary endpoint not met."
AGN,JUVÉDERM VOLLURE  Correction of moderate to severe facial wrinkles and folds,Approved,"03/20/2017  Approval announced March 20, 2017."
LLY,"Abemaciclib - MONARCH 1 and 2  Second-line hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer and HR+, HER2- breast cancer",Approved,"03/20/2017  Phase 3 data released March 20, 2017 - PFS primary endpoint met."
NKTR,NKTR-181 Lower back pain,PDUFA,"03/20/2017  Phase 3 data released March 20, 2017 - endpoints met."
JAZZ,JZP-110  Excessive sleepiness associated with obstructive sleep apnea,Phase 3,"03/20/2017  Phase 3 data released March 20, 2017 - primary endpoints met."
NVS,RELAX-AHF-2 (RLX030)  Acute heart failure,Phase 3,"03/22/2017  Phase 3 data released March 22, 2017 - primary endpoints not met."
PFE,Avelumab  Metastatic Merkel cell carcinoma,Approved,"03/23/2017  Priority review announced November 29, 2016. Approval announced March 23, 2017."
XENE,XEN801  Acne,Phase 2,03/24/2017  Phase 2 data released March 24 2017 - endpoints not met.
AUPH,Voclosporin - AURION trial  Lupus,Phase 2,"03/27/2017  48-week data from open-label AURION study presented March 27, 2017 - primary endpoint met."
PRTK,Sarecycline  Severe acne vulgaris,Approved,03/27/2017  Phase 3 data released March 27 2017 - primary endpoints met. NDA filing due 2H 2017.
AGN,Sarecycline  Severe acne vulgaris,Approved,03/27/2017  Phase 3 data released March 27 2017 - primary endpoints met. NDA filing due 2H 2017.
TSRO,Niraparib - NOVA (Niraparib Ovarian) Cancer - ovarian,Approved,"03/27/2017  PDUFA date under priority review was June 30, 2017. Approved March 27, 2017."
FOMX,FMX101 - FX2017-22  Acne,Phase 3,"03/27/2017  Phase 3 data released March 27, 2017 - three of four primary endpoints met across two trials."
VRTX,Tezacaftor (VX-661) / ivacaftor  Cystic fibrosis - Two Copies of the F508del Mutation,PDUFA priority review,"03/28/2017  Phase 3 data released March 28, 2017 - primary endpoint met. NDA filing due 3Q 2017."
RTTR,RP-G28  Lactose intolerance,Phase 3,"03/28/2017  Phase 2/3 top-line data released March 28, 2017. Primary endpoint met. End of Phase 2 meeting with FDA planned."
VRTX,Tezacaftor (VX-661) / ivacaftor  Cystic fibrosis - Two Copies of the F508del Mutation,Approved,"03/28/2017  Phase 3 data released March 28, 2017 - primary endpoint met. NDA filing due 3Q 2017."
REGN,Dupixent (dupilumab)  Atopic dermatitis,Approved,"03/28/2017  Approved under priority review - March 28, 2017."
SNY,Dupixent (dupilumab)  Atopic dermatitis,Approved,"03/28/2017  Approved under priority review - March 28, 2017."
CRBP,Anabasum (Resunab)  Cystic Fibrosis,Phase 2b,"03/30/2017  Phase 2 data released March 30, 2017 - primary endpoint met but some concerns regarding efficacy."
HALO,FOLFIRINOX and PEGPH20 Pancreatic and gastric cancers,Phase 1/2,03/30/2017  Phase 1/2 enrollment closed due to lack of efficacy.
PGNX,Azedra  Pheochromocytoma,Approved,"03/30/2017  Pivotal Phase 2 trial resumed January 2015 following suspension of trial in 2010 due to lack of funding. Primary endpoint met - March 30, 2017. NDA filing due mid-2017."
NVCR,Tumor Treating Fields (TTFields) - INNOVATE  Ovarian cancer,Phase 2,"03/31/2017  Phase 2 data presented December 12, 2016. Further promising PFS data released March 31, 2017."
AZN,Tagrisso  Epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC),Approved,"03/31/2017  Approval announced March 31, 2017."
PFE,"IBRANCE (palbociclib)  HR+, HER2- Metastatic Breast Cancer",Approved,"03/31/2017  sNDA acceptance announced December 21, 2016. Approval announced March 31, 2017."
XBIT,514G3 Staphylococcus Aureus Bacteremia,Phase 1/2,"04/03/2017  Phase 1/2 top-line data released April 3, 2017. 4 patient deaths noted."
BMY,CM - 067 Opdivo in combination with Yervoy  Melanoma,Phase 3,"04/03/2017  Phase 3 first overall survival (OS) positive data released April 3, 2017"
PRTK,Omadacycline  Community-acquired bacterial pneumonia (CABP),Approved,"04/03/2017  Phase 3 data released April 3, 2017 - all endpoints met."
BMY,CM-143 – Opdivo Second-line Glioblastoma (GBM) cancer,Phase 3,"04/03/2017  Phase 3 data released April 3, 2017 - primary endpoint not met."
NLNK,Indoximod in combination with KEYTRUDA or Opdivo - Indigo301  Melanoma - cancer,Phase 3,"04/04/2017  Phase 2 interim analysis released at AACR meeting April 4, 2017."
KPTI,Selinexor - SADAL Cancer - Diffuse Large B-Cell Lymphoma (DLBCL),Phase 2b,"04/04/2017  Phase 2b additional interim data released April 4, 2017 at AACR. Final top-line data due mid-2018."
SUPN,Trokendi Migraine,Approved,"04/05/2017  Tentative approval August 19 2016, subject to the pediatric exclusivity which expires March 28, 2017. Final approval announced April 6, 2017."
NKTR,Cipro DPI Bronchiectasis,Phase 3,"04/05/2017  Phase 3 second trial did not meet endpoint - April 5, 2017."
AGN,Botox Depression,Phase 2,"04/05/2017  Phase 2 top-line data released April 5, 2017 - primary endpoint missed. Phase 3 planned."
ONCE,SPK-9001  Hemophilia B,Phase 1/2,"04/06/2017  Phase 1/2 updated data at ASH 2016. Further update released April 6, 2017."
MRK,Januvia (Sitagliptin)  Type 2 Diabetes,CRL,04/07/2017  CRL issued April 7 2017. sNDA for approved drug requested to include data on cardiovascular effects
GERN,Imetelstat - IMbarkStudy  Myelofibrosis,Phase 2,"04/10/2017  Phase 2 clinical hold lifted Nov 2014. Phase 2 initiated September 2015. Internal review conducted September 2016. Low dose discontinued, high dose enrollment suspended. Further review conducted April 2017 - further development pending FDA feedback and longer term data."
JNJ,Imetelstat - IMbarkStudy  Myelofibrosis,Phase 2,"04/10/2017  Phase 2 clinical hold lifted Nov 2014. Phase 2 initiated September 2015. Internal review conducted September 2016. Low dose discontinued, high dose enrollment suspended. Further review conducted April 2017 - further development pending FDA feedback and longer term data."
MESO,MPC-150-IM - Class 2/3  Chronic heart failure (CHF),Phase 3,"04/10/2017  Noted April 10, 2017 that interim analysis has been completed - trial to continue as planned."
CELG,Demcizumab plus Abraxane - YOSEMITE  First-line pancreatic cancer,Phase 2,"04/10/2017  Phase 2 data released April 10, 2017 - primary endpoint not met."
NBIX,INGREZZA  Tardive dyskinesia,Approved,"04/11/2017  Approved April 11, 2017."
NOVN,SB208  Fungal infections,Phase 2,"04/12/2017  Phase 2 data released April 12, 2017. Primary endpoint met."
PLX,AIR DNase (PRX-110)  Cystic Fibrosis,Phase 2,"04/12/2017  Phase 2 interim data released January 3, 2017. Full data released April 12, 2017. Company noted data were positive but results showed efficacy down on January data."
INCY,Baricitinib  Rheumatoid arthritis,Approved,"04/14/2017  Announced January 19 2016 that NDA Filing had been submitted. Three month delay announced January 13, 2017. CRL received April 14, 2017."
LLY,Baricitinib  Rheumatoid arthritis,Approved,"04/14/2017  Announced January 19 2016 that NDA Filing had been submitted. Three month delay announced January 13, 2017. CRL received April 14, 2017."
OMED,Tarextumab - PINNACLE trial  Small cell lung cancer,Phase 2,"04/17/2017  Phase 2 data released April 17, 2017 - primary endpoint not met."
MTFB,Iclaprim -REVIVE-1  Acute bacterial skin and skin structure infections (ABSSSI),Phase 3,"04/18/2017  Phase 3 data released April 18, 2017 - primary endpoint of non-inferiority met."
RARE,Crysvita (Burosumab)  X-Linked Hypophosphatemia (XLH),Approved,"04/18/2017  Phase 3 data released April 18, 2017 - primary endpoint met, two of three secondary endpoints met (missed on pain)."
RARE,Crysvita (Burosumab)  X-Linked Hypophosphatemia (XLH),PDUFA priority review,"04/18/2017  Phase 3 data released April 18, 2017 - primary endpoint met, two of three secondary endpoints met (missed on pain)."
ABBV,Veliparib  Squamous non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC),Phase 3,"04/19/2017  Phase 3 trial did not meet primary endpoints - April 19, 2017."
EIGR,Lonafarnib  Chronic hepatitis delta virus (HDV),Phase 2,"04/21/2017  Phase 2 end of trial data released April 21, 2017. Meeting with FDA scheduled for 4Q 2017."
MRK,RENFLEXIS - SB2 (infliximab biosimilar)  Biosimilar candidate of Remicade,Approved,"04/21/2017  BLA acceptance announced May 23, 2016 by partner Samsung Bioepis. Approval annuonced April 21, 2017."
ACHN,JNJ-4178 Hepatitis C (HCV),Phase 2a,"04/22/2017  Phase 2a ongoing. Updated data presented at EASL April 22, 2017."
AKTX,Coversin  Paroxysmal nocturnal hemoglobinuria (PNH),Phase 2,"04/24/2017  Phase 2 interim data released April 24, 2017. Phase 3 program to commence 4Q 2017 with initial data due 1Q 2019."
JAZZ,Xyrem  Pediatric narcolepsy patients with cataplexy,Approved,"04/24/2017  Phase 2/3 positive data released April 24, 2017. sNDA filing due 4Q 2017."
AKTX,Coversin  Paroxysmal nocturnal hemoglobinuria (PNH),Phase 3,"04/24/2017  Phase 2 interim data released April 24, 2017. Phase 3 program to commence 4Q 2017 with initial data due 1Q 2019."
LLY,"Abemaciclib - MONARCH 3  HR+, HER2-locoregionally recurrent or metastatic breast cancer (MBC)",Approved,"04/24/2017  Phase 3 interim analysis April 24, 2017 met primary endpoint. Detailed data due 2H 2017 with regulatory filings due 3Q 2017."
XOMA,XOMA 213  Hyperprolactinemia,Phase 2,"04/24/2017  Phase 2 proof-of-concept results released April 24, 2017."
LLY,"Abemaciclib - MONARCH 3  HR+, HER2-locoregionally recurrent or metastatic breast cancer (MBC)",PDUFA priority review,"04/24/2017  Phase 3 interim analysis April 24, 2017 met primary endpoint. Detailed data due 2H 2017 with regulatory filings due 3Q 2017."
REGN,Praluent (alirocumab) High low-density lipoprotein (LDL) cholesterol,Approved,"04/25/2017  sBLA Approval announced April 25, 2017."
SNY,Praluent (alirocumab) High low-density lipoprotein (LDL) cholesterol,Approved,"04/25/2017  sBLA Approval announced April 25, 2017."
CAPR,CAP-1002 HOPE-Duchenne  Duchenne Muscular Dystrophy (DMD),Phase 2,"04/25/2017  Phase 1/2 data released April 25, 2017. Noted improvement in certain measures of cardiac and upper limb function. 12-month data due 4Q 2017."
CAPR,CAP-1002 HOPE-Duchenne  Duchenne Muscular Dystrophy (DMD),Phase 1/2,"04/25/2017  Phase 1/2 data released April 25, 2017. Noted improvement in certain measures of cardiac and upper limb function. 12-month data due 4Q 2017."
JAZZ,JZP-110  Excessive sleepiness associated with narcolepsy,PDUFA,"04/26/2017  Phase 3 data released April 26, 2017. NDA to be filed late 2017."
BMRN,Cerliponase alfa  Batten Disease,Approved,"04/27/2017  PDUFA date extended by three months to April 27 2017. Approval announced April 27, 2017."
TGTX,TG-1101 - ULTIMATE I  Multiple Sclerosis,Phase 3,"04/28/2017  Phase 2 preliminary results presented at American Academy of Neurology (AAN) annual meeting April 28, 2017."
RDUS,TYMLOS (Abaloparatide)  Osteoporosis,Approved,"04/28/2017  PDUFA date originally scheduled for March 30 2017 delayed by three months to June 30, 2017. Approval announced April 28, 2017."
NVS,Rydapt (Midostaurin - PKC412)  Acute myeloid leukemia (AML),Approved,"04/28/2017  Priority review granted November 14, 2016. Approval announced April 28, 2017."
NTRP,Bryostatin  Alzheimer's disease,Phase 2,"05/01/2017  Phase 2 data released May 1, 2017 - primary endpoint not met."
AEZS,Zoptrex  Endometrial cancer,Phase 3,"05/01/2017  Phase 3 trial did not meet primary endpoint - May 1, 2017."
AZN,Urothelial carcinoma - Bladder cancer  Bladder cancer,Approved,"05/01/2017  BLA acceptance announced December 9, 2017. PDUFA under priority review. Approval announced May 1, 2017."
AMAG,Feraheme  Adults with iron deficiency anemia (IDA),Approved,"05/02/2017  Phase 3 trial completion announced May 2, 2017 - endpoints met. sNDA due mid-2017."
AMAG,Feraheme  Adults with iron deficiency anemia (IDA),PDUFA,"05/02/2017  Phase 3 trial completion announced May 2, 2017 - endpoints met. sNDA due mid-2017."
BPMX,BPX-01  Acne,Phase 2b,"05/03/2017  Phase 2b data released May 3, 2017 - primary endpoint met, secondary missed."
ZFGN,ZGN-1061  Diabetes,Phase 2,"05/04/2017  Phase 1 positive safety data released May 4, 2017. Phase 2 initiation due 2H 2017."
REGN,Dupixent (dupilumab)  Eosinophilic esophagitis,Phase 2,"05/04/2017  Phase 2 data released May 4, 2017."
SNY,Dupixent (dupilumab)  Eosinophilic esophagitis,Phase 2,"05/04/2017  Phase 2 data released May 4, 2017."
TXMD,Yuvvexy - TX-004HR  Moderate-to-severe vaginal pain,Approved,"05/08/2017  CRL announced May 8, 2017. Company noted that FDA cited a lack of long-term endometrial safety data."
CELG,Demcizumab plus carboplatin and pemetrexed - DENALI  First-line non-squamous Non-small cell lung cancer (NSCLC),Phase 2,"05/08/2017  Announced November 1, 2016 that it has discontinued further enrollment. Phase 2 data released May 8, 2017 - endpoints not met."
ABBV,ABT-494  Crohn’s Disease,Phase 2b,"05/09/2017  Phase 2 positive data at DDW Meeting May 9, 2017. Phase 3 trial to be initiated later in 2017."
BTX,OpRegen  Dry age-related macular degeneration (AMD),Phase 1/2,"05/09/2017  Phase 2 second cohort underway. Interim data presented at May 8, 2017 at ARVO conference."
ABBV,ABT-494  Crohn’s Disease,Phase 3,"05/09/2017  Phase 2 positive data at DDW Meeting May 9, 2017. Phase 3 trial to be initiated later in 2017."
PFE,Avelumab  Urothelial Carcinoma,Approved,"05/09/2017  Approval announced May 9, 2017."
MRK,Keytruda  First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer,Approved,"05/10/2017  Approved May 10, 2017."
GSK,Mepolizumab  Chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype,CRL,05/10/2017  Phase 3 METREX trial met primary endpoint. Phase 3 METREO failed to meet endpoint.
AZN,"Tralokinumab (STRATOS1)  Severe, uncontrolled asthma",Phase 3,"05/10/2017  Phase 3 trial did not meet primary endpoint - May 10, 2017."
CORI,Corplex Donepezil  Alzheimer's disease,Phase 1,"05/11/2017  Pilot bioequivalence data due released May 11, 2017. Pivotal trial to commence fall of 2017 with preliminary data due February 2018."
ARDX,Tenapanor (T3MPO-1)  Constipation-predominant irritable bowel syndrome (IBS-C),Phase 3,"05/12/2017  Phase 3 data released May 12, 2017. Primary endpoint met - however, competitive concerns raised."
LLY,"Galcanezumab - EVOLVE-1, EVOLVE-2 and REGAIN  Migraine prevention",Approved,"05/12/2017  Phase 3 data released May 12, 2017 - primary endpoints hit in all trials. BLA filing due 2H 2017."
CAPR,CAP-1002 ALLSTAR Myocardial infarction (heart attack),Phase 2,"05/12/2017  Phase 2 data released May 12, 2017 - primary endpoint unlikely to be met."
AZN,Durvalumab (PACIFIC)  Lung cancer,Approved,"05/12/2017  Phase 3 interim analysis released May 12, 2017 - PFS primary endpoint already met. OS endpoint to be assessed."
IONS,Inotersen (IONIS-TTRRx)  NEURO-TTR - familial amyloid polyneuropathy (FAP).,Approved,"05/15/2017  Phase 3 data released May 15, 2017 - primary endpoint met but with safety concerns."
PTCT,Inotersen (IONIS-TTRRx)  NEURO-TTR - familial amyloid polyneuropathy (FAP).,Approved,"05/15/2017  Phase 3 data released May 15, 2017 - primary endpoint met but with safety concerns."
AKCA,Inotersen (IONIS-TTRRx)  NEURO-TTR - familial amyloid polyneuropathy (FAP).,Approved,"05/15/2017  Phase 3 data released May 15, 2017 - primary endpoint met but with safety concerns."
FOLD,ATB200  Pompe Disease,Phase 1/2,"05/15/2017  Phase 1/2 additional data released February 15, 2017. Further data released May 15, 2017."
MRK,KEYTRUDA  First and Second line locally advanced or metastatic urothelial cancer - bladder cancer,Approved,"05/18/2017  Approved May 18, 2017."
RVNC,RT002 - ASPEN  Cervical dystonia,Phase 3,"05/18/2017  Phase 2 additional data released May 18, 2017 with oral presentation June 7, 2017 at International Congress of Parkinson's Disease and Movement Disorders."
LJPC,GiaprezaTM (angiotensin II)  Increase blood pressure in adults with septic or other distributive shock,Approved,"05/22/2017  Phase 3 data released February 27, 2016 - primary endpoint hit. Secondary endpoints not mentioned. Data released May 22, 2017 confirmed primary endpoint was met but with lack of mortality improvement."
CELG,Ozanimod - RADIANCE  Relapsing Multiple Sclerosis,Phase 3,"05/22/2017  Phase 3 data due released May 22, 2017 - primary endpoint met, disability endpoint not met."
AMGN,EVENITY (Romosozumab)  Osteoporosis,BLA Filing,"05/22/2017  PDUFA date July 19, 2017. However, likely to be delayed due to safety data from ARCH trial released May 22, 2017."
SNY,Sarilumab  Rheumatoid arthritis,Approved,"05/22/2017  CRL October 28, 2016. Resubmitted with FDA Approval announced May 22, 2017."
SBPH,Inarigivir - ACHIEVE  Hepatitis B (HBV),Phase 2a,"05/23/2017  Phase 2a initial data released May 23, 2017. Second cohort enrolling with top-line results due 4Q 2017."
MRK,KEYTRUDA  Microsatellite Instability-High Cancer,Approved,"05/23/2017  PDUFA date March 8, 2017 extended to June 9, 2017 due to submission of extra data. Approved May 23, 2017."
NBIX,INGREZZA - T-Force GOLD  Tourette syndrome - juvenile,Phase 2b,05/23/2017  Phase 2 data released May 23 - primary endpoint not met.
PBYI,Neratinib (NERLYNX)  Extended adjuvant HER2-positive early stage breast cancer,Approved,"05/24/2017  Announced acceptance of NDA Filing September 20, 2016. PDUFA estimate July 20, 2017. Advisory Committee Meeting May 24, 2017 voted 12-4 in favor of recommending approval."
AERI,Roclatan  Glaucoma,PDUFA,"05/24/2017  Phase 3 Mercury 1 data released September 14, 2016. Primary endpoint met. Mercury 2 trial data released may 24, 2017 - primary endpoint also hit with NDA filing due 1H 2018."
BCRX,BCX7353 - APeX-2  Reduce or eliminate attacks in HAE patients,Phase 3,"05/25/2017  Phase 2 interim data released February 27, 2017. Top-line data released May 25, 2017."
NVS,Zykadia  First-line use in patients with ALK+ metastatic NSCLC,Approved,"05/26/2017  Priority review granted February 22, 2017. Approval announced May 26, 2017."
GILD,Bictegravir/F/TAF  HIV,Approved,05/30/2017  Phase 3 data released May 30 - primary endpoint met. NDA filing due 2Q 2017.
MRK,ISENTRESS  HIV-1,Approved,"05/30/2017  Approval announced May 30, 2017."
GILD,Bictegravir/F/TAF  HIV,PDUFA priority review,05/30/2017  Phase 3 data released May 30 - primary endpoint met. NDA filing due 2Q 2017.
NVO,Nonacog beta pegol  haemophilia B,Approved,"05/31/2017  Approval announced May 31, 2017."
RETA,Omaveloxolone - MOXIe  Friedreich’s ataxia (FA),Phase 2,"06/01/2017  Phase 2 initial data released June 1, 2017. Primary endpoint not met."
DVAX,SD-101 + Pembrolizumab  Melanoma and head and neck squamous cell carcinoma (HNSCC),Phase 1/2,"06/02/2017  Phase 1b/2 poster at ASCO June 3, 2017. Noted June 2 ORR of 7/7 in anti-PD-1/L1-naïve patients"
BMY,"CM-358 – Opdivo Cervical, vaginal and vulvar cancers",Phase 1/2,"06/02/2017  Phase 1/2 preliminary data presented at ASCO June 2, 2017. ORR=21%."
NLNK,Indoximod + taxane  Cancer - breast,Phase 2,"06/02/2017  Phase 2 trial did not meet endpoints - noted June 2, 2017."
ECYT,EC1169 Castrate-resistant prostate cancer (mCRPC),Phase 1,"06/02/2017  Phase 1 data due by end of 2017. Noted June 2, 2017 decision to only assess taxane-exposed patients and ending treatment of taxane-naïve patients."
ECYT,EC1456  Solid tumors (NSCLC),Phase 1,"06/02/2017  Phase 1 enrollment to be stopped - announced June 2, 2017."
IMDZ,CMB305 Soft tissue sarcomas,Phase 3,"06/02/2017  Phase 2 data at ASCO June 2, 2017."
JNJ,ZYTIGA (abiraterone acetate) - LATITUDE  metastatic hormone-naïve prostate cancer (mHNPC),sNDA Filing,"06/03/2017  Phase 3 data presented at ASCO June 3, 2017 - PFS 33 months."
LOXO,Larotrectinib (LOXO-101)  Solid tumors that harbor a TRK fusion.,PDUFA priority review,"06/03/2017  Announced 76% ORR at ASCO - June 3, 2017. Primary analysis by the end of 2017 with NDA filing late 2017 or early 2018."
JNJ,ZYTIGA (abiraterone acetate) - LATITUDE  metastatic hormone-naïve prostate cancer (mHNPC),Approved,"06/03/2017  Phase 3 data presented at ASCO June 3, 2017 - PFS 33 months."
BMY,BMS-986016 - LAG-3 + Opdivo  Melanoma,Phase 1/2,"06/03/2017  Phase 1/2 ORR rate of 12.5% noted at ASCO June 3, 2017."
MTNB,MAT2203  Refractory mucocutaneous candidiasis,Phase 2a,"06/03/2017  Phase 2a open label data due released June 3, 2017 at ASM Microbe."
PBYI,Neratinib HER2-positive metastatic breast cancer patients with brain metastases,Phase 2,"06/03/2017  Phase 2 data released at ASCO June 3, 2017."
TSRO,Niraparib and Keytruda (TOPACIO)  Triple-negative Breast Cancer or Ovarian Cancer,Phase 1/2,06/03/2017  Phase 1/2 enrolling. Initial data presented at ASCO investor event. ORR 4/13 patients. Further data due 2H 2017.
TGTX,TG-1101 and IMBRUVICA (GENUINE trial)  Chronic Lymphocytic Leukemia (CLL) cancer,Phase 3,"06/03/2017  Phase 3 trial met primary endpoint - March 6, 2017. Data presented at ASCO 2017. Meeting with FDA in 2H 2017."
ARQL,Derazantinib (ARQ 087)  intrahepatic cholangiocarcinoma (iCCA),Phase 3,"06/03/2017  Phase 2 data at ASCO June 3, 2017 - ORR 21%. Phase 3 trial planned for 3Q 2017."
INCY,"Epacadostat with Keytruda - ECHO-202/KEYNOTE-037  NSCLC, RCC, Triple-Negative Breast, Ovarian, Urothelial Carcinoma, Solid Tumors",Phase 1/2,"06/03/2017  Phase 1/2 data presented at ASCO 2017. 35% ORR noted in NSCLC arm. UC, RCC, SCCHN data also presented June 5."
MRK,"Epacadostat with Keytruda - ECHO-202/KEYNOTE-037  NSCLC, RCC, Triple-Negative Breast, Ovarian, Urothelial Carcinoma, Solid Tumors",Phase 1/2,"06/03/2017  Phase 1/2 data presented at ASCO 2017. 35% ORR noted in NSCLC arm. UC, RCC, SCCHN data also presented June 5."
HALO,PEGPH20 - HALO-301  Pancreatic cancer,Phase 3,"06/04/2017  Phase 2 data released January 5, 2017. Oral presentation of Phase 2 data at ASCO June 4, 2017 showed ORR of 45%."
PIRS,PRS-080  Anemia of chronic disease,Phase 2a,"06/04/2017  Phase 1b data released at ERA-EDTA June 4, 2017."
FPRX,Cabiralizumab (FPA008)  Pigmented Villonodular Synovitis (PVNS),Phase 1/2,"06/04/2017  Phase 1/2 initial data released at ASCO June 4, 2017."
RNN,RX-3117  Advanced bladder cancer - 3rd line,Phase 2a,"06/04/2017  Phase 2a initial presented at ASCO June 4, 2017."
MRK,Keytruda - KEYNOTE-045 Bladder Cancer,Phase 3,06/04/2017  Phase 3 trial met its primary endpoint - October 2016. Updated data presented at ASCO 2017. HR 0.70. OS 10.3 months.
AZN,Lynparza  Breast cancer,Approved,"06/04/2017  Phase 3 data released February 17, 2016 - primary endpoint met. Late breaker at ASCO June 4, 2017 showed HR of 0.58 (42% reduction of risk of disease progression or death)."
MRK,Lynparza  Breast cancer,Approved,"06/04/2017  Phase 3 data released February 17, 2016 - primary endpoint met. Late breaker at ASCO June 4, 2017 showed HR of 0.58 (42% reduction of risk of disease progression or death)."
CELG,Lico-cel (CD-19 JCAR017) - TRANSCEND  r/r B cell non-Hodgkin lymphoma - cancer,Phase 1/2,"06/05/2017  Pivotal trial to be initiated in 2017. ASCO Poster Session June 5, 2017 - ORR 86%."
CALA,CX-1158-101  Solid tumors - cancer,Phase 1,"06/05/2017  Phase 1 oral presentation at ASCO, June 5, 2017."
BGNE,BGB-A317  Solid tumors,Phase 1/2,"06/05/2017  Phase 1/2 preliminary data presented at ASCO June 5, 2017."
NLNK,Indoximod + Sipuleucel-T  Metastatic castration resistant prostate cancer (mCRPC),Phase 2,"06/05/2017  Phase 2 poster presentation at ASCO June 5, 2017."
BMY,Opdivo + Yervoy  Malignant pleural mesothelioma (MPM),Phase 2,"06/05/2017  Phase 2 late breaker at ASCO June 5, 2017. Control rate 44%. ORR 19%."
INCY,Epacadostat with Opdivo (nivolumab) - (ECHO-204)  Solid tumors,Phase 1/2,"06/05/2017  Phase 1/2 trial enrolling. Oral presentation at ASCO June 5, 2017."
BMY,Epacadostat with Opdivo (nivolumab) - (ECHO-204)  Solid tumors,Phase 1/2,"06/05/2017  Phase 1/2 trial enrolling. Oral presentation at ASCO June 5, 2017."
IOVA,LN-144  Refractory metastatic melanoma,Phase 2,"06/05/2017  Phase 2 second cohort commenced enrollment - May 19, 2017. Initial data presented at ASCO June 5, 2017."
CRVS,CPI-444  Solid tumors - cancer,Phase 1b,"06/05/2017  Phase 1/1b preliminary data released November 2016. Further update at ASCO June 5, 2017."
CLSN,GEN-1 OVATION 2  Ovarian cancer,Phase 1/2,06/05/2017  Phase 1b interim data released at ASCO 2017 - ORR 86%.
PBYI,Roche (RHHBY) - Perjeta + Herceptin (APHINITY)  Adjuvant HER2+ breast cancer,Phase 3,"06/05/2017  Note this trial is conducted by competitor Roche (RHHBY), NOT by Puma. Primary endpoint was met March 2, 2017. Data released June 5, 2017 - HR 0.81. Disease-free-survival +0.9% over Herceptin."
GLYC,Uproleselan (GMI-1271)  Acute myeloid leukemia (AML) newly diagnosed and refractory - cancer,Phase 1/2,"06/05/2017  Phase 2 enrollment completed - announced May 31, 2017. Data updates at ASCO June 5, 2017."
GILD,Axicabtagene ciloleucel - KTE-C19 (ZUMA-3) Adult patients with r/r ALL - cancer,Phase 1/2,"06/05/2017  Phase 2 data due 2018. Phase 1 data released at ASCO June 5, 2017. Complete remission 73%."
BLUE,bb2121  Relapsed/refractory multiple myeloma,Phase 1,"06/05/2017  Phase 1 interim data released November 30, 2016 - 78% ORR. Pivotal trial to be initiated 2017. Updated data at ASCO June 5, 2017 - ORR 89%."
CELG,bb2121  Relapsed/refractory multiple myeloma,Phase 1,"06/05/2017  Phase 1 interim data released November 30, 2016 - 78% ORR. Pivotal trial to be initiated 2017. Updated data at ASCO June 5, 2017 - ORR 89%."
ALKS,Aristada  Schizophrenia,Approved,"06/06/2017  Approved October 5 2015. sNDA filed for 2-month option with approval announced June 6, 2017."
ABBV,ABT-494 (upadacitinib) - SELECT-NEXT  Rheumatoid arthritis,Phase 3,"06/07/2017  Phase 3 top-line data released June 7, 2017 - primary endpoints met."
NVS,Kymriah (CTL019 )- JULIET  Cancer - Diffuse Large B-Cell Lymphoma (DLBCL),PDUFA priority review,"06/07/2017  Phase 2 pivotal primary analysis due International Conference on Malignant Lymphoma (ICML) on June 14, 2017. Abstract released June 7, 2017. ORR 45%."
NVS,Kymriah (CTL019 )- JULIET  Cancer - Diffuse Large B-Cell Lymphoma (DLBCL),Approved,"06/07/2017  Phase 2 pivotal primary analysis due International Conference on Malignant Lymphoma (ICML) on June 14, 2017. Abstract released June 7, 2017. ORR 45%."
LXRX,Sotagliflozin  Type 1 Diabetes,PDUFA,"06/09/2017  Phase 3 data released September 9, 2016 met primary endpoint. Secondary endpoint data due May 2017. Data from second trial released December 21, 2016 - primary endpoint met. Data from third trial also met primary endpoint - June 9, 2017."
SNY,Sotagliflozin  Type 1 Diabetes,PDUFA,"06/09/2017  Phase 3 data released September 9, 2016 met primary endpoint. Secondary endpoint data due May 2017. Data from second trial released December 21, 2016 - primary endpoint met. Data from third trial also met primary endpoint - June 9, 2017."
XBIT,Xilonix  Colorectal cancer,Phase 3,"06/09/2017  Phase 3 interim analysis announced June 9, 2017 - trial to be terminated due to lack of efficacy."
JNJ,INVOKANA CANVAS  Type 2 diabetes,Approved,"06/12/2017  Cardiovascular Outcomes trial data released June 12, 2017 - 14% reduction in the risk of the composite primary endpoint of CV mortality."
RGLS,RG-101 Hepatitis C virus (HCV),Phase 2,"06/12/2017  Clinical hold placed June 2016. Noted June 12, 2017 that it plans to discontinue program."
XLRN,Dalantercept - DART Study  Renal Cell Carcinoma (RCC) - cancer,Phase 2,"06/12/2017  Phase 2 data released June 12, 2017 - primary endpoint not met."
CHRS,CHS-1701  Pegfilgrastim biosimilar,Approved,"06/12/2017  CRL announced June 12, 2017."
BTX,Renevia  Restoring normal skin contours in for patients with HIV,Phase 3,"06/14/2017  Pivotal trial data released June 14, 2017 - primary endpoint met."
RDHL,BEKINDA -GUARD  Gastroenteritis,Phase 3,"06/14/2017  Phase 3 top-line data released June 14, 2017 - primary endpoint met."
ALDX,Reproxalap (ADX-102)  Allergic conjunctivitis,Phase 3,"06/14/2017  Phase 2b data released June 14 2017 - primary endpoint not met. However, Phase 3 trial is planned."
KURA,Tipifarnib  Relapsed or refractory peripheral T-cell lymphoma,Phase 2,"06/14/2017  Phase 2 data presented at ICML conference on June 14, 2017 - 3/18 partial responses."
EPZM,Tazemetostat  Follicular lymphoma,Phase 2,"06/14/2017  Phase 2 data released June 14, 2017 - DLBCL ORR 29%."
SELB,SEL-212  Tophaceous gout,Phase 3,"06/15/2017  Phase 2 dosing commenced late October 2016. Initial data released at EULAR June 15, 2017."
PTLA,Cerdulatinib (PRT2070)  Refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia - cancer,Phase 2,"06/15/2017  Phase 2 enrollment commenced May 2016. Interim data released June 15, 2017 - noted CLL/SLL 67% partial responese rate + two patient deaths."
ADMP,Epinephrine Pre-filled Syringe (PFS) Emergency treatment of anaphylaxis.,Approved,"06/15/2017  CRL issued March 27 2015. CRL issued again June 6, 2016. Approval announced June 15, 2017 following third submission."
JNJ,DARZALEX (Daratumumab) + pomalidomide and dexamethasone  Relapsed or refractory multiple myeloma,Approved,"06/16/2017  Approval announced June 16, 2017 - note: submitted by Janssen Biotech, Inc."
CLVS,Rucaparib ARIEL3 Ovarian cancer patients with a BRCA-like mutation,Approved,06/19/2017  Phase 3 data released June 20 2017 - primary endpoint met. sNDA filing due 3Q or early 4Q 2017.
NEOS,Cotempla XR-ODT  Attention deficit hyperactivity disorder (ADHD),Approved,"06/19/2017  Approval announced June 19, 2017."
CLVS,Rucaparib ARIEL3 Ovarian cancer patients with a BRCA-like mutation,PDUFA priority review,06/19/2017  Phase 3 data released June 20 2017 - primary endpoint met. sNDA filing due 3Q or early 4Q 2017.
LPCN,LPCN 1021  Men with low testosterone (Low T),-,"06/19/2017  CRL issued June 2016. Flexibility trial data announced June 19, 2017 - primary endpoint met with NDA fiing due 3Q 2017."
SGEN,Vadastuximab Talirine (CASCADE)  Acute myeloid leukemia (AML) - cancer,Phase 3,"06/19/2017  Phase 3 trial discontinued due to higher rate of deaths - June 19, 2017."
EGLT,OXAYDO  Acute and chronic moderate to severe pain,CRL,"06/20/2017  CRL announced June 20, 2017."
NVS,RTH258 (brolucizumab)  Neovascular AMD,Phase 3,"06/20/2017  Phase 3 data released June 20, 2017 - primary and key secondary endpoints met."
IMUC,ICT-107 dendritic cell vaccine  Glioblastoma antigens and cancer stem cells,Phase 3,"06/21/2017  Phase 2b failed to meet primary endpoint. Phase 3 initiated dosing June 2016 - noted June 21, 2017 that further enrollment to be suspended."
CARA,IV CR845  Acute pain,Phase 3,"06/21/2017  Interim conditional power analysis conducted June 21, 2017 - trial completion due 4Q 2017."
PFE,Epoetin alfa biosimilar,CRL,"06/22/2017  CRL issued June 22, 2017."
NVS,Tafinlar (dabrafenib) and Mekinist (trametinib)  Non-small cell lung cancer (NSCLC) with BRAF V600E mutation,Approved,"06/22/2017  FDA Approval announced June 22, 2017."
HALO,Subcutaneous rituximab  Various blood cancers,Approved,"06/22/2017  Approval announced June 22, 2017."
XOMA,ACZ885 (canakinumab) CV risk reduction,CRL,06/22/2017  Phase 3 trial met primary endpoint - data to be presented later in 2017 at a medical congress.
NVS,ACZ885 (canakinumab) CV risk reduction,CRL,06/22/2017  Phase 3 trial met primary endpoint - data to be presented later in 2017 at a medical congress.
BLUE,HGB-205  Transfusion-Dependent β-Thalassemia (TDT) and Severe Sickle Cell Disease (SCD),Phase 1/2,"06/23/2017  Phase 1/2 data presented at EHA June 23, 2017."
STML,SL-401  Blastic plasmacytoid dendritic cell neoplasm (BPDCN) cancer,PDUFA priority review,"06/23/2017  Phase 2 update on patients enrolled in Stages 1 and 2 presented at EHA June 23, 2017."
PTLA,Bevyxxa (betrixaban)  Venous thromboembolism (VTE) Prevention,Approved,"06/23/2017  FDA Approval noted June 23, 2017."
BLCM,BPX-501  Adjunct T-cell therapy administered after allogeneic HSCT - (hematopoietic stem cell transplantation) - cancer,Phase 1/2,"06/23/2017  Phase 1/2 update June 23, 2017."
GBT,GBT440 HOPE-KIDS 1  Sickle cell disease - children age 6-17.,Phase 2a,"06/23/2017  Phase 2a initiated June 2016. Preliminary data released at European Hematology Association (EHA) - June 23, 2017."
BLUE,LentiGlobin - HGB-207 Northstar-2  non-β0/β0 transfusion-dependent thalassemia (TDT),Phase 3,"06/23/2017  Phase 3 early data released at EHA June 23, 2017."
NVO,Semaglutide (NN9536)  Obesity,Phase 2,"06/23/2017  Phase 2 data released June 23, 2017 with Phase 3 trial to commence 2018."
AGIO,AG-348  Pyruvate kinase deficiency,Phase 3,"06/24/2017  Phase 2 updated data released at EHA June 24, 2017."
MTNB,MAT2203  Vulvovaginal candidiasis (VVC),Phase 2,"06/26/2017  Phase 2 top-line data released June 26, 2017. Not successful in demonstrating meaningful clinical response."
SGEN,ADCETRIS in combination with chemotherapy ECHELON-1 Frontline Hodgkin lymphoma,PDUFA priority review,"06/26/2017  Phase 3 data released June 26, 2017 - primary endpoint met."
SGEN,ADCETRIS in combination with chemotherapy ECHELON-1 Frontline Hodgkin lymphoma,Approved,"06/26/2017  Phase 3 data released June 26, 2017 - primary endpoint met."
AMAG,Makena - auto injector  Reduce the risk of preterm birth in women with a singleton pregnancy,Approved,"06/26/2017  sNDA filing announced April 17, 2017. PDUFA date February 14, 2018. 10-month review despite initial expectations of a 6-month review."
ATRS,Makena - auto injector  Reduce the risk of preterm birth in women with a singleton pregnancy,Approved,"06/26/2017  sNDA filing announced April 17, 2017. PDUFA date February 14, 2018. 10-month review despite initial expectations of a 6-month review."
AMAG,Makena - auto injector  Reduce the risk of preterm birth in women with a singleton pregnancy,PDUFA,"06/26/2017  sNDA filing announced April 17, 2017. PDUFA date February 14, 2018. 10-month review despite initial expectations of a 6-month review."
ATRS,Makena - auto injector  Reduce the risk of preterm birth in women with a singleton pregnancy,PDUFA,"06/26/2017  sNDA filing announced April 17, 2017. PDUFA date February 14, 2018. 10-month review despite initial expectations of a 6-month review."
MRK,Anacetrapib (MK-0859)  Raising HDL-C and reducing LDL-C,Phase 3,"06/27/2017  Phase 3 data due released June 27, 2017. Primary endpoint met."
XENE,TV-45070  Postherpetic neuralgia,Phase 2b,"06/27/2017  Phase 2b data released June 27, 2017. Endpoints not met."
RARX,RA101495  Paroxysmal nocturnal hemoglobinuria (PNH),Phase 2,"06/27/2017  Phase 2 initial data from two patients released June 27, 2017."
ALDR,ALD403 - PROMISE 1  Frequent episodic migraine,Phase 3,"06/27/2017  Phase 3 PROMISE 1 top-line data released June 27, 2017, Primary and key secondary endpoints met but competitive concerns raised."
GEMP,Gemcabene - COBALT-1  Homozygous Familial Hypercholesterolemia (HoFH),Phase 2b,"06/28/2017  Phase 2b data released June 28, 2017 - primary endpoint met."
AMGN,Vectibix (Panitumumab)  Wild-Type RAS Metastatic Colorectal Cancer,Approved,"06/29/2017  sBLA approval announced June 29, 2017."
CARA,CR845 Osteoarthritis (OA),Phase 2b,"06/29/2017  Phase 2b data released June 29, 2017 - trial failed."
ALKS,ALKS 3831 - ENLIGHTEN-1  Schizophrenia,Phase 3,"06/29/2017  Phase 3 preliminary data released June 30, 2017. Primary endpoint met - adverse events included weight gain."
MRK,KEYTRUDA - KEYNOTE-183  Multiple myeloma,Phase 2,"07/05/2017  Phase 3 clinical hold announced July 6, 2017 - also applies to KEYNOTE-185."
BMY,ORENCIA  Psoriatic Arthritis (PsA),Approved,"07/06/2017  Approval announced July 6, 2017."
RCKT,Trabodenoson and latanoprost  Glaucoma,Phase 2,"07/07/2017  Phase 2 trial failed - noted July 7, 2017."
IMRN,IMM-124E  Nonalcoholic steatohepatitis (NASH),Phase 2,"07/10/2017  Phase 2 top-line data due 4Q 2017. Interim analysis July 10, 2017 showed no statistical difference with placebo."
ALNY,Fitusiran Hemophilia A and B,Phase 2,"07/10/2017  Phase 2 Open-label Extension Study data released July 10, 2017 at ISTH."
ONCE,SPK-9001  Hemophilia B,Phase 1/2,"07/10/2017  Phase 1/2 updated data released July 10, 2017. 99% fall in infusion rate."
ARNA,Ralinepag  Pulmonary Arterial Hypertension,Phase 3,"07/10/2017  Phase 2 data released July 10, 2017. Primary endpoint met. Secondary missed."
UTHR,Ralinepag  Pulmonary Arterial Hypertension,Phase 3,"07/10/2017  Phase 2 data released July 10, 2017. Primary endpoint met. Secondary missed."
QURE,AMT-060  hemophilia B,Phase 1/2,"07/10/2017  Phase 1/2 long term updated data presented July 10, 2017."
SVRA,Aironite - INDIE  Heart failure with preserved ejection fraction (HFpEF),Phase 2,"07/11/2017  Phase 2 interim data released July 11, 2017."
AMGN,BLINCYTO  Ph+ R/R ALL,Approved,"07/11/2017  PDUFA date under priority review August 14, 2017. Approval announced July 11, 2017."
PFE,Mylotarg (gemtuzumab ozogamicin)  Acute myeloid leukemia (AML),Approved,"07/11/2017  Advisory Committee Meeting July 11, 2017 voted in favor 6-1 of a favorable risk:benefit profile."
BMRN,Valoctocogene roxaparvovec (BMN 270)  Hemophilia A,Phase 3,"07/11/2017  Phase 1/2 updated data released July 11, 2017. 97% reduction in Annualized Bleed Rate (ABR)."
OCUL,DEXTENZA  Ocular inflammation and pain following cataract surgery,PDUFA,"07/11/2017  CRL July 25 2016 - due to manufacturing deficiencies. NDA resubmitted, PDUFA date July 19, 2017. Further CRL issued July 11, 2017 with FDA noting deficiencies in manufacturing processes and analytical testing."
KDMN,KD025 - ROCKstar (KD025-213)  Chronic graft-versus-host disease (cGVHD),Phase 2,"07/11/2017  Phase 2 interim data presented July 11, 2017. ORR 71%."
AMGN,KYPROLIS (ASPIRE)  Relapsed Multiple Myeloma,Approved,07/12/2017  Phase 3 trial met primary endpoint. HR 79%.
NVS,Kymriah (CTL019)  Relapsed/Refractory B-Cell Acute lymphoblastic leukemia,Approved,"07/12/2017  Advisory Committee Meeting July 12, 2017 voted 10-0 recommending approval."
JNJ,Guselkumab  Plaque psoriasis,Approved,"07/13/2017  Approval announced July 13, 2017."
AMGN,EVENITY (Romosozumab)  Osteoporosis,BLA Filing,"07/16/2017  CRL issued July 16, 2017."
PBYI,Neratinib (NERLYNX)  Extended adjuvant HER2-positive early stage breast cancer,Approved,"07/17/2017  Approval announced July 17, 2017."
PRTK,Omadacycline - oral  Acute bacterial skin and skin structure infections (ABSSSI),Phase 3,"07/17/2017  Phase 3 data released July 17, 2017 - all endpoints met."
CBAY,Seladelpar  Primary biliary cholangitis (PBC),Phase 3,"07/17/2017  Phase 2 top-line data released late May 2016. Positive interim data from second trial data released July 17, 2017."
VRTX,VX-152 in combination with tezacaftor and ivacaftor  Cystic fibrosis who have one F508del mutation and one minimal function mutation and patients with two copies of the F508del mutation,Phase 2,"07/18/2017  Phase 2 data released July 18, 2017. ppFEV1 of 9.7 percentage points."
VRTX,VX-659 in combination with tezacaftor and ivacaftor  Cystic fibrosis (CF) who have one F508del mutation and one minimal function mutation (F508del/Min),Phase 3,"07/18/2017  Phase 1 data released July 18, 2017. ppFEV1 of 9.6 percentage points."
VRTX,VX-440 in combination with tezacaftor and ivacaftor  Cystic fibrosis who have one F508del mutation and one minimal function mutation and patients with two copies of the F508del mutation,Phase 2,"07/18/2017  Phase 2 data released July 18, 2017. ppFEV1 of 12.0 percentage points."
GILD,Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)  Hepatitis C virus (HCV),Approved,"07/18/2017  Approval announced July 18, 2017."
TBPH,Revefenacin  COPD,Approved,"07/19/2017  12 month safety trial data released July 19, 2017 with NDA filing due 4Q 2017."
MYL,Revefenacin  COPD,Approved,"07/19/2017  12 month safety trial data released July 19, 2017 with NDA filing due 4Q 2017."
MRK,LUSDUNA Nexvue  Diabetes,Approved,"07/20/2017  Tentative approval announced July 20, 2017 - subject to an automatic stay due to a lawsuit from Sanofi claiming patent infringement."
BVXV,M-001  Universal flu vaccine,Phase 3,"07/20/2017  Phase 2b data released July 20, 2017 - endpoints met."
IRWD,IW-3718 Gastroesophageal reflux disease (GERD),Phase 3,"07/20/2017  Phase 2b data released July 20, 2017. Primary endpoint met but data below expectations."
GSK,Benlysta (belimumab) - subcutaneous  Systemic lupus erythematosus (SLE),Approved,"07/21/2017  Approval announced July 21, 2017."
MRK,KEYNOTE-040 KEYTRUDA  Recurrent or metastatic head and neck squamous cell carcinoma (HNSCC),Approved,"07/24/2017  Phase 3 trial did not meet primary endpoint - July 24, 2017. Awarded accelerated approval in 2016."
RETA,Bardoxolone methyl - CARDINAL  Chronic Kidney Disease Caused by Alport Syndrome,Phase 2/3,"07/24/2017  Phase 2/3 trial initiation announced February 23, 2017. Data from Phase 2 part of trial released July 24, 2017."
GNCA,GEN-003  Genital herpes,-,"07/24/2017  Phase 2b data released January 6, 2017. 12-month data released July 24, 2017. Phase 3 to commence 4Q 2017."
NVAX,RSV F Vaccine immunogenicity trial  Respiratory Syncytial Virus (RSV) in older adults,Phase 2,"07/24/2017  Phase 2 safety and immunogenicity data released July 24, 2017 - efficacy trial to be initiated 2018."
CYTX,ECCS-50  Scleroderma,Phase 3,"07/24/2017  Pivotal trial data released June 24, 2017 - endpoints not met."
PCRX,EXPAREL  Post surgical pain,Approved,"07/25/2017  Phase 3 data released July 25, 2017. Upper extremity met primary endpoint, lower extremity trial missed endpoint."
PCRX,EXPAREL  Post surgical pain,PDUFA,"07/25/2017  Phase 3 data released July 25, 2017. Upper extremity met primary endpoint, lower extremity trial missed endpoint."
TTPH,Eravacycline (TP-434) - IGNITE4  cIAI (complicated intra-abdominal infections),Approved,"07/25/2017  Phase 3 data released July 25, 2017 - primary endpoint met. NDA filing due 1Q 2018."
EGRX,Ryanodex  Exertional heat stroke (EHS),CRL,"07/26/2017  CRL issued July 26, 2017. Additional trial required."
AZN,Tagrisso - FLAURA  First-line lung cancer,Approved,"07/27/2017  Phase 3 data released July 27, 2017 - PFS improvement noted."
AZN,Durvalumab +/- tremelimumab (MYSTIC)  Lung cancer,Phase 3,"07/27/2017  Phase 3 data released July 27, 2017 - primary endpoint not met."
AZN,Tagrisso - FLAURA  First-line lung cancer,PDUFA priority review,"07/27/2017  Phase 3 data released July 27, 2017 - PFS improvement noted."
DVAX,HEPLISAV-B Hepatitis B,Approved,"07/28/2017  Advisory Committee Meeting July 28, 2017 voted 11 -1 in favor of recommending approval."
ICPT,Obeticholic acid (OCA) AESOP  Primary Sclerosing Cholangitis (PSC),Phase 2,"07/31/2017  Phase 2 data released July 31, 2017 - primary endpoint met."
NVIV,Neuro-Spinal Scaffold: INSPIRE 2.0  Complete Thoracic AIS A Spinal Cord Injury,Phase 3,"07/31/2017  Noted July 31, 2017 that enrollment has been temporarily halted as it discusses potential changes to patient enrollment criteria due to patient deaths - enrollment now due to be completed 1H 2018 with Humanitarian Device Exemption (HDE) application due 2H 2018."
ICPT,Obeticholic acid (OCA) - CONTROL  NASH patients taking statins,Phase 2,"07/31/2017  Phase 2 primary endpoint met - July 31, 2017. One patient death noted but DSMB noted unlikely to be related to OCA (company unsure)."
RDHL,RHB-104 MAP US  Crohn’s disease,Phase 3,"07/31/2017  Phase 3 DSMB safety analysis released December 13, 2016 - trial to continue as planned. Further analysis July 31, 2017 recommended trial continue as planned."
BMY,CM-142 – Opdivo (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (CRC),Approved,"08/01/2017  Approval announced August 1, 2017."
ACRX,Zalviso  Post-operative pain following open abdominal surgery and hip or knee replacement surgery,Phase 3,"08/01/2017  Phase 2 data released August 1, 2017."
AGIO,IDHIFA (enasidenib) - AG-221 Advanced hematologic malignancies with an IDH2 mutation,Approved,"08/01/2017  Approval announced August 1, 2017."
CELG,IDHIFA (enasidenib) - AG-221 Advanced hematologic malignancies with an IDH2 mutation,Approved,"08/01/2017  Approval announced August 1, 2017."
JNJ,Imbruvica  Second-line Chronic graft-versus-host disease (GVHD),Approved,"08/02/2017  Approval announced August 2, 2017."
TBPH,Velusetrag (TD-5108)  Gastroparesis,Phase 2b,"08/02/2017  Phase 2b data released August 2, 2017. Primary endpoint not met."
JNJ,Sirukumab Rheumatoid arthritis,CRL,"08/02/2017  BLA filing announced September 23, 2016. PDUFA estimate September 23, 2017. Advisory Committee Meeting August 2, 2017 voted 12-1 against that safety data is adequate to support approval. 13-0 in favor of efficacy."
ONCE,SPK-8011  Hemophilia A,Phase 1/2,"08/02/2017  Phase 1/2 promising initial data released from first two patients - August 2, 2017. 11% and 14% Factor VIII."
ENTA,Glecaprevir/Pibrentasvir (G/P) Hepatitis C virus (HCV),Approved,"08/03/2017  Approval announced August 3, 2017."
ABBV,Glecaprevir/Pibrentasvir (G/P) Hepatitis C virus (HCV),Approved,"08/03/2017  Approval announced August 3, 2017."
PFE,Xeljanz  Psoriatic arthritis,Phase 3,"08/03/2017  PDUFA date December 2017. No exact date given. December 31, 2017 noted as last possible date using guidance of ""December 31"". Advisory Committee Meeting August 3, 2017 voted 10-1 in favor of recommending approval."
JAZZ,Vyxeos  Acute myeloid leukemia,Approved,"08/03/2017  Approval announced August 3, 2017."
CRIS,CUDC-907  Diffuse-large B-cell lymphoma (DLBCL),Phase 2,"08/03/2017  Phase 2 initial data released August 3, 2017 - ORR 19%."
LLY,Lasmiditan - SPARTAN  Migraine,NDA Filing,"08/04/2017  Phase 3 data released August 4, 2017 - endpoints met. NDA filing due 2H 2018."
FGEN,Pamrevlumab (FG-3019)  Idiopathic pulmonary fibrosis,Phase 2,"08/07/2017  Phase 2 data released August 7, 2017 - primary endpoint met."
BHC,Latanoprostene bunod  Open angle glaucoma (OAG) or ocular hypertension (OHT),Approved,"08/07/2017  CRL issued August 7, 2017."
MYOK,MYK-461 - EXPLORER-HCM  Hypertrophic cardiomyopathy (HCM),Phase 3,"08/07/2017  Phase 2 data released August 7, 2017 - primary endpoint met."
GEMP,Gemcabene - ROYAL-1  Heterozygous Familial Hypercholesterolemia (HeFH),Phase 2b,"08/07/2017  Phase 2b data released August 7, 2017 - primary endpoint met but lower than expectations."
ZYNE,ZYN002 - STAR 1  Adult Epilepsy Patients with Refractory Focal Seizures,Phase 2,"08/07/2017  Phase 2 data released August 7, 2017 - endpoints not met."
ACHN,ACH-4471  Paroxysmal nocturnal hemoglobinuria (PNH),Phase 2,"08/08/2017  Phase 2 initiation announced April 6, 2017. Interim data released August 8, 2017."
ESPR,Bempedoic Acid/ Ezetimibe (1002FDC-053)  Hypercholesterolemia,Phase 3,"08/08/2017  Phase 2 data released August 8, 2017. Primary endpoint met."
GLPG,GLPG1690 - FLORA Idiopathic pulmonary fibrosis,Phase 2a,"08/09/2017  Phase 2a top-line data released August 10, 2017. Disease progression halted. Further trials planned."
ABIO,Gencaro - GENETIC-AF trial Chronic Heart Failure,Phase 2b,"08/09/2017  Phase 2b interim analysis August 9, 2018 - trial to continue to completion. Data 1Q 2018."
TGTX,TG-1101 and TGR-1202 - UNITY-NHL study  Diffuse large B-cell lymphoma (DLBCL) cancer,Phase 2/3,"08/10/2017  Phase 2b enrollment commenced June 2016. First interim analysis August 10, 2017 determined that enrollment in TGR-1202 arm will stop but continue in TG-1101 + TGR-1202 arm. TGR-1202 arm replaced by combo of TG-1101, TGR-1202, and bendamustine."
ZYNE,ZYN002 - STOP  Osteoarthritis,Phase 2,"08/14/2017  Phase 2 data released August 14, 2017 - primary endpoint not met. However, company still intends to initiate Phase 3 trial pending discussions with FDA."
OPHT,Fovista  Wet age-related macular degeneration (Wet-AMD),Phase 3,"08/14/2017  Phase 3 data released December 12, 2016 - primary endpoint not met. Data from third trial released August 14, 2017- primary endpoint not met."
GTXI,Enobosarm Breast cancer - advanced AR+ TNBC,Phase 2,"08/14/2017  Noted August 14, 2017 that trial will not continue due to insufficient clinical benefit response (CBR)."
REGN,REGN2222  Respiratory syncytial virus (RSV),Phase 3,"08/14/2017  Phase 3 data released August 14, 2017 - primary endpoint not met."
CVM,Multikine  Head and Neck cancer,Phase 3,"08/14/2017  Initiated Dec 2010. Announced partial clinical hold September 27, 2016. Full clinical hold noted May 2017. Clinical hold released - August 14, 2017."
BMY,CM-214 – Opdivo + Yervoy  First-line Renal cell carcinoma (RCC),Approved,"08/15/2017  Phase 3 data released August 15, 2017 - one of two co-primary endpoints met."
BMY,CM-214 – Opdivo + Yervoy  First-line Renal cell carcinoma (RCC),PDUFA priority review,"08/15/2017  Phase 3 data released August 15, 2017 - one of two co-primary endpoints met."
PFE,Inotuzumab Ozogamicin  Relapsed or Refractory Acute Lymphoblastic Leukemia in Adults,Approved,"08/17/2017  Approval announced August 17, 2017."
AZN,Lynparza - SOLO 2  Second-line ovarian cancer,Approved,"08/17/2017  Approval announced August 17, 2017."
IRWD,DUZALLO (LESINURAD AND ALLOPURINOL)  Hyperuricemia associated with gout,Approved,"08/21/2017  Approval announced August 21, 2017."
RARE,Aceneuramic acid extended release (Ace-ER)  GNE Myopathy,Phase 3,"08/22/2017  Phase 3 data released August 22, 2017 - endpoints not met."
ADMS,ADS-5102  Levodopa-Induced Dyskinesia,Approved,"08/24/2017  Approval announced August 24, 2017."
NVO,Victoza (liraglutide)  Type 2 diabetes,Approved,"08/25/2017  Approval announced August 25, 2017."
KMDA,KamRAB  Prophylaxis of rabies disease,Approved,"08/25/2017  Approval announced August 25, 2017."
XOMA,ACZ885 (canakinumab) CV risk reduction,CRL,"08/27/2017  Data presented August 27, 2017 showed a 77% reduction in lung cancer mortality."
NVS,ACZ885 (canakinumab) CV risk reduction,CRL,"08/27/2017  Data presented August 27, 2017 showed a 77% reduction in lung cancer mortality."
ANTH,Blisibimod  IgA nephropathy,Phase 2,"08/28/2017  Previously announced that Phase 2 primary endpoint not met following interim analysis. Trial to continue as a Phase 2 trial (initially planned as a Phase 2/3 trial). Top-line data released August 28, 2017."
AZN,"Faslodex (fulvestrant)  Monotherapy for expanded use in women with HR+, HER2- advanced breast cancer",Approved,"08/28/2017  Expanded approval announced August 28, 2017."
ACOR,INBRIJA (CVT-301)  OFF episodes of Parkinson’s disease (PD),PDUFA,"08/29/2017  Phase 3 data released February 9, 2017 - primary endpoint met. NDA filing announced June 29, 2017. However, FDA issued a Refuse-To-File letter August 30, 2017 (i.e. NDA not accepted)."
MDCO,Meropenem-vaborbactam  Complicated urinary tract infections (cUTI),Approved,"08/29/2017  Approved August 29, 2017."
MRK,Anacetrapib (MK-0859)  Raising HDL-C and reducing LDL-C,Phase 3,"08/29/2017  Phase 3 data due released June 27, 2017. Primary endpoint met but noted August 29, 2017 that key secondary endpoint was not met."
OTIC,OTO-104 AVERTS-1 Meniere's disease,Phase 3,08/30/2017  Phase 3 data released August 30 failed to meet primary and key secondary endpoints.
NVS,Kymriah (CTL019)  Relapsed/Refractory B-Cell Acute lymphoblastic leukemia,Approved,"08/30/2017  PDUFA date under priority review announced March 29, 2017. Approval announced early - August 30, 2017."
OTIC,OTIVIDEX  Ménière's disease,Phase 3,"08/30/2017  Phase 3 development suspended following failure of AVERTS-1 trial - August 30, 2017."
UTHR,Trevyent  Pulmonary Arterial Hypertension (PAH),NDA Filing,"08/31/2017  Refusal to file Letter (RTF) issued August 31, 2017 in response to NDA filing."
PFE,Mylotarg (gemtuzumab ozogamicin)  Acute myeloid leukemia (AML),Approved,"09/01/2017  Approval announced September 1, 2017."
CLLS,UCART123  Acute myeloid leukemia (AML) and in blastic plasmacytoid dendritic cell neoplasm (BPDCN).,Phase 1,"09/04/2017  Clinical hold announced September 4, 2017 following one fatality in the BPDCN clinical trial (ABC study)."
NVS,Fingolimod  Multiple Sclerosis (MS),Approved,09/05/2017  Phase 3 trial met primary endpoint.
BLPH,INOpulse delivery device  Pulmonary Hypertension associated with COPD (PH-COPD),Phase 2,"09/05/2017  Phase 2 trial met primary endpoint - noted September 5, 2017."
VYGR,VY-AADC01 Advanced Parkinson’s disease,Phase 1b,"09/06/2017  Phase 1b trial ongoing. Interim data released December 7, 2016. Positive Cohort 3 data released September 6, 2017. Phase 2/3 trial to commence late 2017."
VSTM,Duvelisib - DUO  Chronic lymphocytic leukemia (CLL)//Small Lymphocytic Lymphoma (SLL)/Follicular Lymphoma,Approved,"09/06/2017  Phase 3 data released September 6, 2017 - primary endpoint met."
SRPT,Golodirsen - Exon 53  Duchenne muscular dystrophy,NDA Filing,"09/06/2017  Phase 1/2 data released September 6, 2017 - endpoints met."
ALNY,Fitusiran Hemophilia A and B,Phase 2,"09/07/2017  Phase 2 trial suspended dosing due to fatal thrombotic event - noted September 7, 2017."
ABBV,ABT-494  Atopic Dermatitis,Phase 3,"09/07/2017  Phase 2b data released September 7, 2017 - primary endpoint met."
AMGN,Tezepelumab - NAVIGATOR  Asthma,Phase 3,"09/07/2017  Phase 2b data released September 7, 2017 - primary endpoint met."
AZN,Tezepelumab - NAVIGATOR  Asthma,Phase 3,"09/07/2017  Phase 2b data released September 7, 2017 - primary endpoint met."
BMY,CM-214 – Opdivo + Yervoy  First-line Renal cell carcinoma (RCC),Approved,09/07/2017  Phase 3 trial stopped early due to clear efficacy.
NLNK,Indoximod in combination with KEYTRUDA or Opdivo - Indigo301  Melanoma - cancer,Phase 3,"09/07/2017  Updated data released September 7, 2017 showed improvement in Complete Response (CR) to 20% (10/51 patients) compared to CR of 12% (6/51 patients)."
VRNA,RPL554  COPD,Phase 2a,"09/07/2017  Phase 2a positive data released September 7, 2017."
ADMS,ADS-4101  Partial onset seizures in patents with epilepsy,Phase 1b,"09/07/2017  Phase 1b top-line data released September 7, 2017."
CELG,"Durvalumab - FUSION  Relapsed and/or refractory multiple myeloma (RRMM), myelodysplastic syndromes and AML",Phase 1/2,"09/07/2017  Phase 1/2 MM trials placed on clinical hold - September 7, 2017. AML/MDS trials to continue."
KURA,Tipifarnib  Head and neck squamous cell carcinomas (HNSCC),Phase 2,09/07/2017  Phase 2 trial met primary endpoint prior to completion of enrollment.
BMY,CM-214 – Opdivo + Yervoy  First-line Renal cell carcinoma (RCC),PDUFA priority review,09/07/2017  Phase 3 trial stopped early due to clear efficacy.
UTHR,Orenitram Pulmonary arterial hypertension (PAH),Phase 3,"09/08/2017  Phase 3 data due 2H 2018. Independent data monitoring committee (DMC) noted September 8, 2017 that the trial should continue following its interim analysis."
LLY,KEYTRUDA + chemo (KEYNOTE-021)  First-Line Nonsquamous Non-small cell lung cancer (NSCLC),Approved,"09/08/2017  Phase 2 data presented at ESMO 2017 - ORR 57%, PFS 19 months, HR 0.54"
MRK,KEYTRUDA + chemo (KEYNOTE-021)  First-Line Nonsquamous Non-small cell lung cancer (NSCLC),Approved,"09/08/2017  Phase 2 data presented at ESMO 2017 - ORR 57%, PFS 19 months, HR 0.54"
SGEN,Tisotumab Vedotin (innovaTV 204 )  Cervical Cancer,Phase 2,09/08/2017  Phase 1/2 data presented at ESMO 2017. Response rate 32%.
IMDZ,CMB305 Soft tissue sarcomas,Phase 3,"09/08/2017  Phase 2 data at ESMO September 2017. PFS 2.6 months, Disease Control Rate 61%."
BGNE,Pamiparib (BGB-290)  Solid tumors - cancer,Phase 1/2,09/08/2017  Phase 1/2 preliminary data presented at ESMO 2017 - ORR 33%.
AZN,Tagrisso - FLAURA  First-line lung cancer,Approved,"09/09/2017  Late breaker at ESMO September 9, 2017 showed PFS 18.9 months compared with 10.2 SOC."
AZN,Durvalumab (PACIFIC)  Lung cancer,Approved,"09/09/2017  Late breaker at ESMO September 9, 2017 showed PFS 16.8 months v 5.6 months for placebo."
AZN,Tagrisso - FLAURA  First-line lung cancer,PDUFA priority review,"09/09/2017  Late breaker at ESMO September 9, 2017 showed PFS 18.9 months compared with 10.2 SOC."
EXEL,Cabozantinib - CABOSUN  First-Line RCC - cancer,Approved,09/09/2017  Late breaker at ESMO September 2017 showed PFS 8.6 months versus 5.3 months for sunitinib. HR 0.48
BPMC,BLU-554  Advanced hepatocellular carcinoma (HCC),Phase 1,"09/10/2017  Updated Phase 1 presented at ESMO September 10, 2017. 16% ORR in patients with FGFR4-driven HCC. 49% had tumor reduction."
PFE,PF-05280014  Herceptin biosimilar,Phase 3,09/10/2017  Phase 3 data presented at ESMO - risk ratio of 0.940.
BMY,CM-238 – Opdivo (Adjuvant)  Melanoma,Approved,"09/10/2017  Phase 3 interim data released June 6, 2017 - primary endpoint met. Data presented at ESMO September 10, 2017 - HR 0.65 compared to Yervoy."
IDRA,Tilsotolimod + ipilimumab - ILLUMINATE 204  Cancer - melanoma,Phase 2,"09/10/2017  Phase 1/2 data released September 10, 2017. 6/9 disease control with one CR. Phase 3 trial to be initiated 1Q 2018."
FPRX,FP-1039  Mesothelioma cancer,Phase 1b,09/11/2017  Data at ESMO showed ORR 48%.
INO,INO-5150  Prostate cancer,Phase 1b,09/11/2017  Phase 1b interim data presented at ESMO 2017.
ABBV,ABT-494 - SELECT-BEYOND  Rheumatoid arthritis,Phase 3,"09/11/2017  Phase 3 top-line released September 11, 2017. Endpoints met but with two patient deaths."
MRNS,Ganaxolone  CDKL5 disorder,Phase 3,"09/11/2017  Phase 2 top-line data released September 11, 2017."
ACHN,JNJ-4178 Hepatitis C (HCV),Phase 2a,"09/11/2017  Janssen noted September 11, 2017 that no further development planned."
ACHN,JNJ-4178 - OMEGA-1  Hepatitis C (HCV),Phase 2b,"09/11/2017  Janssen noted September 11, 2017 that no further development planned."
PFE,XALKORI (crizotinib)  ALK-positive advanced non-small cell lung cancer(NSCLC),Phase 3,09/11/2017  Phase 3 data presented at ESMO 2017 - Overall survial HR=0.760 (p=0.09)
REGN,Dupixent (dupilumab)  Asthma,Approved,"09/11/2017  Phase 3 data released September 11, 2017 - primary endpoints met. 46% improvement after 52 weeks in 300 mg group. sBLA filing due by end of 2017."
SNY,Dupixent (dupilumab)  Asthma,Approved,"09/11/2017  Phase 3 data released September 11, 2017 - primary endpoints met. 46% improvement after 52 weeks in 300 mg group. sBLA filing due by end of 2017."
ALDX,ADX-102  Dry eye syndrome,Phase 2b,"09/12/2017  Phase 2a data released September 11, 2017 - noted statistically and clinically significant activity."
SAGE,SAGE-547  SRSE,Phase 3,"09/12/2017  Phase 3 data released September 12, 2017 - primary endpoint not met."
FOLD,SD-101 Epidermolysis Bullosa (EB),Phase 3,"09/13/2017  Phase 3 top-line data released September 13, 2017 - endpoints not met."
GTXI,Enobosarm Postmenopausal women with stress urinary incontinence (SUI),Phase 2,"09/13/2017  Phase 2 data presented at International Continence Society Annual Meeting, September 13, 2017. Mean stress leaks decreased by 83% percent from baseline over 12 weeks."
GSK,Shingrix Shingles,Approved,"09/13/2017  Advisory Committee Meeting September 13, 2017 voted 11-0 in favor. PDUFA estimate October 24, 2017."
VNDA,Tradipitant  Atopic dermatitis,Phase 3,"09/13/2017  Phase 2 data released September 13, 2017 - primary endpoint not met."
AGEN,Shingrix Shingles,Approved,"09/13/2017  Advisory Committee Meeting September 13, 2017 voted 11-0 in favor. Shingrix, containing Agenus' adjuvant, QS-21 Stimulon."
AGN,MVASITM (bevacizumab-awwb)  Biosimilar candidate to Avastin (bevacizumab),Approved,"09/14/2017  Approved September 14, 2017."
AMGN,MVASITM (bevacizumab-awwb)  Biosimilar candidate to Avastin (bevacizumab),PDUFA,"09/14/2017  Approved September 14, 2017."
MRTX,Sitravatinib plus nivolumab  Non-small cell lung cancer (NSCLC),Phase 2,09/14/2017  Phase 2 preliminary data noted 3 out of 11 patients experienced a confirmed partial response.
PFE,XTANDI (PROSPER)  Non-metastatic high risk hormone-sensitive prostate cancer,Approved,"09/14/2017  Phase 3 data released September 14, 2017 - primary endpoint met."
AZN,Bydureon Type 2 Diabetes,Phase 3,"09/14/2017  Phase 3 Cardiovascular Outcome trial data released September 14, 2017 - primary efficacy objective of a superior reduction in MACE missed statistical significance (p=0.061)."
NEOS,NT-0201  Attention deficit hyperactivity disorder (ADHD),Approved,"09/15/2017  Approval announced September 15, 2017."
OPTN,XHANCE  Nasal polyps,Approved,"09/17/2017  Approval announced September 18, 2017 (prior to IPO)."
NBRV,Lefamulin - LEAP 1  Moderate to severe Community Acquired Bacterial Pneumonia (CABP),Phase 3,"09/18/2017  Phase 3 data released September 18, 2017 - primary endpoints met."
ABBV,Venclexta (MURANO)  Relapsed or refractory Chronic Lymphocytic Leukemia (CLL),Approved,"09/18/2017  Phase 3 data released September 18, 2017 - PFS primary endpoint met."
RHHBY,Venclexta (MURANO)  Relapsed or refractory Chronic Lymphocytic Leukemia (CLL),Approved,"09/18/2017  Phase 3 data released September 18, 2017 - PFS primary endpoint met."
GSK,Trelegy Ellipta (FF/UMEC/VI)  Chronic obstructive pulmonary disease (COPD),Approved,"09/18/2017  Approval announced September 18, 2017."
INVA,Trelegy Ellipta (FF/UMEC/VI)  Chronic obstructive pulmonary disease (COPD),Approved,"09/18/2017  Approval announced September 18, 2017."
SUPN,SPN-810  Impulsive Aggression in ADHD,Phase 3,"09/18/2017  Noted September 18, 2017 that the lower of the two doses will be discontinued following interim analysis."
PFE,Sutent (Sunitinib)  Renal cell carcinoma (RCC),Approved,"09/19/2017  Advisory Committee Meeting September 19, 2017 voted 6-6 the benefits outweigh risks."
KPTI,Selinexor - SEAL  Dedifferentiated liposarcoma,Phase 2/3,"09/20/2017  Phase 2/3 trial initiated January 2016.Topline data for the Phase 2 portion released September 20, 2017 - PFS HR 0.60. Phase 3 data due 2019."
ALNY,Patisiran Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR,Approved,"09/20/2017  Phase 3 top-line data released September 20, 2017 - all endpoints met. NDA filing due by end of 2017."
SNY,Patisiran Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR,Approved,"09/20/2017  Phase 3 top-line data released September 20, 2017 - all endpoints met. NDA filing due by end of 2017."
TBPH,Closed Triple - IMPACT  COPD,Phase 3,"09/20/2017  Phase 3 data released September 20, 2017 - primary endpoint met."
GSK,Closed Triple - IMPACT  COPD,Phase 3,"09/20/2017  Phase 3 data released September 20, 2017 - primary endpoint met."
INVA,Closed Triple - IMPACT  COPD,Phase 3,"09/20/2017  Phase 3 data released September 20, 2017 - primary endpoint met."
ARAV,"VRS-317 VELOCITY  Growth hormone deficiency, or GHD - pediatric",Phase 3,"09/21/2017  Phase 3 top-line data released September 21, 2017 - primary endpoint not met."
BCRX,RAPIVAB (peramivir injection)  Acute uncomplicated influenza to pediatric patients,Approved,"09/21/2017  Approved September 21, 2017."
BMY,Opdivo (CM-040)  Previously Treated Hepatocellular Carcinoma,Approved,"09/22/2017  Approved under priority review September 22, 2017."
MRK,Keytruda  Cancer - Third-line Gastric or Gastroesophageal Junction Adenocarcinoma,Approved,"09/22/2017  Approved September 22, 2017 - under priority review."
JNJ,Sirukumab Rheumatoid arthritis,CRL,"09/22/2017  CRL issued September 22, 2017. Advisory Committee Meeting August 2, 2017 voted 12-1 against that safety data is adequate to support approval. 13-0 in favor of efficacy."
EXEL,Esaxerenone (CS-3150)  Essential hypertension,Phase 3,"09/24/2017  Phase 3 trial met primary endpoint - September 24, 2017. Japanese regulatory filing due 1Q 2018."
GNCA,GEN-003  Genital herpes,-,"09/25/2017  Announced September 25, 2017 that development will be ceased."
PRQR,QR-010 Cystic Fibrosis,Phase 1b,"09/25/2017  Phase 1b top-line data released September 25, 2017. FEV levels not significant across four doses. One of four doses showed significance in subgroup."
IPCI,Rexista  Pain relief,CRL,"09/25/2017  CRL issued September 25, 2017. Advisory Committee Meeting July 26, 2017 had previously voted 22-1 against recommending approval."
ABUS,ARB-1467  Hepatitis B (HBV),Phase 2,"09/25/2017  Phase 2 Cohort 4 data released September 25, 2017 with detailed data due at AASLD in October 2017."
FCSC,FCX-007  Recessive dystrophic epidermolysis bullosa,Phase 1/2,"09/26/2017  Phase 1/2 initial data from three patients released September 26, 2017."
AXON,Intepirdine - MINDSET  Alzheimer's disease,Phase 3,"09/26/2017  Phase 3 data released September 26, 2017 - primary endpoints not met."
AZRX,MS1819-SD Exocrine pancreatic insufficiency (EPI) caused by chronic pancreatitis (CP),Phase 2,"09/27/2017  Phase 2a data from first six patients released September 27, 2017. CFA improvement of 21% noted in highest dose."
ZYNE,ZYN002  Fragile X syndrome,Phase 3,"09/28/2017  Phase 2 data released September 28, 2017. Company noted data were positive with primary endpoint met. Note though that trial was uncontrolled/open-label."
PRTA,PRX003  Psoriatic Arthritis,Phase 1b,"09/28/2017  Phase 1b data released September 28, 2017 - insufficient meaningful clinical effect for further development."
PTCT,Ataluren  Duchenne muscular dystrophy caused by nonsense mutations (nmDMD),CRL,"09/28/2017  Received a Refusal to File letter for their NDA Filing - February 23 2016. Appeal rejected October 17, 2016. Decision made to resubmit NDA during 1Q 2017 under protest. New PDUFA date October 24, 2017. Advisory Committee Meeting September 28, 2017 voted that although it is possible that ataluren may be effective, the data are inconclusive, and more work would be needed to establish whether ataluren is effective."
ZGNX,ZX008 - (Study 1)  Dravet syndrom,Phase 3,"09/29/2017  Phase 3 data released September 29, 2017 - primary endpoint met."
NVO,Fiasp (fast-acting insulin aspart)  Type 1 and type 2 diabetes,Approved,"09/29/2017  Approved September 29, 2017."
BHVN,BHV-4157 Trigriluzole  Spinocerebellar Ataxia,Phase 2/3,"10/02/2017  Phase 2b/3 negative top-line data released October 2, 2017."
MCRB,SER-287 Mild-to-Moderate Ulcerative Colitis,Phase 1b,"10/02/2017  Phase 1b data released October 2, 2017 - did not perform better than placebo."
RDHL,BEKINDA IBS-D,Phase 2,"10/03/2017  Phase 2 top-line data released October 3, 2017 - primary endpoint met (borderline) - p=0.05."
AGN,Botox Forehead lines,Approved,"10/03/2017  Approval (third indication) announced October 3, 2017."
RIGL,Fostamatinib  Autoimmune hemolytic anemia (AIHA),Phase 2,"10/03/2017  Phase 2 data from Stage 1 of trial released October 3, 2017 - sufficient efficacy shown to progress to Stage 2."
CATB,Edasalonexent (CAT-1004)  Duchenne muscular dystrophy (DMD),Phase 3,"10/04/2017  Phase 1/2 data from open-label extension trial presented October 4, 2017 - deemed sufficient to proceed to Phase 3 development."
FOLD,ATB200  Pompe Disease,Phase 1/2,"10/04/2017  Phase 1/2 additional data released February 15, 2017. Further data released May 15, 2017 and October 4, 2017 - update expected 1H 2018 regarding regulatory path forward."
MTFB,Iclaprim - REVIVE-2  Acute bacterial skin and skin structure infections (ABSSSI),PDUFA priority review,"10/04/2017  Phase 3 data released October 4, 2017 - primary endpoint met. NDA filing due 1Q 2018."
CAPR,CAP-1002 HOPE-Duchenne  Duchenne Muscular Dystrophy (DMD),Phase 2,"10/04/2017  Phase 1/2 data to be presented October 6, 2017."
CAPR,CAP-1002 HOPE-Duchenne  Duchenne Muscular Dystrophy (DMD),Phase 1/2,"10/04/2017  Phase 1/2 data to be presented October 6, 2017."
LLY,"Abemaciclib - MONARCH 1 and 2  Second-line hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer and HR+, HER2- breast cancer",Approved,"10/04/2017  Approved October 4, 2017."
BLUE,Lenti-D - Starbeam  Childhood cerebral adrenoleukodystrophy (CCALD),Phase 2/3,"10/04/2017  Phase 2/3 trial initiated October 2013. Interim top-line data released June 26, 2017. Further data released October 4, 2017 - 88% free of free of major functional disabilities."
MYL,Glatiramer Acetate Injection - Generic for Copaxone  Multiple sclerosis (MS),Approved,"10/04/2017  Approval announced October 4, 2017."
NBIX,INGREZZA  Tardive dyskinesia,Approved,"10/05/2017  Approval for sNDA 80 mg capsules announced October 5, 2017."
LIFE,Resolaris  Early onset facioscapulohumeral muscular dystrophy (FSHD),Phase 1/2,"10/05/2017  Phase 1/2 final data presented October 5, 2017 at the International Annual Congress of the World Muscle Society (WMS)."
FLXN,Zilretta - FX006  Osteoarthritis of the knee,Approved,"10/06/2017  Approval announced October 6, 2017."
SRPT,Golodirsen - Exon 53  Duchenne muscular dystrophy,NDA Filing,"10/07/2017  Phase 1/2 late breaking poster presented at World Muscle Society October 7, 2017."
MYL,MYL-1401H  Neulasta biosimilar,Approved,"10/10/2017  CRL issued October 10, 2017."
ANAB,ANB020 - etokimab  Moderate-to-severe adult atopic dermatitis,Phase 2b,"10/10/2017  Phase 2a positive data released October 10, 2017"
LLY,Abemaciclib - JUNIPER  Thrid line KRAS mutation positive Non-small cell lung cancer (NSCLC),Phase 3,"10/10/2017  Phase 3 data released October 10, 2017 - primary endpoint not met"
ARDX,Tenapanor (T3MPO-2)  Constipation-predominant irritable bowel syndrome (IBS-C),PDUFA,"10/11/2017  Phase 3 data released October 11, 2017. Primary endpoint met but with relatively high rates of diarrhea."
MRK,Anacetrapib (MK-0859)  Raising HDL-C and reducing LDL-C,Phase 3,"10/11/2017  Phase 3 data due released June 27, 2017. Primary endpoint met but noted August 29, 2017 that key secondary endpoint was not met. Announced October 11, 2017 that it will not seek regulatory approval."
ATRS,XYOSTED (testosterone enanthate)  Testosterone deficiency,Approved,"10/12/2017  PDUFA date October 20, 2017. Noted October 12, 2017 that the FDA has identified deficiencies with the NDA."
ONCE,Luxturna (voretigene neparvovec)  Inherited retinal dystrophies,Approved,"10/12/2017  Advisory Committee Meeting October 12, 2017 voted 16-0 in favor of recommending approval."
ACRX,DSUVIA (ARX-04)  Moderate-to-severe acute pain following a surgical procedure,Approved,"10/12/2017  CRL issued October 12, 2017."
PFE,LYRICA (pregabalin) Postherpetic neuralgia (PHN),Approved,"10/12/2017  Approval announced October 12, 2017."
AERI,Rhopressa  Glaucoma,Approved,"10/13/2017  PDUFA date February 28, 2018. Advisory Committee meeting October 13, 2017 voted 9-1 in favor that efficacy outweighs safety risks,"
JNJ,STELARA (USTEKINUMAB)  Plaque psoriasis,Approved,"10/13/2017  Approval announced October 13, 2017."
EXEL,Cabozantinib (CELESTIAL)  Advanced hepatocellular cancer (HCC),Phase 3,"10/16/2017  Phase 3 data released October 16, 2017 - primary endpoint met. sNDA filing due 1Q 2018."
FENC,Pedmark (sodium thiosulfate) Cisplatin-induced ototoxicity,Phase 3,"10/16/2017  Phase 3 trial met primary endpoint - full data released October 16, 2017."
SPPI,Poziotinib  Non-small cell lung cancer (NSCLC),Phase 2,"10/18/2017  Phase 2 initiation announced March 30, 2017 with preliminary data due released October 18, 2017 - ORR 73%."
RXDX,STARTRK-2 entrectinib  Solid tumors - cancer,Phase 2,"10/18/2017  Updated promising data released October 18, 2017.ORR 69%, PFS 29.6 months."
NVO,Semaglutide  Type 2 diabetes,Approved,"10/18/2017  Advisory Committee Meeting October 18, 2017 voted 16-0 in favor."
GILD,Yescarta (axicabtagene ciloleucel)  Refractory Non-Hodgkin's Lymphoma (NHL) - cancer,Phase 2,"10/18/2017  Approved October 18, 2017 (acquired from Kite Pharma)."
CRBP,Lenabasum (resunab)  Dermatomyositis,Phase 2,"10/19/2017  Phase 2 data released October 19, 2017 - primary endpoint met."
DRRX,POSIMIR - PERSIST 3  Post-operative pain relief,Phase 3,"10/19/2017  CRL Feb 12 2014. Phase 3 commenced November 2015 in response to CRL. Noted October 19, 2017 that primary endpoint was not met."
CELG,GED-0301 (CD-002)  Crohn’s disease,Phase 3,"10/19/2017  Phase 3 trial to discontinue due to lack of efficacy - noted October 19, 2017."
ATRS,XYOSTED (testosterone enanthate)  Testosterone deficiency,Approved,"10/20/2017  CRL issued October 20, 2017."
JNJ,SIMPONI ARIA  Psoriatic arthritis (PsA),Approved,"10/20/2017  Approval announced October 20, 2017."
DBVT,Viaskin Peanut (PEPITES)  Peanut allergy,Phase 3,"10/20/2017  Phase 3 top-line data released October 20, 2017 - primary endpoint not met."
AGEN,Shingrix Shingles,Approved,"10/20/2017  Approval announced October 20, 2017."
ALXN,Eculizumab  Refractory generalized myasthenia gravis (gMG),Approved,"10/23/2017  Approval announced October 23, 2017."
ENTA,EDP-305  Non-alcoholic steatohepatitis (NASH),Phase 2,"10/23/2017  Phase 1 data at AASLD meeting - October 23, 2017."
GBT,GBT440  Hypoxemia in patients with idiopathic pulmonary fibrosis (IPF) who are on supplemental oxygen at rest,Phase 2a,"10/23/2017  Phase 2a discontinuation announced October 23, 2017 due to lack of efficacy."
GILD,GS-0976  Nonalcoholic steatohepatitis (NASH),Phase 2,"10/24/2017  Phase 2 data released October 24, 2017. Positive high dose data, low dose negative."
VRTX,Tezacaftor (VX-661) / ivacaftor  Cystic fibrosis - one copy of the F508del mutation and a second mutation that results in a gating mutation,Phase 3,"10/25/2017  Phase 3 data released October 25, 2017 - primary endpoint not met."
PTCT,Ataluren  Duchenne muscular dystrophy caused by nonsense mutations (nmDMD),CRL,"10/25/2017  CRL issued October 25, 2017."
ABBV,Risankizumab  Psoriasis,Phase 3,"10/26/2017  Phase 3 data released October 26, 2017 - primary endpoints met."
ABBV,Risankizumab  Psoriasis,BLA Filing,"10/26/2017  Phase 3 data released October 26, 2017 - primary endpoints met."
TSRO,"Rolapitant - intravenous (IV)  Prevention of chemotherapy induced nausea and vomiting, or CINV in HEC patients",Approved,"10/26/2017  CRL January 11 2017. FDA Approval announced October 25, 2017 following resubmission."
EGRX,"PEMFEXY,  Nonsquamous Non-Small Cell Lung Cancer (NSCLC) and Mesothelioma",Approved,"10/27/2017  Tentative approval announced October 27, 2017. Full approval pending patent litigation with Eli Lilly."
CELG,Ozanimod - SUNBEAM  Relapsing Multiple Sclerosis,Phase 3,"10/28/2017  Phase 3 data due released Feb 17, 2017 - primary endpoint met, disability endpoint not met. Full data released October 27, 2017 at ECTRIMS meeting."
NVS,Fingolimod  Multiple Sclerosis (MS),Approved,"10/28/2017  Phase 3 trial met primary endpoint - data released at ECTRIMS-ACTRIMS meeting October 28, 2017."
MNOV,MN-166  Progressive multiple sclerosis (progressive MS),Phase 2b,"10/28/2017  Phase 2b top-line data released October 28, 2017 at Joint ECTRIMS – ACTRIMS meeting. Primary endpoint met."
CELG,Ozanimod - RADIANCE  Relapsing Multiple Sclerosis,Phase 3,"10/28/2017  Phase 3 data due released May 22, 2017 - primary endpoint met, disability endpoint not met. Full data released October 28, 2017 at ECTRIMS meeting."
JNJ,XARELTO (rivaroxaban)  Reduce the Risk of Recurrent Venous Thromboembolism (VTE),Approved,"10/30/2017  Approval announced October 30, 2017."
AZN,Acalabrutinib  Relapsed or Refractory Mantle Cell Lymphoma,Approved,"10/31/2017  Priority Review announced August 2, 2017. Approval announced October 31, 2017."
STML,SL-401  Blastic plasmacytoid dendritic cell neoplasm (BPDCN) cancer,PDUFA priority review,"10/31/2017  Top-line data from Stage 3 met primary endpoint - October 31, 2017 CR rate of 54% (7/13), with detailed data at ASH 2017."
RYTM,Setmelanotide  Bardet-Biedl Syndrome,Phase 2,"10/31/2017  Preliminary Phase 2 data due released October 31, 2017. 4 of 5 patients showed weight loss of 10-12%."
AZN,"Tralokinumab (STRATOS2)  Severe, uncontrolled asthma",Phase 3,"11/01/2017  Phase 3 data released November 1, 2017 - primary endpoint not met."
KMDA,Alpha-1 Antitrypsin (AAT)  Pediatric patients newly diagnosed with type 1 diabetes,Phase 2,"11/01/2017  Phase 2 data released November 3, 2017. No significant treatment effect noted overall."
BHC,Latanoprostene bunod  Open angle glaucoma (OAG) or ocular hypertension (OHT),Approved,"11/02/2017  Approval announced November 2, 2017."
ALNY,Patisiran Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR,Approved,"11/02/2017  Positive full data released November 2, 2017."
SNY,Patisiran Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR,Approved,"11/02/2017  Positive full data released November 2, 2017."
IONS,Inotersen (IONIS-TTRRx)  NEURO-TTR - familial amyloid polyneuropathy (FAP).,Approved,"11/02/2017  Full data presented November 2, 2017."
PTCT,Inotersen (IONIS-TTRRx)  NEURO-TTR - familial amyloid polyneuropathy (FAP).,Approved,"11/02/2017  Full data presented November 2, 2017."
AKCA,Inotersen (IONIS-TTRRx)  NEURO-TTR - familial amyloid polyneuropathy (FAP).,Approved,"11/02/2017  Full data presented November 2, 2017."
XNCR,XmAb5871  IgG4-Related Disease (IgG4-RD),Phase 2,"11/04/2017  Phase 2 final data presented November 4, 2017."
CLLS,UCART123  Acute myeloid leukemia (AML) and in blastic plasmacytoid dendritic cell neoplasm (BPDCN).,Phase 1,"11/06/2017  Release of clinical hold announced November 6, 2017."
KERX,Auryxia  Iron deficiency anemia in non-dialysis dependent CKD patients,Approved,"11/07/2017  sNDA FDA Approval announced November 7, 2017."
COLL,Xtampza ER (oxycodone) Severe pain,Approved,"11/07/2017  Approval announced November 7, 2017."
PFE,Staphylococcus aureus vaccine,PDUFA,"11/07/2017  Advisory Committee Meeting held November 7, 2017. No votes cast."
NVS,LEE011: MONALEESA-7  Breast cancer - (pre-menopausal),Phase 3,"11/08/2017  Phase 3 trial met primary endpoint - November 8, 2017."
ONCS,ImmunoPulse IL-12  Melanoma,Phase 2,"11/08/2017  SITC presentation - November 10, 2017. Updated data showed 57% PFS rate at 15 months."
OTIC,OTIVIDEX  Ménière's disease,Phase 3,"11/08/2017  Company noted that Phase 3 development suspended following failure of AVERTS-1 trial - August 30, 2017. However, company announced November 8, 2017 that the trial actually met the primary endpoint."
SGEN,ADCETRIS  Cancer - ALCANZA trial for relapsed CD30-positive cutaneous T-cell lymphoma,Approved,"11/09/2017  Approval announced November 9, 2017."
ADAP,NY-ESO T-cell therapy  Synovial sarcoma - cancer,Phase 1/2,"11/09/2017  Oral presentation at CTOS November 9, 2017."
HRTX,CINVANTI (HTX-019)  Prevention of chemotherapy-induced nausea and vomiting (CINV),Approved,"11/09/2017  Approval announced November 9, 2017."
IOVA,LN-144  Refractory metastatic melanoma,Phase 2,"11/09/2017  Late breaker at SITC November 10, 2017 showed a DCR of 78%."
ADAP,NY-ESO T-cell therapy  Myxoid round cell liposarcoma (MRCLS),Phase 1/2,"11/09/2017  Poster at CTOS November 9, 2017."
MRK,Letermovir  Cytomegalovirus (CMV) Infection,Approved,"11/09/2017  Approval announced November 9, 2017."
SAGE,Brexanolone - SAGE-547 (202C)  Postpartum Depression - moderate,PDUFA priority review,"11/09/2017  Phase 3 data released November 9, 2017. Primary endpoint met."
DVAX,HEPLISAV-B Hepatitis B,Approved,"11/09/2017  Final approval announced November 9, 2017"
BMY,Sprycel (dasatinib)  Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia,Approved,"11/10/2017  Approval announced November 10, 2017."
INO,MEDI0457 HPV-associated squamous cell carcinoma of the head & neck (SCCHN),Phase 1/2,"11/10/2017  Presentation at SITC Meeting - November 10, 2017."
AZN,MEDI0457 HPV-associated squamous cell carcinoma of the head & neck (SCCHN),Phase 1/2,"11/10/2017  Presentation at SITC Meeting - November 10, 2017."
FATE,FATE-NK100  Acute myelogenous leukemia (AML),Phase 1,"11/10/2017  Phase 1 initial data released at SITC November 10, 2017."
BMY,BMS-986205 and Nivolumab  Advanced tumors,Phase 1/2,"11/10/2017  Late-breaker at SITC November 11, 2017. ORR 14-32%."
NKTR,"NKTR-214 + OPDIVO (nivolumab) - PIVOT-02  Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers",Phase 1/2,11/12/2017  Phase 1/2 promising data presented at SITC November 2017. 63% response rate for melanoma patients. 46% for Renal Cell Carcinoma.
BMY,"NKTR-214 + OPDIVO (nivolumab) - PIVOT-02  Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers",Phase 1/2,11/12/2017  Phase 1/2 promising data presented at SITC November 2017. 63% response rate for melanoma patients. 46% for Renal Cell Carcinoma.
MRTX,Glesatinib (MGCD265)  Non-small cell lung cancer (NSCLC) patients with driver alterations in MET,Phase 2,"11/13/2017  Noted November 13, 2017 that further development has been suspended."
AGN,Cariprazine  Maintenance Treatment of Schizophrenia,Approved,"11/13/2017  Approval announced November 13, 2017."
AZN,"Benralizumab  Severe, uncontrolled asthma",Approved,"11/14/2017  Approval announced November 14, 2017."
ACHN,ACH-4471  C3 glomerulopathy (C3G),Phase 2,"11/14/2017  Phase 2 interim data released November 14, 2017."
ACOR,Tozadenant  Parkinson’s disease (PD),Phase 3,"11/15/2017  Phase 3 data due 1Q 2018. Noted November 15, 2017 seven cases of sepsis, five of which were fatal."
RARE,MEPSEVII (vestronidase alfa)  Mucopolysaccharidosis 7 (MPS 7),Approved,"11/15/2017  Approval announced November 15, 2017."
PFE,Sutent (Sunitinib)  Renal cell carcinoma (RCC),Approved,"11/16/2017  Approval announced 16 November, 2017."
TBPH,Closed Triple  COPD,Approved,"11/18/2017  Approval announced September 19, 2017."
GSK,Closed Triple  COPD,Approved,"11/18/2017  Approval announced September 19, 2017."
INVA,Closed Triple  COPD,Approved,"11/18/2017  Approval announced September 19, 2017."
DBVT,Viaskin Peanut (REALISE)  Peanut allergy,Phase 3,"11/20/2017  Phase 3 positive safety data released November 20, 2017."
GLPG,GLPG2222 - ALBATROSS  Cystic fibrosis (CF),Phase 2a,"11/20/2017  Phase 2a postive top-line data released November 20, 2017."
ARDX,RDX7675  Hyperkalemia,Phase 2,"11/21/2017  Onset of action trial data released November 21, 2017 - noted significantly reduced serum potassium in patients. Development to be discontinued."
GSK,Dolutegravir + rilpivirine  HIV,Approved,"11/21/2017  Approval announced November 21, 2017."
CYTK,Tirasemtiv - VITALITY  Amyotrophic lateral sclerosis (ALS),Phase 3,"11/21/2017  Phase 3 data released November 21, 2017 - primary endpoint not met."
NKTR,Inhaled Amikacin Solution (BAY41-6551T)  Gram-Negative Pneumonia (INHALE 1),Phase 3,"11/24/2017  Phase 3 data released November 24, 2017. Endpoints not met."
REGN,EYLEA + nesvacumab  Diabetic macular edema (DME),Phase 2,"11/27/2017  Phase 2 data released November 27, 2017 - insufficient efficacy shown to warrant further development."
CPRX,Firdapse  Lambert-Easton Myasthenic Syndrome (LEMS),PDUFA priority review,"11/27/2017  Refusal to file letter reported on February 17, 2016. Data from second Phase 3 trial released November 27, 2017 - endpoints met."
VKTX,VK5211  Acute Hip Fracture,Phase 2,"11/28/2017  Phase 2 trial met endpoints - November 28, 2017."
EARS,AM-111 HEALOS  Acute inner ear hearing loss,Phase 3,"11/28/2017  Phase 3 HEALOS trial did not meet primary endpoint - November 28, 2017."
PFE,Avelumab  Gastric cancer,Phase 3,"11/28/2017  Phase 3 data released November 28, 2017 - primary endpoint not met."
EARS,AM-111 ASSENT  Acute inner ear hearing loss,Phase 3,"11/28/2017  Phase 3 ASSENT trial terminated - November 28, 2017."
EGLT,Egalet-002  Moderate to severe chronic pain,Phase 3,"11/28/2017  Phase 3 trial met primary endpoint - November 28, 2017."
BMY,CM-078 – Opdivo  Second-line Non-small cell lung cancer (NSCLC),Phase 3,"11/30/2017  Phase 3 trial met primary endpoint - November 30, 2017."
AMGN,Repatha  Cardiovascular disease,Approved,"12/01/2017  Approval announced December 1, 2017."
MYL,Ogivri - trastuzumab biosimilar  Trastuzumab biosimilar,Approved,"12/01/2017  Approval announced December 1, 2017."
LLY,Taltz  Psoriatic Arthritis,Approved,"12/01/2017  Approval announced December 1, 2017."
RARX,RA101495  Paroxysmal nocturnal hemoglobinuria (PNH),Phase 2,"12/04/2017  Phase 2 data released December 4, 2017. Primary endpoint met but with competitive concerns."
IRWD,IW-1973  Diabetic nephropathy,Phase 2,"12/04/2017  Phase 2a data released December 4, 2017 - Noted data encouraging but with one serious adverse event."
GALT,GR-MD-02 Non-alcoholic steatohepatitis (NASH) with cirrhosis,Phase 2b,"12/05/2017  Phase 2 top-line data released December 5, 2017 did not meet primary endpoint across all patients - noted subgroup improvement."
RDHL,RIZAPORT (RHB-103)  Migraine,NDA Filing,"12/05/2017  Noted December 5, 2017 that an Incomplete Response Letter has been received from the FDA and termination of license agreement with IntelGenx Corp."
RVNC,"RT002 - SAKURA 1, 2 and 3  Moderate to severe glabellar (frown) lines",Phase 3,"12/05/2017  Phase 3 data released December 5, 2017 - endpoints met."
NVO,Semaglutide  Type 2 diabetes,Approved,"12/05/2017  Approval announced December 5, 2017."
MDGL,MGL-3196 Non-alcoholic steatohepatitis (NASH),Phase 2,"12/06/2017  Phase 2 top-line data released December 6, 2017 - primary endpoint met."
IMMU,SACTUZUMAB GOVITECAN (IMMU-132) Cancer - metastatic triple-negative breast cancer,PDUFA priority review,"12/06/2017  Phase 3 trial initiated October 2017. Phase 2 updated data released December 6, 2017 - ORR 31%."
SAGE,SAGE-217  Major Depressive Disorder (MDD),Phase 3,"12/07/2017  Phase 2 initiation announced December 19, 2016. Top-line data released December 7, 2017 - primary endpoint met."
AKTX,Coversin  Paroxysmal nocturnal hemoglobinuria (PNH),Phase 2,"12/08/2017  Phase 2 further update December 8, 2017 noted that three additional patients together with earlier five patients met primary endpoint."
AKTX,Coversin  Paroxysmal nocturnal hemoglobinuria (PNH),Phase 3,"12/08/2017  Phase 2 further update December 8, 2017 noted that three additional patients together with earlier five patients met primary endpoint."
LLY,Ramucirumab - RAINFALL  First-line gastric cancer,Phase 3,12/08/2017  Phase 3 PFS data met primary endpoint but overall survival not improved. Will not seek regulatory approval.
PFE,Talazoparib BRCA-mutated breast cancer,Approved,"12/08/2017  Phase 3 data presented December 8, 2017. HR 0.54."
BMRN,Valoctocogene roxaparvovec (BMN 270)  Hemophilia A,Phase 3,12/09/2017  Phase 1/2 updated data released at ASH 2017. Noted median annualized bleed rates dropped to zero after four weeks among six patients.
VSTM,Duvelisib - DUO  Chronic lymphocytic leukemia (CLL)//Small Lymphocytic Lymphoma (SLL)/Follicular Lymphoma,Approved,"12/10/2017  Phase 3 data released September 6, 2017 - PFS primary endpoint met. Noted at ASH 2017 that OS secondary endpoint not met."
KURA,Tipifarnib  Chronic myelomonocytic leukemia (CMML) - cancer,Phase 2,12/10/2017  Preliminary data at ASH 2017 - ORR 33% among 9 patients.
IMDZ,G100 Follicular non-Hodgkin Lymphoma - cancer,Phase 2,12/10/2017  Phase 2 data ASH 2017 - ORR 39%.
BLUE,LentiGlobin - HGB-206  Sickle disease,Phase 1/2,12/10/2017  Data at ASH 2017 showed 51% and 28% anti-sickling HbAT87Q at six and nine months for two patients.
BLUE,bb2121  Relapsed/refractory multiple myeloma,Phase 1,"12/10/2017  Phase 1 data released at ASH 2017 - ORR 94%, CR 56%."
CELG,bb2121  Relapsed/refractory multiple myeloma,Phase 1,"12/10/2017  Phase 1 data released at ASH 2017 - ORR 94%, CR 56%."
BLUE,HGB-205  Transfusion-Dependent β-Thalassemia (TDT) and Severe Sickle Cell Disease (SCD),Phase 1/2,12/11/2017  Phase 1/2 data presented at ASH 2017 - noted 2/3 patients showed meaningful clinical improvement.
SGEN,ADCETRIS and Opdivo CM-812  Relapsed Hodgkin Lymphoma,Phase 3,12/11/2017  Data from Phase 1/2 at ASH 2017 showed a 83% ORR and 62% CR.
BMY,ADCETRIS and Opdivo CM-812  Relapsed Hodgkin Lymphoma,Phase 3,12/11/2017  Data from Phase 1/2 at ASH 2017 showed a 83% ORR and 62% CR.
CELG,Lico-cel (CD-19 JCAR017) - TRANSCEND  r/r B cell non-Hodgkin lymphoma - cancer,Phase 1/2,"12/11/2017  Phase 1 updated data presented at ASH 2017 - 74% ORR, 68% CR."
FBIO,CAEL‐101  AL amyloidosis,Phase 2/3,12/11/2017  Phase 1/2 data at ASH December showed 67% response rate.
TGTX,Umbralisib (TGR-1202) + Pembrolizumab + Ublituximab (TG-1101)  Relapsed or refractory Chronic Lymphocytic Leukemia (CLL),Phase 1/2,12/11/2017  Phase 1/2 poster at ASH 2017 showed 78% (7 of 9) ORR.
PTI,PTI-428  Cystic fibrosis,Phase 2,"12/11/2017  Phase 2 28-day data released December 11, 2017 - showed improvements in FEV1 of 5.2%."
RETA,Omaveloxolone - REVEAL  Metastatic melanoma,Phase 1/2,"12/11/2017  Phase 1b data released December 11, 2017 - 27% ORR."
ARGX,ARGX-110  Acute myeloid leukemia (AML),Phase 1,12/11/2017  Phase 1/2 interim data at ASH 2017 - all six patients showed response including 3/6 with complete remission.
AFMD,AFM13 with Keytruda  Hodgkin Lymphoma - Cancer,Phase 1b,12/11/2017  Phase 1b poster at ASH 2017.ORR 83% (5/6).
KDMN,KD025 - ROCKstar (KD025-213)  Chronic graft-versus-host disease (cGVHD),Phase 2,12/11/2017  Updated data at ASH December 2017 showed ORR 63%.
ARGX,ARGX-110  Relapsed/refractory cutaneous T-cell lymphoma (CTCL),Phase 2,"12/11/2017  Phase 2 interim data ASH 2017 - of 22 patients 1 CR, 2 PRs, 10 SD."
GILD,Axicabtagene ciloleucel - KTE-C19 (ZUMA-3) Adult patients with r/r ALL - cancer,Phase 1/2,12/11/2017  Complete remission 73%. Data released at ASH 2017 showed complete remission of 71%.
SYRS,SY-1425  Relapsed or refractory Acute myeloid leukemia (AML) and relapsed high-risk Myelodysplastic Syndrome (MDS) - cancer,Phase 2,12/11/2017  Phase 2 data at ASH showed 1 complete response from 48 patients.
XENT,SINUVA Sinus Implant  Recurrent sinus obstruction,Approved,"12/11/2017  Approval announced December 11, 2017."
ARGX,Efgartigimod  Myasthenia gravis (MG),Phase 3,"12/11/2017  Phase 2 data released December 11, 2017 - 75% of patients showed meaningful improvement."
SNY,Admelog (insulin lispro injection)  Diabetes,Approved,"12/11/2017  Approval announced December 11, 2017."
ADAP,NY-ESO T-cell therapy  Myeloma,Phase 1/2,12/11/2017  Updated data at ASH December 2017 - Overall response rate (ORR) at 100 days and one year were 76% and 44%.
TRIL,"TTI-621-01  Diffuse Large B-cell Lymphoma (DLBCL), Cutaneous T-cell lymphoma (CTCL)",Phase 1,12/11/2017  Phase 1a/b updated data released at ASH 2017 - 5/18 objective response rate.
ONCE,SPK-8011  Hemophilia A,Phase 1/2,12/11/2017  Further data due at ASH 2017 showed promising reductions in bleeding shown but inconsistent levels of Factor VII.
GSK,Mepolizumab  Eosinophilic Granulomatosis with Polyangiitis (EGPA),Approved,"12/12/2017  Approval announced December 12, 2017."
GLYC,Uproleselan (GMI-1271)  Acute myeloid leukemia (AML) newly diagnosed and refractory - cancer,Phase 1/2,12/12/2017  Phase 3 trial to be initiated mid-2018. Phase 1/2 data released at ASH 2017 showed clinical remission (CR+CRi) was 43%. Median overall survival was 9.4 months.
STML,SL-401  Cancer- adult relapsed or refractory acute myeloid leukemia (AML),Phase 2,12/13/2017  Phase 2 ongoing. ASH 2017 data showed 5/16 patients relapse-free for at least 5+ months including 2 ongoing.
STML,SL-401  Blastic plasmacytoid dendritic cell neoplasm (BPDCN) cancer,PDUFA priority review,"12/13/2017  Phase 2 enrollment completed - noted March 23, 2017. Update on patients enrolled in Stages 1 and 2 at EHA June 23, 2017. Top-line data from Stage 3 met primary endpoint - October 31, 2017. ASH data showed 54% (7/13) CR + CRc rate + 77% ORR."
GERN,Imetelstat - IMerge Study  Myelodysplastic syndromes,Phase 2/3,"12/13/2017  Poster at ASH for patients in Part 1 of the trial - December 11, 2017. 38% (12/32) of patients achieved ≥8-week RBC TI."
JNJ,Imetelstat - IMerge Study  Myelodysplastic syndromes,Phase 2/3,"12/13/2017  Poster at ASH for patients in Part 1 of the trial - December 11, 2017. 38% (12/32) of patients achieved ≥8-week RBC TI."
CLLS,UCART123  Acute myeloid leukemia (AML) and in blastic plasmacytoid dendritic cell neoplasm (BPDCN).,Phase 1,12/13/2017  ASH 2017 data showed five out seven patients treated achieved molecular remission.
STML,SL-401  High Risk Myeloproliferative Neoplasms,Phase 2,12/13/2017  ASH 2017 data showed 65% (11/17 evaluable) of CMML and MF patients had spleen reductions >25%.
PFE,IXIFI  Remicade (infliximab) biosimilar,Approved,"12/13/2017  Approval announced December 13, 2017."
JNJ,DARZALEX (Daratumumab) - ALCYONE  Frontline multiple myeloma (non-transplant),Approved,12/13/2017  LBA at ASH 2017 - HR 0.50.
ADRO,CRS-207 with pembrolizumab  Mesothelioma - cancer,Phase 2,"12/13/2017  Development to be discontinued - December 12, 2017."
MRK,Keytruda  Cancer - Third-line Gastric or Gastroesophageal Junction Adenocarcinoma,Approved,"12/14/2017  Approved Sept. 22, 2017 under accelerated approval in patients undergoing third-line treatment following data from Phase 2 Keynote-59 trial. Phase 3 data released December 14, 2017 in patients undergoing second-line treatment, did not meet the primary endpoint of overall survival, nor did it show a significant improvement in PFS."
AMPE,Ampion  Osteoarthritis of the Knee,Phase 3,12/14/2017  Third Phase 3 trial met primary endpoint.
PFE,Xeljanz  Psoriatic arthritis,Phase 3,"12/14/2017  Approval announced December 14, 2017."
EGLT,ARYMO ER  Abuse-Deterrent Morphine,Approved,"12/15/2017  Approved January 9, 2017. Tentative approval for label expansion announced December 15, 2017. Final approval expected October 2, 2018."
ACRS,ESKATA (hydrogen peroxide)  Seborrheic keratosis (SK),Approved,"12/15/2017  Approval announced December 15, 2017."
AERI,Rhopressa  Glaucoma,Approved,"12/18/2017  PDUFA date February 28, 2018. Approved ahead of schedule - December 18, 2017."
RXII,RXI-109-1402  Connective tissue growth factor (CTGF),Phase 2,12/18/2017  Phase 2 data released December 18 2017 - primary effectiveness objective was met.
AGN,Cariprazine  Bipolar I depression,Phase 3,"12/18/2017  Phase 3 data released December 18, 2017 - primary endpoint met."
ONCE,Luxturna (voretigene neparvovec)  Inherited retinal dystrophies,Approved,"12/19/2017  PDUFA date January 12, 2018 under priority review. Approval announced December 19, 2017."
PFE,BOSULIF (BOSUTINIB)  First-Line Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia,Approved,"12/19/2017  Approval announced December 19, 2017."
EXEL,Cabozantinib - CABOSUN  First-Line RCC - cancer,Approved,"12/19/2017  Approval announced December 19, 2017, ahead of PDUFA date of February 15, 2018."
MRK,Ertugliflozin  Type 2 diabetes,Approved,"12/20/2017  Approval announced December 20, 2017."
PFE,Ertugliflozin  Type 2 diabetes,Approved,"12/20/2017  Approval announced December 20, 2017."
ABBV,ABT-494 - SELECT-MONOTHERAPY  Rheumatoid arthritis,Phase 3,"12/20/2017  Phase 3 data released December 20, 2017 - primary endpoint and key secondary endpoints met."
AEZS,Macimorelin Acetate - Macrilen  Adult Growth Deficiency,Approved,"12/20/2017  Approval announced December 20, 2017."
BMY,CM-238 – Opdivo (Adjuvant)  Melanoma,Approved,"12/20/2017  Approval announced December 20, 2017."
LJPC,GiaprezaTM (angiotensin II)  Increase blood pressure in adults with septic or other distributive shock,Approved,"12/21/2017  Approval announced December 21, 2017."
BIIB,BAN2401 (Aβ mAb)  Alzheimer’s disease,Phase 2,"12/21/2017  Noted December 21, 2017 that Independent Data Monitoring Committee determined trial did not meet criteria for success."
CELG,REVLIMID - RELEVANCE  Newly Diagnosed Follicular Lymphoma,Phase 3,"12/21/2017  Phase 3 data released December 21, 2017 - co-primary endpoints not met."
AGRX,Twirla  Contraceptive patch,CRL,"12/22/2017  CRL issued 2013. Further CRL issued December 22, 2017."
BHC,LUMIFY (brimonidine tartrate ophthalmic solution 0.025%)  Eye Brightener,Approved,"12/22/2017  Approval announced December 22, 2017."
BOLD,AT132 - ASPIRO  X-Linked Myotubular Myopathy,Phase 1/2,"01/04/2018  Phase 1/2 dosing has commenced - noted September 21, 2017 with preliminary data released January 4, 2018."
AMGN,XGEVA  Multiple Myeloma,Approved,"01/05/2018  sBLA approval announced January 5, 2017."
OHRP,OHR-102 (MAKO)  Neovascular (Wet) Age-related Macular Degeneration (AMD),Phase 3,"01/05/2018  Phase 3 data released January 5, 2017 - primary endpoint not met."
KALA,KPI‑121 0.25% - STRIDE 2  Dry eye disease,NDA Filing,"01/05/2018  Phase 3 data released January 5, 2017 - one of two primary endpoints met."
KALA,INVELTYS - STRIDE 1  Dry eye disease,Phase 3,"01/05/2018  Phase 3 data released January 5, 2017 - both primary symptom endpoints met. Primary sign endpoint missed."
ACRS,A-101 THWART-1 and THWART-2  Common warts (verruca vulgaris),Phase 3,"01/08/2018  Phase 2 data released January 8, 2018 - endpoints met. Phase 3 trial to be initiated 2H 2018."
ALDR,ALD403 - PROMISE 2  Frequent episodic migraine,Phase 3,"01/08/2018  Phase 3 PROMISE 2 data released January 8, 2017 - endpoints met."
RVNC,RT002  Plantar fasciitis,Phase 2a,"01/08/2018  Phase 2a data released January 8, 2017. Primary endpoint was not met."
AXON,Nelotanserin Visual hallucinations in subjects with Lewy body dementia,Phase 2,"01/08/2018  Phase 2 data released January 8, 2018. Dementia endpoint missed."
AXSM,AXS-02 CREATE-1  Complex regional pain syndrome (CRPS),Phase 3,"01/09/2018  Phase 3 interim efficacy analysis January 9, 2017 recommended trial to discontinue due to futility."
AXON,Intepirdine - HEADWAY-DLB  Dementia with Lewy bodies (DLB),Phase 2b,01/09/2018  Phase 2 data released January 2018 - negative data.
AXSM,AXS-02 COAST-1  Knee Osteoarthritis Associated with Bone Marrow Lesions,Phase 3,"01/09/2018  Phase 3 interim efficacy analysis January 9, 2017 recommended trial continue to full enrollment."
AXON,Intepirdine  Gait and Balance Impairments in Dementia,Phase 2,01/09/2018  Phase 2 data released January 2018 - negative data.
LPCN,LPCN 1021  Men with low testosterone (Low T),-,"01/10/2018  Advisory Committee meeting January 10, 2018 voted 6-13 against approval."
ARDM,Linhaliq (Pulmaquin)  Non-cystic fibrosis bronchiectasis (non-CF BE).,CRL,"01/11/2018  Advisory Committee Meeting January 11, 2018 voted 3-12 against recommending approval."
ARDM,Linhaliq (Pulmaquin)  Non-cystic fibrosis bronchiectasis (non-CF BE).,PDUFA priority review,"01/11/2018  Advisory Committee Meeting January 11, 2018 voted 3-12 against recommending approval."
AZN,Lynparza  Breast cancer,Approved,"01/12/2018  Approval announced January 12, 2018."
MRK,Lynparza  Breast cancer,Approved,"01/12/2018  Approval announced January 12, 2018."
TEVA,Trisenox  Acute Promyelocytic Leukemia,Approved,"01/15/2018  Approved January 15, 2018."
EXEL,Cabozantinib (CELESTIAL)  Advanced hepatocellular cancer (HCC),Phase 3,"01/16/2018  Phase 3 data to be presented at 2018 ASCO-GI Symposium, January 19, 2018 - OS 10.2 months vs 8 months placebo (HR 0.76, p=0.0049). Median PFS 5.2 months vs 1.9 months placebo (HR 0.44, p<0.0001)."
EIGR,Ubenimex - LIBERTY Pulmonary arterial hypertension (PAH),Phase 2,"01/16/2018  Phase 2 trial did not meet endpoints - January 16, 2018."
ONTX,IV Rigosertib - INSPIRE  2nd-line HR-MDS (high risk myelodysplastic syndromes),Phase 3,"01/17/2018  Phase 3 trial recommended to continue by Data Monitoring Committee (DMC) following interim analysis January 17, 2018."
AMGN,KYPROLIS (ENDEAVOR)  Relapsed Multiple Myeloma,Approved,"01/17/2018  sNDA approved January 17, 2018."
NCNA,NUC-1031 (Acelarin)  Front-Line Treatment of Advanced Biliary Tract Cancer,Phase 1b,"01/19/2018  Data from open label Phase 1b trial released at ASCO GI 2018 - Partial Response 3/8, Stable Disease 1/8."
TCON,TRC105 and Nexavar  Hepatocellular carcinoma (HCC) - cancer,Phase 2,"01/19/2018  Phase 2 poster presented January 19, 2018 at ASCO GI showed 2/8 partial responses."
RNN,RX-3117  Relapsed and refractory pancreatic cancer,Phase 2,"01/19/2018  Updated Phase 2a data presented at ASCO GI January 19, 2018. 1/43 partial responses; 11/43 (28%) stable disease."
VICL,ASP0113 Vaccine  Hematopoietic cell transplant recipients,Phase 3,"01/22/2018  Phase 3 data released January 22, 2018 - endpoints not met."
CCXI,CCX872  Non-resectable pancreatic cancer,Phase 1b,01/22/2018  Noted 29% overall survival data when combined with FOLFIRINOX.
CERS,INTERCEPT Chronic anemia in thalassemia patients,Phase 3,"01/23/2018  Phase 3 trial met endpoints - January 23, 2018. CE mark submission due 2H 2018."
IOVA,LN-145  Head and neck cancer,Phase 2,"01/24/2018  Data released January 24, 2018 showed 3/8 PRs."
PFE,"PF-05280586 (Biosimilar to Rituxan/ MabThera)  CD20-positive, low tumor burden, follicular lymphoma",PDUFA,"01/24/2018  Demonstrated equivalence in overall response rate (ORR) - met primary endpoint - January 24, 2018."
IOVA,LN-145  Head and neck cancer,Phase 2,"01/24/2018  Phase 2 data released January 24, 2018 showed 3/8 PRs."
IOVA,LN-145  Cervical cancer,Phase 2,"01/24/2018  Initial data released January 24, 2018 - 1 PR and 1 SD out of two patients."
SMMT,Ezutromid  Duchenne muscular dystrophy,Phase 2,"01/25/2018  Phase 2 24-week data released January 25, 2018. 23% decrease myosin."
SGYP,Trulance (plecanatide)  Constipation-predominant irritable bowel syndrome (IBS-C),Approved,"01/25/2018  Approval announced January 25, 2018."
NVS,Lutathera  Inoperable progressive midgut NETs,Approved,"01/26/2018  Approved January 26, 2018. Acquired from Advanced Accelerator Applications (NASDAQ: AAAP)."
AZN,PT010  Chronic obstructive pulmonary disease (COPD),Phase 3,"01/26/2018  Phase 3 data released January 26, 2018 - 8/9 primary endpoints met. Regulatory filing due 2H 2018."
NVS,Lutathera  Inoperable progressive midgut NETs,Approved,01/26/2018  http://investorrelations.adacap.com/phoenix.zhtml?c=253874&p=irol-newsArticle&ID=2328710
ARDM,Linhaliq (Pulmaquin)  Non-cystic fibrosis bronchiectasis (non-CF BE).,CRL,"01/29/2018  CRL announced January 29, 2018 - two-year additional Phase 3 trial requested by FDA."
BLCM,BPX-501  Adjunct T-cell therapy administered after allogeneic HSCT - (hematopoietic stem cell transplantation) - cancer,Phase 1/2,"01/30/2018  Clinical hold announced January 30, 2018."
SAGE,SAGE-217  Insomnia,Phase 1/2,"01/31/2018  Phase 1/2 trial met primary endpoint - January 31, 2018."
AGN,AVYCAZ (ceftazidime and avibactam)  Complicated Urinary Tract Infections (cUTI),Approved,"02/01/2018  Further approval to include hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia (HABP/VABP) announced February 1, 2018"
ICPT,Obeticholic acid (Ocaliva)  Primary biliary cirrhosis (PBC) - POISE,Approved,"02/01/2018  Updated U.S. label for Ocaliva released February 1, 2018."
AFMD,AFM13 with Keytruda  Hodgkin Lymphoma - Cancer,Phase 1b,"02/01/2018  Phase 1b preliminary data released February 1, 2018 - Objective response rate (ORR) of 89% (8/9), 4/9 CRs and 4/9 PRs. 3-month data due mid-2018."
AFMD,AFM13  CD30-positive lymphoma,Phase 1/2,"02/01/2018  Phase 1b/2a preliminary data showed 1/3 PR. 1/3CR, 1/3 SD - released February 1, 2018."
TGTX,TG-1101 (ublituximab)  Relapsing forms of Multiple Sclerosis (RMS),Phase 2a,"02/02/2018  Phase 2a updated data February 2, 2018 - 100% reduction of T1 Gd-enhancing lesions Wk 24 (n=38), 99% B-cell depletion Wk 4 and maintained at Wk (n=40)."
SPPI,SPI-2012 (ROLONTIS)  Chemotherapy-Induced Neutropenia,Phase 3,02/05/2018  Phase 3 ADVANCE trial met primary endpoint of non-inferiority in comparison to pegfilgrastim. Additional Phase 3 RECOVER trial ongoing with BLA to be filed 4Q 2018.
EYEG,EGP-437  Ocular inflammation and pain post cataract surgery,Phase 2b,"02/05/2018  Phase 2b data released February 5, 2018 - co-primary endpoints not met."
AMAG,Feraheme  Adults with iron deficiency anemia (IDA),Approved,"02/05/2018  Approval for sNDA filing announced February 5, 2018."
ARRY,Binimetinib - COLUMBUS  BRAF mutant melanoma cancer,Approved,"02/06/2018  Phase 3 data released September 26, 2016 met primary endpoint. PDUFA date June 30, 2018 - no Adcom anticipated. Noted February 6, 2018 33.6 month overall survival HR=0.61."
CELG,MM-007 OPTIMISMM  Multiple Myeloma - refractory,Phase 3,"02/06/2018  Phase 3 data released February 6, 2018 - primary endpoint (PFS) met."
GILD,Bictegravir/F/TAF  HIV,Approved,"02/07/2018  Approved February 7, 2018."
GILD,Bictegravir/F/TAF  HIV,Approved,"02/07/2018  Approval announced February 7, 2018."
BIIB,Natalizumab (α4-integrin inhibitor)  Acute ischemic stroke,Phase 2b,"02/07/2018  Phase 2b data released February 8, 2018 - primary endpoint not met."
JNJ,ZYTIGA (abiraterone acetate) - LATITUDE  metastatic hormone-naïve prostate cancer (mHNPC),Approved,"02/08/2018  sNDA approval announced February 8, 2018."
NVS,Cosentyx  Psoriasis,Approved,"02/08/2018  FDA approval announced February 8, 2018."
MDGL,MGL-3196 Heterozygous familial hypercholesterolemia (HeFH),Phase 2,"02/08/2018  Phase 2 top-line data released February 8, 2018 - primary endpoint met."
ABEO,ABO-102 Sanfilippo syndrome type A (MPS IIIA),Phase 1/2,"02/08/2018  Phase 1/2 updated data released February 8, 2018. CSF heparan sulfate levels decreased 57%/64%."
CBIO,CB 2679d/ ISU304  Hemophilia B,Phase 1/2,"02/09/2018  Phase 1/2 top-line positive data presented at EAHAD February 9, 2018."
RNN,RX-3117  Advanced bladder cancer - 3rd line,Phase 2a,"02/09/2018  Phase 2a data presented at ASCO GU February 9, 2018 noted 33% of patients had PFS of 2 months or more."
GSK,Fluarix Quadrivalent (Influenza Vaccine)  Influenza A - children 6-35 months of age.,Approved,"02/10/2018  Approval announced January 11, 2018."
MBVX,MVT-5873  Pancreatic cancer,Phase 1/2,"02/12/2018  Phase 1 interim data released February 12, 2018. Noted all patients had ""had measurable tumor reductions""."
VRTX,Tezacaftor (VX-661) / ivacaftor  Cystic fibrosis - Two Copies of the F508del Mutation,Approved,"02/12/2018  PDUFA date under priority review February 28, 2017. Approval announced February 12, 2018."
KDMN,KD025  Idiopathic pulmonary fibrosis (IPF),Phase 2,"02/12/2018  Phase 2 data released February 12, 2018. Open label - noted data were ""positive""."
TTPH,Eravacycline (TP-434) - IGNITE3  cUTI - complicated urinary tract infections,Phase 3,"02/13/2018  Phase 3 trial did not meet endpoints September 2015. Additional Phase 3 trial also did not meet primary endpoints - noted February 13, 2018."
MRK,MK-8931 (019) - Verubecestat  Mild-to-moderate Alzheimer's,Phase 3,02/13/2018  Phase 3 interim analysis by DMC advised trial to be discontinued due to lack of benefit vs risk.
EXEL,Cabozantinib  Thyroid Carcinoma,Phase 3,"02/13/2018  Phase 2 data released February 13, 2018. 54% ORR, 43% SD."
TTPH,Eravacycline (TP-434) - IGNITE3  cUTI - complicated urinary tract infections,Phase 3,"02/13/2018  Additional Phase 3 trial also did not meet primary endpoints - noted February 13, 2018."
VRTX,VX-150  Acute pain following bunionectomy surgery,Phase 2,"02/14/2018  Phase 2 data due released February 14, 2018. Primary endpoint met."
GLMD,Aramchol - ARRIVE HIV-associated lipodystrophy and nonalcoholic fatty liver disease (NAFLD),Phase 2,"02/14/2018  Phase 2 top-line data released February 14, 2018 did not meet primary endpoint."
JNJ,Apalutamide  Non-metastatic castration-resistant prostate cancer (CRPC),Approved,"02/14/2018  Approval announced February 8, 2018."
GLMD,Aramchol - ARRIVE HIV-associated lipodystrophy and nonalcoholic fatty liver disease (NAFLD),Phase 2,"02/14/2018  Phase 2 top-line data released February 14, 2018, primary endpoint not met."
AMAG,Makena - auto injector  Reduce the risk of preterm birth in women with a singleton pregnancy,Approved,"02/14/2018  Approval announced February 14, 2018."
ATRS,Makena - auto injector  Reduce the risk of preterm birth in women with a singleton pregnancy,Approved,"02/14/2018  Approval announced February 14, 2018."
PCRX,EXPAREL  Post surgical pain,PDUFA,"02/15/2018  Advisory Committee Meeting February 14-15, 2018 voted 4-6 against approval."
KURA,Tipifarnib  Head and neck squamous cell carcinomas (HNSCC),Phase 2,02/15/2018  Presentation of updated data due February 15 2018 showed 5/6 partial responses (PRs).
APRI,Vitaros  Erectile dysfunction,CRL,"02/16/2018  CRL issued for NDA resubmission - February 16, 2018."
ABBV,Risankizumab  Psoriasis,Phase 3,02/17/2018  Phase 3 data showed 37% and 51% of patients achieved clear skin vs 14% and 25% for placebo. Regulatory filing due 2018.
AZN,Durvalumab (PACIFIC)  Lung cancer,Approved,"02/19/2018  Approval announced February 19, 2018."
AIMT,AR101 PALISADE  Peanut Allergy,Phase 3,"02/20/2018  Phase 3 data released February 20, 2018 met primary endpoint but noted 20% discontinued treatment, 12% due to adverse event. Additional data presented March 4, 2018"
VRTX,VX-659 in combination with tezacaftor and ivacaftor  Cystic fibrosis (CF) who have one F508del mutation and one minimal function mutation (F508del/Min),Phase 3,02/21/2018  Phase 2 data showed ppFEV1 of +13.3%.
NBIX,Elagolix Uterine Fibroids,Phase 3,"02/21/2018  Phase 3 data released February 21, 2018 - primary endpoint met."
ABBV,Elagolix Uterine Fibroids,Phase 3,"02/21/2018  Phase 3 data released February 21, 2018 - primary endpoint met."
MESO,MSC-100-IV acute graft versus host disease (aGVHD) in children,Phase 3,"02/22/2018  Phase 3 data released February 22, 2018 - primary endpoint met. Day 100-day survival data due 2Q 2018."
APLS,APL-2  Geographic atrophy (GA) associated with age-related macular degeneration (AMD),Phase 3,"02/22/2018  Phase 2 18 month safety & efficacy data released February 22, 2018."
KMPH,Apadaz (KP201/APAP)  Acute pain,Approved,"02/23/2018  CRL issued June 13, 2016. Resubmitted, and issued FDA Approval February 23, 2018."
KMPH,Apadaz (KP201/APAP)  Acute pain,PDUFA,"02/23/2018  Resubmitted, and issued FDA Approval February 23, 2018."
OBSV,OBE001 - IMPLANT2  IVF,Phase 3,"02/26/2018  Phase 3 data released February 26,2018 - primary endpoint met. Improvement shown in ET D5 subgroup but not in ET D3."
LLY,"Abemaciclib - MONARCH 3  HR+, HER2-locoregionally recurrent or metastatic breast cancer (MBC)",Approved,"02/26/2018  Approval announced February 26, 2018."
ABIO,Gencaro - GENETIC-AF trial Chronic Heart Failure,Phase 2b,"02/26/2018  Phase 2b data released February 26, 2018 - no benefit shown in overall population. Intends to discuss Phase 3 plans with FDA."
CELG,Ozanimod - RADIANCE  Relapsing Multiple Sclerosis,Phase 3,"02/27/2018  Phase 3 data due released May 22, 2017 - primary endpoint met, disability endpoint not met. NDA filed December 2017. Refusal-to-file letter issued February 27, 2018."
TBPH,Telavancin  Bacteremia,Phase 3,02/27/2018  Phase 3 trial discontinued following recent interim analysis - announced during earnings release. Exact date unclear.
NVAX,NanoFlu vaccine  Influenza,Phase 2,"02/28/2018  Phase 1/2 top-line data released February 28, 2018."
MBVX,"MVT-1075  Pancreatic, colon and lung cancers",Phase 1,"02/28/2018  Phase 1 interim data released February 28, 2018 showed 2/3 patients with stable disease and 1/3 with progressive disease."
SRNE,ZTlido (lidocaine patch 1.8%)  Pain associated with post-herpetic neuralgia (PHN),Approved,"02/28/2018  Approval announced February 28, 2018."
HTBX,HS-110 and nivolumab (Opdivo)  Non-small cell lung cancer (NSCLC),Phase 2,"02/28/2018  Phase 2 initial data released February 28, 2018. 17% partial response; 40% stable disease."
RETA,Omaveloxolone - MOTOR  Mitochondrial myopathies (MM),Phase 2,"03/01/2018  Phase 2 initial data released March 1, 2018 - endpoints not met."
VRNA,RPL554  Cystic fibrosis,Phase 2a,"03/02/2018  Phase 2a data released March 2, 2018."
VRNA,RPL554  Cystic fibrosis,Phase 2a,"03/02/2018  Phase 2a data released March 2, 2018. Noted a 6% improvement in FEV1."
OTIC,OTIPRIO  Acute otitis externa,Approved,"03/02/2018  Approval announced March 2, 2018."
GTHX,Trilaciclib  First-line small-cell lung cancer,Phase 2,"03/05/2018  Phase 2a top-line data released March 5, 2018 - consequences of chemotherapy-induced myelosuppression versus placebo. PFS/ORR rates not currently significant but data are immature."
DERM,Olumacostat glasaretil (DRM01)  Acne,Phase 3,"03/05/2018  Phase 3 data released March 5, 2018 - failed to meet all co-primary endpoints."
CLSD,Suprachoroidal CLS-TA - PEACHTREE  Macular edema associated with non-infectious uveitis,Phase 3,"03/05/2018  Phase 3 data released March 5, 2018 - primary endpoint and key secondary endpoints met."
VNDA,HETLIOZ (tasimelteon)  Jet Lag Disorder,Phase 2,"03/05/2018  Phase 2 data released March 5, 2018 - primary endpoint met."
BMY,Opdivo - 4 week applications,Approved,"03/06/2018  Approval announced March 6, 2018."
THERF,Ibalizumab Multi-drug resistant HIV-1,Approved,"03/06/2018  Approval announced March 6, 2018."
ESPR,Bempedoic acid - CLEAR LDL-C Lowering Program 1002-048  Hypercholesterolemia,Phase 2,"03/07/2018  Phase 3 data released March 7, 2018."
RARE,DTX301  Ornithine Transcarbamylase (OTC) Deficiency,Phase 1/2,"03/07/2018  Phase 1/2 first cohort data released March 7, 2018 - 1/3 patients showed substantially increased levels of ureagenesis."
IMRN,IMM-124E  Nonalcoholic steatohepatitis (NASH),Phase 2,"03/08/2018  Phase 2 Interim analysis July 10, 2017 showed no statistical difference with placebo. However, company noted March 8, 2018 that top-line data were positive."
MCRB,SER-262 Primary Clostridium Difficile infection (CDI),Phase 1b,03/08/2018  Phase 1b trial showed no relevant difference in risk of recurrence compared to placebo - company did note was not powered to detect a statistically significant difference in recurrence rates.
VBLT,VB-111  Recurrent glioblastoma (rGBM) cancer,Phase 3,"03/08/2018  Phase 3 top-line data released March 8, 2018 - primary endpoint not met."
REGN,Praluent (alirocumab) ODYSSEY OUTCOMES  Cardiovascular events,Phase 3,"03/10/2018  Phase 3 trial met primary endpoint - March 10, 2018."
SNY,Praluent (alirocumab) ODYSSEY OUTCOMES  Cardiovascular events,Phase 3,"03/10/2018  Phase 3 trial met primary endpoint - March 10, 2018."
SVRA,Aironite - INDIE  Heart failure with preserved ejection fraction (HFpEF),Phase 2,"03/11/2018  Phase 2 top line data presented March 11, 2018 failed to meet primary endpoint."
SVRA,Aironite - INDIE  Heart failure with preserved ejection fraction (HFpEF),Phase 2,"03/12/2018  Phase 2 top line data presented March 11, 2018 failed to meet primary endpoint."
ANTH,Sollpura - RESULT  Exocrine pancreatic insufficiency,Phase 3,"03/12/2018  Phase 3 data released March 12, 2018 did not meet primary endpoint."
IMDZ,G100 Follicular non-Hodgkin Lymphoma - cancer,Phase 2,"03/12/2018  Phase 2 data ASH 2017 - ORR 39%, increased to 54% March 12, 2018."
ADXS,Axalimogene filolisbac + durvalumab  Recurrent or refractory HPV-associated cervical cancer and head & neck cancer,Phase 1/2,"03/12/2018  Clinical hold announced March 12, 2018."
NBIX,Elagolix Uterine Fibroids,Phase 3,"03/13/2018  Phase 3 data released February 21, 2018 - primary endpoint met. Second Phase 3 trial also met primary endpoint - March 13, 2018."
ABBV,Elagolix Uterine Fibroids,Phase 3,"03/13/2018  Phase 3 data released February 21, 2018 - primary endpoint met. Second Phase 3 trial also met primary endpoint - March 13, 2018."
PLX,OPRX-106  Ulcerative Colitis,Phase 2,"03/13/2018  Phase 2 data released March 13, 2018 - key endpoints met."
EARS,Keyzilen (AM-101) - TACTT3  Acute inner ear tinnitus,Phase 3,"03/13/2018  Phase 3 data released March 13, 2018 - primary endpoint not met."
NBIX,Elagolix Uterine Fibroids,Phase 3,"03/13/2018  Second Phase 3 trial also met primary endpoint - March 13, 2018."
ABBV,Elagolix Uterine Fibroids,Phase 3,"03/13/2018  Second Phase 3 trial also met primary endpoint - March 13, 2018."
LPTX,DKN-01 + KEYTRUDA  Esophagogastric adenocarcinoma,Phase 1/2,"03/14/2018  Monotherapy data released March 14, 2018. 2/16 PRs, 5/16 SD."
SLDB,SGT-001  Duchenne Muscular Dystrophy,Phase 1/2,"03/14/2018  Phase 1/2 trial initiated November 2017 for low dose. Clinical hold announced March 14, 2018."
ADAP,NY-ESO T-cell therapy  Myxoid round cell liposarcoma (MRCLS),Phase 1/2,"03/15/2018  Phase 1/2 data released March 15, 2018. 3/4 PRs, 1 SD."
REGN,EYLEA - PANAROMA  Nonproliferative Diabetic Retinopathy,Phase 3,"03/19/2018  Phase 3 data released March 19, 2018 - primary endpoint met. Regulatory filing due 2H 2018."
CDTX,Rezafungin - ReSTORE  Candidemia,Phase 3,"03/19/2018  Phase 2 data released March 19, 2018. Primary objectives met. Phase 3 trials to commence mid-2018."
HRTX,HTX-011  Post operative pain,NDA Filing,"03/19/2018  Phase 3 data released March 19, 2018 - primary and secondary endpoints met."
ARNA,Etrasimod  Ulcerative colitis,Phase 2,"03/19/2018  Phase 2 data released March 19, 2018 - primary and secondary endpoints met."
SGEN,ADCETRIS in combination with chemotherapy ECHELON-1 Frontline Hodgkin lymphoma,Approved,"03/20/2018  sBLA approval announced March 20, 2018. PDUFA date under priority review was May 1, 2018."
RETA,Bardoxolone methyl - LARIAT  Pulmonary hypertension due to interstitial lung disease - PH-ILD,Phase 2,"03/22/2018  Phase 2 primary endpoint met - noted March 22, 2018."
ABBV,Rova-T (TRINITY)  Third-line Small Cell Lung Cancer,Phase 2,"03/22/2018  Phase 2 pivotal data released March 22, 2018. ORR of 16% + overall survival 5.6 months noted."
PTGX,PTG-100  Ulcerative colitis,Phase 2b,"03/26/2018  Phase 2b trial discontinued following interim analysis - March 26, 2018."
LLY,"Abemaciclib - MONARCH 3  HR+, HER2-locoregionally recurrent or metastatic breast cancer (MBC)",Approved,"03/26/2018  Approval announced February 26, 2018."
TSRO,Niraparib and Keytruda (TOPACIO)  Triple-negative Breast Cancer or Ovarian Cancer,Phase 1/2,"03/26/2018  Data presented at SGO March 26, 2018 showed ORR 25%, control rate 68%."
VRNA,RPL554  COPD,Phase 2a,"03/26/2018  Phase 2b data released March 26, 2018 - primary endpoint met."
ABLX,Vobarilizumab  Systemic lupus erythematosus (SLE),Phase 2,"03/26/2018  Phase 2 trial did not meet primary endpoint - March 26, 2018."
FLKS,FLX-787 (Aust)  Multiple Sclerosis,Phase 2,"03/26/2018  Phase 2 data released March 26, 2018 - 27% decrease in spasms."
ESPR,Bempedoic Acid - 1002-039  Hypercholesterolemia,Phase 2,"03/27/2018  Phase 2 data released March 27, 2018. Primary endpoint met. LDL-C lowering 30%."
EDGE,EG-1962  Improving patient outcomes following an aneurysmal subarachnoid hemorrhage (aSAH),Phase 3,"03/28/2018  Phase 3 trial discontinued March 28, 2018 following interim analysis showing poor efficacy."
MNOV,MN-166  Methamphetamine dependence,Phase 2,"03/29/2018  Phase 2 data released March 29, 2018 - primary endpoint not met."
PFE,Tafamidis  TTR amyloid cardiomyopathy,Phase 3,"03/29/2018  Phase 3 data released March 30, 2018 - primary endpoint met."
MNOV,MN-001  NASH (nonalcoholic steatohepatitis),Phase 2,"04/02/2018  Noted April 2, 2018 that trial has been terminated early due meeting one of two primary endpoints (data from second endpoint not released)."
SLS,NeuVax in combination with Herceptin  Breast cancer - 1+/2+,Phase 2b,04/02/2018  Phase 2b interim analysis noted hazard ratio of 0.67. p value not released.
ALKS,ALKS 5461  Major depressive disorder,PDUFA,"04/02/2018  NDA filed but Refusal To File Letter announced April 2, 2018. Additional trials required."
NVO,Semaglutide - oral - PIONEER  Type 2 diabetes,Phase 3,"04/03/2018  Phase 3 data released February 22, 2018 - primary endpoint met. Data from nine further trials due 2018."
BIIB,Natalizumab (α4-integrin inhibitor)  Acute ischemic stroke,Phase 2b,"04/03/2018  Phase 2b data released February 8, 2018 - primary endpoint not met."
MDGL,MGL-3196 Heterozygous familial hypercholesterolemia (HeFH),Phase 2,"04/03/2018  Phase 2 top-line data released February 8, 2018 - primary endpoint met."
KDMN,KD025  Idiopathic pulmonary fibrosis (IPF),Phase 2,"04/03/2018  Phase 2 data released February 12, 2018. Open label - noted data were ""positive""."
RIGL,Fostamatinib  IgA nephropathy,Phase 2,"04/03/2018  Phase 2 data released April 3, 2018. Primary endpoint not met."
AGN,Cariprazine  Bipolar I Depression,Phase 3,"04/03/2018  Phase 3 data released April 3, 2018. Primary endpoint met."
GWPH,GWP42006 (CBDV)  Epilepsy,Phase 2,"04/03/2018  Phase 2 data released February 21, 2018 - primary endpoint not met."
BPTH,Prexigebersen - BP1001  Acute myeloid leukemia (AML),Phase 2,"04/03/2018  Phase 2 first patient enrolled November 2016. Interim data released April 3, 2018. Response rate 8/17 including 4 CR and 4 SD."
BMY,Opdivo - 4 week applications,Approved,"04/04/2018  Approval announced March 6, 2018."
ANTH,Sollpura - RESULT  Exocrine pancreatic insufficiency,Phase 3,"04/04/2018  Phase 3 data released March 12, 2018 did not meet primary endpoint."
CNAT,Emricasan  Liver fibrosis post-orthotopic liver transplant due to Hepatitis C virus infection (HCV-POLT),Phase 2b,"04/04/2018  Phase 2b data released April 4, 2018. Primary endpoint not met."
SGEN,ADCETRIS in combination with chemotherapy ECHELON-1 Frontline Hodgkin lymphoma,Approved,"04/04/2018  sBLA approval announced March 20, 2018."
LLY,Ramucirumab REACH-2  Hepatocellular Carcinoma,Phase 3,"04/04/2018  Phase 3 data released April 4, 2018. Primary endpoint met."
MYOK,MYK-461 - EXPLORER-HCM  Hypertrophic cardiomyopathy (HCM),Phase 3,"04/04/2018  Phase 2 top-line data released August 7, 2017 - primary endpoint met. Data from low dose cohort due released March 8, 2018 - primary endpoint also met."
INCY,Epacadostat with Keytruda - ECHO-301  Cancer - first-line metastatic melanoma.,Phase 3,"04/06/2018  Phase 3 trial did not meet primary endpoint - noted April 6, 2018."
MRK,Epacadostat with Keytruda - ECHO-301  Cancer - first-line metastatic melanoma.,Phase 3,"04/06/2018  Phase 3 trial did not meet primary endpoint - noted April 6, 2018."
CLVS,Rucaparib ARIEL3 Ovarian cancer patients with a BRCA-like mutation,Approved,"04/06/2018  Approval announced April 6, 2018."
PCRX,EXPAREL  Post surgical pain,Approved,"04/06/2018  Approval announced April 6, 2018."
ABBV,ABT-494 - SELECT-COMPARE  Rheumatoid arthritis,Phase 3,"04/09/2018  Phase 3 data released April 9, 2018. Primary and secondary endpoints met."
VTVT,Azeliragon - STEADFAST Mild Alzheimer’s disease,Phase 3,"04/09/2018  Phase 3 data (Part A) released April 9, 2018 did not meet endpoints. Part B to be discontinued."
MNLO,Serlopitant  Pruritus associated with atopic dermatitis,Phase 2,"04/09/2018  Phase 2 data released April 9, 2018. Endpoints not met."
TRPX,THX-110  Tourette Syndrome,Phase 2b,"04/09/2018  Phase 2a data released April 9, 2018. Primary endpoint met."
MRK,Keytruda - KEYNOTE-042  Non-small cell lung cancer (NSCLC),Phase 3,"04/09/2018  Phase 3 data released April 9, 2018. Overall survival endpoint met. Trial to continue to PFS, data due at upcoming meeting."
SPPI,Poziotinib  Non-small cell lung cancer (NSCLC) with exon 20 insertion mutation in EGFR or HER2,Phase 2,"04/10/2018  Phase 2 update with ORR 64% in first 11 patients, median PFS yet to be reached."
SELB,SEL-212  Tophaceous gout,Phase 3,"04/10/2018  Phase 2 updated data released April 10, 2018. Noted 25% gout flares. Five-monthly dose data due 3Q 2018."
PFE,INLYTA (axitinib)  Recurrent renal cell carcinoma (RCC),Phase 3,04/10/2018  Phase 3 trial discontinued due to futility.
RETA,Bardoxolone methyl - CARDINAL  Chronic Kidney Disease Caused by Alport Syndrome,Phase 2/3,"04/11/2018  Additional Phase 2 data due released April 11, 2018 - increase in kidney function maintained through Week 36."
CBAY,Seladelpar  Primary biliary cholangitis (PBC),Phase 3,"04/11/2018  Phase 2 positive interim data from second trial data released July 17, 2017. Further data released April 11, 2018. Phase 3 trial to be initiated 2H 2018."
BLCM,BPX-501  Adjunct T-cell therapy administered after allogeneic HSCT - (hematopoietic stem cell transplantation) - cancer,Phase 1/2,"04/11/2018  Clinical hold announced January 30, 2018. Announced April 11, 2018 that hold has been lifted."
IMDZ,CMB305 Soft tissue sarcomas,Phase 3,"04/12/2018  Phase 2 data released March 12, 2018, Median overall survival 23.7 months."
NLNK,Indoximod in combination with KEYTRUDA or Opdivo - Indigo301  Melanoma - cancer,Phase 3,"04/15/2018  Phase randomization portion will not be initiated - noted April 15, 2018."
MRK,KEYTRUDA - EORTC1325/KEYNOTE-054  Melanoma,PDUFA,"04/15/2018  Phase 3 data released January 8, 2018 met primary endpoint. Data presented at AACR April 15, 2018 - HR 0.54-0.57."
CLDX,Glembatumumab vedotin  Metastatic triple negative breast cancers that overexpress gpNMB,Phase 2b,"04/16/2018  Phase 2b data released April 16, 2018 - primary endpoint not met."
BMY,CM-214 – Opdivo + Yervoy  First-line Renal cell carcinoma (RCC),Approved,"04/16/2018  Approved April 16, 2018."
LLY,(MK-3475-189/KEYNOTE-189)  First Line Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC),Approved,"04/16/2018  Phase 3 trial met primary endpoints of overall survival (OS) and progression-free survival (PFS). Data presented at AACR April 16, 2018 - HR 0.49."
MRK,(MK-3475-189/KEYNOTE-189)  First Line Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC),Approved,"04/16/2018  Phase 3 trial met primary endpoints of overall survival (OS) and progression-free survival (PFS). Data presented at AACR April 16, 2018 - HR 0.49."
RHHBY,TECENTRIQ (atezolizumab) - IMpower150  Non-squamous non-small cell lung cancer (NSCLC),Phase 3,"04/16/2018  Phase 3 overall survival endpoint met. Data to presented at AACR April 16, 2018."
BMY,CM-227 – Opdivo + Yervoy  First-line Non-small cell lung cancer (NSCLC),PDUFA,"04/16/2018  Phase 3 interim data released February 5, 2018 - co-primary endpoint of PFS met. Data presented at AACR Meeting April 16, 2018 (HR 0.58)."
TSRO,TSR-042 - GARNET  Solid tumors,Phase 1,"04/16/2018  Phase 1 preliminary data at AACR April 16, 2018. ORR 47%."
NVCR,Tumor Treating Fields (TTFields) STELLAR  Mesothelioma,Phase 2,"04/17/2018  Phase 2 top-line data released April 17, 2018 noted improvements in overall survival and progression free survival. Data to be presented at upcoming conference."
RARE,Crysvita (Burosumab)  X-Linked Hypophosphatemia (XLH),Approved,"04/17/2018  Approval announced April 17, 2018."
RIGL,Tavalissetm (Fostamatinib)  Immune Thrombocytopenic Purpura (ITP),Approved,"04/17/2018  Approved April 17, 2018."
ADMS,GOCOVRI (amantadine)  Dyskinesia patients with Parkinson's disease,Phase 3,"04/19/2018  Phase 3 open-label data released April 19, 2018."
AZN,Tagrisso - FLAURA  First-line lung cancer,Approved,"04/19/2018  Approval announced April 19, 2018."
EPZM,Tazemetostat  Adult patients with mesothelioma characterized by BAP1 loss-of-function,Phase 2,"04/23/2018  Noted April 23, 2018 that all Tazemetostat trials have been placed on partial clinical hold."
PRTA,NEOD001 VITAL  AL Amyloidosis,Phase 3,"04/23/2018  Phase 3 trial discontinued due to futility - April 23, 2018."
PRTA,NEOD001 PRONTO  Previously-treated patients with AL amyloidosis and persistent cardiac dysfunction,Phase 2b,"04/23/2018  Phase 2b trial did not meet primary endpoint - April 23, 2018."
INCY,Baricitinib  Rheumatoid arthritis,Approved,"04/23/2018  Advisory Committee Meeting April 23, 2018 voted for lower dose but against higher dose. PDUFA date June 2018. Exact date unclear."
LLY,Baricitinib  Rheumatoid arthritis,Approved,"04/23/2018  Advisory Committee Meeting April 23, 2018 voted for lower dose but against higher dose. PDUFA date June 2018. Exact date unclear."
MRTX,Mocetinostat and durvalumab  Non-small cell lung cancer (NSCLC),Phase 2,"04/24/2018  Update provided April 24, 2018 - 3/23 partial responses."
MRTX,Sitravatinib plus nivolumab  Non-small cell lung cancer (NSCLC),Phase 2,"04/24/2018  Update provided April 24, 2018 - 6/23 partial responses."
AZN,Durvalumab +/- tremelimumab (ARCTIC)  Non-small cell lung cancer (NSCLC),Phase 3,"04/24/2018  Phase 3 data released April 24, 2018 - primary endpoints not met."
GSK,Trelegy Ellipta (FF/UMEC/VI)  Chronic obstructive pulmonary disease (COPD),Approved,"04/24/2018  Approval announced April 24, 2018."
INVA,Trelegy Ellipta (FF/UMEC/VI)  Chronic obstructive pulmonary disease (COPD),Approved,"04/24/2018  Approval announced April 24, 2018."
NVS,AVXS-101 Spinal muscular atrophy (SMA) Type 1,BLA Filing,"04/24/2018  Initial pivotal trial data released April 24, 2018 - no serious adverse events reported."
TSRO,Niraparib - (QUADRA trial) Cancer - ovarian,Phase 2,"04/24/2018  Phase 2 top-line data released April 24, 2018."
AXSM,AXS-05 STRIDE-1  Treatment resistant depression,Phase 3,"04/26/2018  Interim analysis April 26, 2018 recommended trial to continue."
IMGN,Mirvetuximab soravtansine - FORWARD I  Cancer - ovarian cancer and relapsed endometrial cancer,Phase 3,"04/26/2018  Interim analysis April 26, 2018 recommended trial to continue to completion. Top-line data due 1H 2019."
AGN,UBROGEPANT  Migraine,Phase 3,"04/27/2018  Phase 3 data due released April 27, 2018. High dose met both primary endpoints. Low dose met one of two."
KPTI,Selinexor  Quadruple Refractory Multiple Myeloma,PDUFA priority review,"04/30/2018  Phase 2b STORM Study Expansion data released April 30, 2018 - ORR 25%."
NVS,Tafinlar (dabrafenib) and Mekinist (trametinib)  Melanoma with BRAF V600E or V600K mutations,Approved,"04/30/2018  Approval announced April 30, 2018."
SIGA,TPOXX  Smallpox,Approved,"05/01/2018  PDUFA date August 8, 2018 under priority review. Advisory Committee Meeting May 1, 2018 voted 17-0 in favor of approval."
NVS,Kymriah (CTL019 )- JULIET  Cancer - Diffuse Large B-Cell Lymphoma (DLBCL),Approved,"05/01/2018  Approval announced May 1, 2018."
AKAO,Plazomicin  Complicated urinary tract infections (cUTI),Approved,"05/02/2018  Advisory Committee Meeting May 2, 2018 voted for in favor of cUTI but against for the treatment of bloodstream infections in patients with limited or no treatment options."
BHC,ULTRA - 7 days  Contact lens,Approved,"05/02/2018  Approval announced March 2, 2018."
ESPR,Bempedoic acid (ETC-1002-040) - Clear Harmony  Hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins,Phase 3,"05/02/2018  Phase 3 long-term safety and tolerability data released May 2, 2018. Primary endpoint met."
ESPR,Bempedoic acid (ETC-1002-040) - Clear Harmony  Hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins,Phase 3,"05/02/2018  Phase 3 long-term safety and tolerability data released May 2, 2018. Primary endpoint met but high number of deaths vs placebo."
NVS,"Biosimilar rituximab  Various blood cancers, rheumatoid arthritis.",CRL,"05/02/2018  CRL issued May 2, 2018."
MNK,Stannsoporfin  Jaundice,CRL,"05/03/2018  Advisory Committee Meeting May 3, 2018 voted 3-21 against approval."
PTLA,Andexxa  Factor Xa inhibitor reversal agent,PDUFA,"05/03/2018  Approval announced May 3, 2018."
JNJ,Esketamine  Treatment resistant depression,NDA Filing,05/06/2018  Mixed data released at APA meeting. Data from other Phase 3 studies will be presented later in 2018.
BHC,Plenvu (NER1006)  Bowel cleansing,Approved,"05/07/2018  Approval announced May 7, 2018."
JNJ,DARZALEX (Daratumumab) - ALCYONE  Frontline multiple myeloma (non-transplant),Approved,"05/07/2018  Approval announced May 7, 2018."
LPCN,LPCN 1021  Men with low testosterone (Low T),-,"05/08/2018  CRL issued May 8, 2018."
VBIV,VBI-1501  Congenital Cytomegalovirus (CMV),Phase 1,"05/10/2018  Final data from the study released May 10, 2018."
EXEL,IMblaze370 - cobimetinib and atezolizumab  Third-line advanced or metastatic colorectal cancer,Phase 3,"05/10/2018  Phase 3 data released May 10, 2018. Primary endpoint not met."
RHHBY,IMblaze370 - cobimetinib and atezolizumab  Third-line advanced or metastatic colorectal cancer,Phase 3,"05/10/2018  Phase 3 data released May 10, 2018. Primary endpoint not met."
IONS,Volanesorsen - APPROACH  Familial chylomicronemia syndrome (FCS),CRL,"05/10/2018  PDUFA August 30, 2017. Advisory Committee Meeting May 10, 2018 voted 10-8 in favor."
AKCA,Volanesorsen - APPROACH  Familial chylomicronemia syndrome (FCS),CRL,"05/10/2018  PDUFA August 30, 2017. Advisory Committee Meeting May 10, 2018 voted 10-8 in favor."
AZN,Fasenra (benralizumab) - GALATHEA  Chronic obstructive pulmonary disease (COPD),Phase 3,"05/11/2018  Phase 3 trial did not meet primary endpoint - noted May 11, 2018."
NVS,Fingolimod  Multiple Sclerosis (MS),Approved,"05/11/2018  Approval announced May 11, 2018."
PFNX,PF708 and Forteo Osteoporosis,Phase 3,"05/14/2018  Top-line data released May 14, 2018. Comparable profile to Forteo (teriparatide). NDA filing due 3Q 2018."
XENE,XEN1101  Epilepsy,Phase 1,"05/15/2018  Phase 1 promising interim data presented May 15, 2018 at EILAT Conference."
EOLS,DWP-450  Glabellar lines,PDUFA,"05/16/2018  CRL announced May 16, 2018."
REGN,Dupixent (dupilumab)  Atopic dermatitis 12-17 year-olds,PDUFA priority review,"05/16/2018  Data released May 16, 2018 - primary and key secondary endpoints met."
SNY,Dupixent (dupilumab)  Atopic dermatitis 12-17 year-olds,PDUFA priority review,"05/16/2018  Data released May 16, 2018 - primary and key secondary endpoints met."
BOLD,AT132 - ASPIRO  X-Linked Myotubular Myopathy,Phase 1/2,"05/17/2018  Data presented at ASGCT meeting May 16, 2018 - noted six SAEs from 2/6 patients."
RARE,KRN23 Burosumab  X-Linked Hypophosphatemia (XLH),Phase 3,"05/17/2018  Phase 3 data in pediatric patients released May 17, 2018 - primary endpoint met."
AMGN,Erenumab  Migraine,Approved,"05/17/2018  Approval announced May 17, 2018."
NVS,Erenumab  Migraine,Approved,"05/17/2018  Approval announced May 17, 2018."
JNJ,Atabecestat  Alzheimer’s disease,Phase 2,"05/18/2018  Announced May 18, 2018 that dosing will be stopped."
AGRX,Twirla  Contraceptive patch,CRL,"05/18/2018  CRL issued 2013. Further CRL issued December 22, 2017. Noted May 18, 2018 that FDA will require further trials for resubmission to take place."
AZN,Lokelma (ZS-9)  Hyperkalaemia,Approved,"05/18/2018  Approval announced May 18, 2018."
RCKT,LVV-based gene therapy  Fanconi Anemia (FA),Phase 1/2,"05/18/2018  Phase 1/2 updated data presented at ASGCT meeting May 18, 2018."
SESN,Vicinium  Non-muscle invasive bladder cancer (NMIBC),Phase 3,"05/21/2018  Phase 3 preliminary data released May 21, 2018. Noted 42% CR. 12-month data due mid-2019."
URGN,MitoGel - UGN-101  Urothelial Carcinoma,Phase 3,"05/21/2018  Interim analysis presented May 21, 2018. 59% CR rate"
RHHBY,Hemlibra  Hemophilia,Approved,"05/21/2018  New Phase 3 HAVEN 3 data presented at WFH May 21, 2018. 96% reduction in bleeds."
NBRV,Lefamulin - LEAP 2  Moderate to severe Community Acquired Bacterial Pneumonia (CABP),Phase 3,05/21/2018  Primary endpoint met with NDA fling due 4Q 2018
DOVA,Avatrombopag  Thrombocytopenia in chronic liver disease (CLD) patients,Approved,"05/21/2018  Approval announced May 21, 2018."
AMGN,Prolia (denosumab) Glucocorticoid-induced osteoporosis (GIOP),Approved,"05/21/2018  Approval announced May 21, 2018."
FBIO,IV Tramadol  Post-operative Pain,Phase 3,"05/21/2018  Phase 3 data released May 21, 2018 - primary endpoint met. Data to be presented at later conference. Further Phase 3 trial to be initiated 3Q 2018."
ATXI,IV Tramadol  Post-operative Pain,Phase 3,"05/21/2018  Phase 3 data released May 21, 2018 - primary endpoint met. Data to be presented at later conference. Further Phase 3 trial to be initiated 3Q 2018."
ONCE,SPK-9001  Hemophilia B,Phase 1/2,"05/22/2018  Phase 1/2 updated data released May 22, 2018 - 98% decrease in bleeding rate."
INSY,Buprenorphine  Moderate to severe postoperative pain after bunionectomy,CRL,"05/22/2018  PDUFA date July 28, 2018. Advisory Committee Meeting May 22, 2018 voted against approval."
BMRN,Valoctocogene roxaparvovec (BMN 270)  Hemophilia A,Phase 2,"05/22/2018  Phase 1/2 update May 22, 2018 noted 97% decrease in bleeding rate."
ESPR,Bempedoic acid - CLEAR LDL-C Lowering Program 1002-046  Hypercholesterolemia - statin intolerance,Phase 3,"05/23/2018  Phase 3 data released May 23, 2018 - primary endpoint met. No fatal events. Discontinuation due to AE was greater than placebo."
REPH,Intravenous (IV) meloxicam Acute pain following bunionectomy surgery,PDUFA,"05/24/2018  CRL announced May 24, 2018."
BMRN,Palynziq (Pegvaliase)  Phenylketonuria (PKU),Approved,"05/24/2018  Approval announced May 24, 2018."
ABBV,Imbruvica and Gazyva - iLLUMINATE  Chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL),Phase 3,"05/24/2018  Phase 3 trial met PFS primary endpoint - May 24, 2018."
ABIO,Gencaro - GENETIC-AF trial Chronic Heart Failure,Phase 2b,"05/27/2018  Oral presentation of data May 27, 2018."
RHHBY,TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) - IMpower130  Squamous non-small cell lung cancer (NSCLC),Phase 3,"05/29/2018  Phase 3 data released May 29, 2018. Primary endpoint met."
VRTX,CTX001  Sickle cell disease,Phase 1,"05/30/2018  IND placed on clinical hold - May 30, 2018."
CRSP,CTX001  Sickle cell disease,Phase 1,"05/30/2018  IND placed on clinical hold - May 30, 2018."
GLPG,Filgotinib - SELECTION Ulcerative colitis,Phase 3,"05/30/2018  Phase 2b interim analysis May 30, 2018 noted trial to continue to Phase 3 portion of trial."
GILD,Filgotinib - SELECTION Ulcerative colitis,Phase 3,"05/30/2018  Phase 2b interim analysis May 30, 2018 noted trial to continue to Phase 3 portion of trial."
IMMP,Eftilagimod alpha and Keytruda  Melanoma,Phase 1,"05/30/2018  Phase 1 data released May 30, 2018 showed ORR of 61% (11/18 patients)."
AZN,Benralizumab - TERRANOVA  COPD,Phase 3,"05/30/2018  Phase 3 data released May 30, 2018. Primary endpoint not met."
TXMD,Yuvvexy - TX-004HR  Moderate-to-severe vaginal pain,Approved,"05/30/2018  CRL announced May 8, 2017. NDA resubmitted with approval announced May 30, 2018."
GLPG,Filgotinib - EQUATOR  Psoriatic arthritis,Phase 2,"05/30/2018  Phase 2 data released May 30, 2018 - primary endpoint met."
GILD,Filgotinib - EQUATOR  Psoriatic arthritis,Phase 2,"05/30/2018  Phase 2 data released May 30, 2018 - primary endpoint met."
PFE,Xeljanz  Ulcerative colitis,Approved,"05/30/2018  Approval announced May 30, 2018."
OGEN,AG013  Oral mucositis (OM),Phase 2,"05/30/2018  Phase 2 interim safety analysis conducted May 30, 2018 noted trial to continue. Top-line data due late-2019."
MDGL,MGL-3196 Non-alcoholic steatohepatitis (NASH),Phase 2,"05/31/2018  Top-line 36-week data released May 31, 2018 met primary endpoint."
VKTX,VK2809  Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease,Phase 2,05/31/2018  Sympathy trade following positive MDGL data.
CLSD,Suprachoroidal CLS-TA - TYBEE  Diabetic Macular Edema (DME),Phase 2,"05/31/2018  Phase 2 data released May 31, 2018 - mixed data. 12.3 ETDRS letters compared to 13.5 ETDRS letters in control arm."
SCPH,Furoscix  Heart failure,CRL,"05/31/2018  PDUFA June 23, 2018. Noted May 31, 2018 that the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements."
MEIP,Pracinostat in combination with Vidaza  High-risk Myelodysplastic Syndrome (MDS),Phase 2,"05/31/2018  Phase 2 commencement of dosing announced June 14, 2017 - analysis from first stage released May 31, 2018 - trial to expand enrollment."
KTOV,KIT-302  Osteoarthritis and Hypertension,Approved,"05/31/2018  Approval announced May 31, 2018."
SLS,NeuVax in combination with Herceptin  Breast cancer - 1+/2+,Phase 2b,"06/01/2018  Noted June 1, 2018 that trial to be discontinued with trial meeting clinical objectives."
AMGN,KYPROLIS (ARROW)  Multiple Myeloma,Approved,"06/01/2018  Phase 3 trial data presented at ASCO June 1, 2018. 3.6 month improvement in PFS."
MTEM,MT-3724 and chemotherapy  Relapsed/refractory diffuse large B-cell lymphoma (DLBCL),Phase 1b,06/01/2018  Phase 2 trial to be initiated 2H 2018. Phase 1 data presented at ASCO June 2018. ORR 30%.
BLUE,bb2121  Relapsed/refractory multiple myeloma,Phase 1,"06/01/2018  Further data due at ASCO June 1, 2018 noted PFS of 11.8 months."
CELG,bb2121  Relapsed/refractory multiple myeloma,Phase 1,"06/01/2018  Further data due at ASCO June 1, 2018 noted PFS of 11.8 months."
AGIO,AG-881  Glioma,Phase 1,"06/01/2018  Phase 1 data presented at ASCO June 1, 2018. 1 minor response + 1 partial response out of 93 patients."
INCY,Baricitinib  Rheumatoid arthritis,Approved,"06/01/2018  FDA approval announced for low dose only - June 1, 2018."
LLY,Baricitinib  Rheumatoid arthritis,Approved,"06/01/2018  FDA approval announced for low dose only - June 1, 2018."
GTHX,G1T38 plus Faslodex  ER+ breast cancer,Phase 1b,06/02/2018  Phase 1b preliminary released at ASCO 2018 - 17% PR.
PBYI,Neratinib plus Kadcyla (T-DM1) HER2-positive metastatic breast cancer,Phase 1/2,"06/02/2018  Phase 1/2 interim data presented at ASCO June 2018. 9 PRs, 3CRs out of 20 patients."
RHHBY,Tecentriq+cb+pac/nab-pac - IMpower131  Squamous non-small cell lung cancer (NSCLC),Phase 3,06/02/2018  https://www.roche.com/media/releases/med-cor-2018-06-02.htm
NKTR,"NKTR-214 + OPDIVO (nivolumab) - PIVOT-02  Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers",Phase 1/2,"06/02/2018  Phase 1/2 preliminary data at ASCO 2018. PR rates - Melanoma 50%; RCC 46%; Urothelial Carcinoma 60%. Updated data likely at SITC meeting November 7-11, 2018."
BMY,"NKTR-214 + OPDIVO (nivolumab) - PIVOT-02  Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers",Phase 1/2,"06/02/2018  Phase 1/2 preliminary data at ASCO 2018. PR rates - Melanoma 50%; RCC 46%; Urothelial Carcinoma 60%. Updated data likely at SITC meeting November 7-11, 2018."
ADAP,NY-ESO T-cell therapy  Myxoid round cell liposarcoma (MRCLS),Phase 1/2,"06/02/2018  Phase 1/2 data released ASCO June 2018 - 3 PRs, 1 unconfirmed PR, 3 SD out of 8 patients."
LOXO,"LOXO-292  RET-fusion non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and other tumors",Phase 1,"06/02/2018  Phase 1 data presented at ASCO June 2018 - 77% ORR RET Fusion Cancers, 45% ORR for Medullary Thyroid Cancer (MTC)."
CLDX,Varlilumab and nivolumab  Solid tumors - cancer,Phase 2,"06/02/2018  Data at ASCO 2018 noted ORR 14%, DCR 38% for ovarian, 20% for Colorectal cancer."
AGIO,AG-120 Ivosidenib  R/R Acute Myeloid Leukemia (AML),Phase 1,06/02/2018  Phase 1 data at ASCO June 2018 noted CR rate was 24%.
DCPH,DCC-2618  Gastrointestinal Stromal Tumors (GIST),Phase 1,06/02/2018  Phase 1 poster at ASCO June 2018 - ORR 9-24% in 2nd- >4th line patients.
SGEN,Enfortumab vedotin  Urothelial cancer,Phase 1,06/03/2018  Presentation at ASCO June 2018. ORR 41%.
IMMU,SACTUZUMAB GOVITECAN (IMMU-132) HR+/HER2- metastatic breast cancer,Phase 2,06/03/2018  Presentation at ASCO June 2018. ORR 31%.
CELG,Lico-cel (CD-19 JCAR017) - TRANSCEND  r/r B cell non-Hodgkin lymphoma - cancer,Phase 1/2,"06/03/2018  Phase 1 data presented at ASCO 2018. 49% ORR, 46% CR at 6 months."
NVS,Kisqali plus fulvestrant: MONALEESA-3 Breast cancer - (post-menopausal),Phase 3,06/03/2018  Phase 3 data presented at ASCO 2018 - PFS 20.5 months v 12.8 months
MRK,KEYTRUDA + carboplatin-paclitaxel or nab-paclitaxel KEYNOTE-407  Squamous non-small cell lung cancer (sNSCLC),Approved,"06/03/2018  Noted May 3, 2018 that sBLA filing has been submitted. Met OS and PFS endpoints - presentation at ASCO June 2018 noted HR=0.64."
JNJ,Erdafitinib  Urothelial cancer,NDA Filing,06/03/2018  Phase 2 data presented at ASCO 2018 - ORR 40%.
MRK,Keytruda - KEYNOTE-042  Non-small cell lung cancer (NSCLC),Phase 3,"06/03/2018  Phase 3 data released April 9, 2018. Overall survival endpoint met. Presentation at ASCO June 2018 HR 0.69."
AGEN,AGEN2034 (anti-PD-1)  Cervical cancer,Phase 1/2,06/04/2018  Phase 1 presentation at ASCO 2018. 42% ORR.
DVAX,SD-101 + Pembrolizumab  Melanoma and head and neck squamous cell carcinoma (HNSCC),Phase 1/2,06/04/2018  Phase 1/2 data released at ASCO 2018. ORR 70%.
MRSN,XMT1522  HER2 - breast cancer,Phase 1,06/04/2018  Phase 1 dose escalation at ASCO June 2018. SD rate 11/13 at higher doses.
CTMX,CX 072  Solid tumors,Phase 1/2,06/04/2018  Phase 1/2 initial data released at ASCO 2018. 15% ORR.
XLRN,Luspatercept Extension Study - PACE-MDS  Myelodysplastic Syndromes,Phase 2,06/04/2018  Phase 2 updated data at ASCO June 2018. 55% achieved a clinically meaningful erythroid improvement.
VXRT,BTA074 5% topical gel (teslexivir)  Condyloma,Phase 2,06/04/2018  Phase 2 trial did not meet primary endpoint.
MYL,MYL-1401H  Neulasta biosimilar,Approved,"06/04/2018  Approval announced June 4, 2018."
CALA,CB-839 plus capecitabine  Solid tumors,Phase 1,06/04/2018  Phase 1 presentation at ASCO June 2018. PFS 26 weeks.
AZN,Lynparza  Castration-Resistant Prostate Cancer,Phase 3,06/04/2018  Phase 2 presentation at ASCO 2018. rPFS 13.8mths.
MRK,Lynparza  Castration-Resistant Prostate Cancer,Phase 3,06/04/2018  Phase 2 presentation at ASCO 2018. rPFS 13.8mths.
AGIO,Enasidenib or ivosidenib with VIDAZA  Frontline AML with IDH1 or IDH2 mutation,Phase 1/2,"06/04/2018  Phase 1/2 updated data at ASCO June 2018. ORR of 78%, CR Rate of 44%."
AGEN,AGEN1884 (anti-CTLA-4)  Solid cancers,Phase 1,06/04/2018  Phase 1 presentation at ASCO 2018. 31% ORR.
INFI,IPI-549 + Nivolumab  Solid tumors,Phase 1,06/04/2018  Data presented at ASCO June 2018. PR 7%.
TSRO,Niraparib and Keytruda (TOPACIO)  Triple-negative Breast Cancer or Ovarian Cancer,Phase 1/2,06/04/2018  Phase 1/2 trial ongoing. Data at ASCO 2018 noted ORR 25%.
PTLA,Cerdulatinib (PRT2070)  Refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia - cancer,Phase 2,06/04/2018  Phase 2 interim data at ASCO June 2018. ORR 47%.
ZIOP,Ad-RTS-hIL-12 + veledimex  Glioblastoma Multiforme (GBM),Phase 1,06/04/2018  Phase 1 presentation at ASCO June 2018. OS 12.7mths.
MEIP,ME-401  Relapsed/refractory Follicular Lymphoma/Chronic Lymphocytic Leukemia (CLL),Phase 1b,06/04/2018  Phase 1b data presented at ASCO June 2018. ORR 90%.
MEIP,ME-344  HER2-negative Breast Cancer,Phase 1,06/04/2018  Phase 1 data presented at ASCO June 2018. Noted primary endpoint P=0.06.
RNN,RX-3117  Advanced bladder cancer - 3rd line,Phase 2a,06/04/2018  Phase 2a data presented at ASCO 2018. ORR 21%.
RNN,Supinoxin RX-5902  Triple negative breast cancer,Phase 2a,06/04/2018  Phase 1b/2a data at ASCO 2018 - 50% response rate.
BMY,CM-227 – Opdivo + Yervoy  First-line Non-small cell lung cancer (NSCLC),PDUFA,"06/04/2018  Phase 3 interim data released February 5, 2018 - co-primary endpoint of PFS met. Data presented at ASCO 2018 - HR 0.74."
TSRO,Niraparib - (QUADRA trial) Cancer - ovarian,Phase 2,06/04/2018  Additional data at ASCO 2018 ORR 29%.
IDRA,Tilsotolimod + ipilimumab - ILLUMINATE 204  Cancer - melanoma,Phase 2,06/04/2018  Phase 2 data at ASCO 2018. 38% ORR.
PLX,OPRX-106  Ulcerative Colitis,Phase 2,"06/05/2018  Phase 2 data released March 13, 2018 - key endpoints met. Data presented at DDW Meeting - 67% of patients experienced a clinical response."
LLY,KEYTRUDA + chemo (KEYNOTE-021)  First-Line Nonsquamous Non-small cell lung cancer (NSCLC),Approved,"06/05/2018  FDA approval (label expansion) announced June 5, 2018."
MRK,KEYTRUDA + chemo (KEYNOTE-021)  First-Line Nonsquamous Non-small cell lung cancer (NSCLC),Approved,"06/05/2018  FDA approval (label expansion) announced June 5, 2018."
LLY,Mirikizumab (LY3074828)  Ulcerative Colitis,Phase 2,"06/05/2018  Phase 2 data presented at DDW June 5, 2018. 41.3-59.7% achieved clinical response vs 20.6% for placebo."
ABBV,ABT-494 - SELECT-EARLY  Rheumatoid arthritis,Phase 3,"06/05/2018  Phase 3 trial met all endpoints - June 5, 2018. Regulatory filing due 2H 2018."
PTI,PTI-801: Corrector Cystic fibrosis,Phase 1,"06/06/2018  Phase 1 additional data released June 6, 2018. Final data due 3Q 2018."
RHHBY,MabThera/ Rituxan (rituximab)  Pemphigus vulgaris,Approved,"06/07/2018  Approval announced June 7, 2018."
AMGN,KYPROLIS (ASPIRE)  Relapsed Multiple Myeloma,Approved,"06/11/2018  sNDA approval announced June 11, 2018."
VICL,VCL-HB01 HSV-2 Therapeutic Vaccine  Genital Herpes in Adults,Phase 2,"06/11/2018  Phase 2 trial did not meet primary endpoint - June 11, 2018."
AGN,ATOGEPANT  Prophylaxis (migraine),Phase 2b,"06/11/2018  Phase 2b top-line data released June 11, 2018 - primary endpoint met."
AZN,Lanabecestat (AZD3293) - AMARANTH  Early Alzheimer's disease,Phase 3,06/11/2018  Announced discontinuation of trial due to futility.
LLY,Lanabecestat (AZD3293) - AMARANTH  Early Alzheimer's disease,Phase 3,06/11/2018  Announced discontinuation of trial due to futility.
ABBV,Venclexta (MURANO)  Relapsed or refractory Chronic Lymphocytic Leukemia (CLL),Approved,"06/11/2018  Approval announced June 11, 2018."
RHHBY,Venclexta (MURANO)  Relapsed or refractory Chronic Lymphocytic Leukemia (CLL),Approved,"06/11/2018  Approval announced June 11, 2018."
VTVT,Azeliragon - STEADFAST Mild Alzheimer’s disease,Phase 3,"06/12/2018  Phase 3 data from Part A released April 9, 2018 did not meet endpoints. Part B data released June 12, 2018 also did not meet endpoints."
GLMD,Aramchol - ARREST  Non-Alcoholic Steatohepatitis (NASH),Phase 2b,"06/12/2018  Phase 2b data released June 12, 2018 - mixed data."
PSTI,"PLX-PAD (stem cells)  Intermittent claudication, or IC",Phase 2,"06/12/2018  Phase 2 data released June 12, 2018 - primary endpoint met."
MRK,KEYTRUDA  Cervical cancer,Approved,"06/12/2018  Approval announced June 12, 2018."
IDRA,IMO-8400  Dermatomyositis,Phase 2,"06/12/2018  Phase 2 data released June 12, 2018 - primary endpoint not met."
MRK,Keytruda  Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL),Approved,"06/13/2018  Approval announced June 13, 2018."
FLKS,FLX-787 COMMIT  Charcot-Marie-Tooth (CMT),Phase 2,"06/13/2018  Phase 2 trial terminated - noted June 13, 2018."
FLKS,FLX-787 - COMMEND US trial  Amyotrophic lateral sclerosis (ALS),Phase 2,"06/13/2018  Phase 2 trial terminated - noted June 13, 2018."
RHHBY,Avastin (bevacizumab) + chemo  Ovarian cancer,Approved,"06/13/2018  FDA approval announced June 13, 2018."
SCPH,Furoscix  Heart failure,CRL,"06/13/2018  CRL issued June 13, 2018 (10 days early). Additional trials required."
BPMC,Avapritnib BLU-285 - EXPLORER  Advanced Systemic mastocytosis (SM),Phase 1,"06/15/2018  Phase 1 updated data due at EHA June 15, 2018. ORR 83%."
TGTX,TGR-1202  Myelofibrosis,Phase 1,06/15/2018  Phase 1 updated data released at EHA June 2018. 2 patients (9%) achieved a durable complete remission.
TEVA,Fremanezumab  Cluster headache,Phase 3,"06/15/2018  Phase 3 trial to be terminated due to lack of efficacy - noted June 15, 2018."
ATRA,ATA 129 Epstein-Barr virus (EBV-PTLD),Phase 2,06/15/2018  Phase 2 presentation at EHA June 2018. Median survival in SOT patients was 21.3 months and was not reached in the HCT population after 23.3 months.
BGNE,Zanubrutinib (BGB-3111)  Waldenström’s macroglobulinemia,Phase 1/2,06/15/2018  Phase 1 data to be presented at EHA June 2018 - ORR 92%.
KDMN,KD025 - ROCKstar (KD025-213)  Chronic graft-versus-host disease (cGVHD),Phase 2,06/15/2018  Updated data at EHA June 2018 noted ORR 67%.
GBT,GBT440 HOPE-KIDS 1  Sickle cell disease - children age 6-17.,Phase 2a,"06/15/2018  Phase 2a Part B data released EHA June 15, 2018."
ARQL,ARQ 531  B-cell malignancies,Phase 1a,06/15/2018  Phase 1 data EHA June 2018. 29-35% tumor reduction.
BLUE,LentiGlobin - HGB-207 Northstar-2  non-β0/β0 transfusion-dependent thalassemia (TDT),Phase 3,06/15/2018  Data released at EHA June 2018. 7/8 patients producing ≥ 7.6 g/dL of HbAT87Q and are maintaining hemoglobin levels of 11.1 – 13.3 g/dL by 6 months.
BLUE,LentiGlobin - HGB-206  Sickle disease,Phase 1/2,06/15/2018  Update at EHA June 2018. All patients (4) in Group C with ≥ 3 months follow-up producing ≥ 30% anti-sickling HbA.
EPZM,Tazemetostat  Follicular lymphoma,Phase 2,06/15/2018  Phase 2 data released at EHA June 2018. Noted FL patients with wild-type ORR 33%; EZH2 ORR 71%.
MOR,MOR208 + idelalisib (COSMOS)  Chronic Lymphocytic Leukemia,Phase 2,06/15/2018  Phase 2 presentation at EHA June 2018. ORR 82%. CR 9%.
BMY,Empliciti (elotuzumab) - ELOQUENT-3  Relapsed/refractory multiple myeloma,Approved,"06/17/2018  Phase 2 trial met primary endpoint - noted June 17, 2018. HR HR 0.54. Median PFS 10.3 months."
BHC,DUOBRII (halobetasol propionate and tazarotene)  Psoriasis,PDUFA,"06/18/2018  CRL issued June 18, 2018."
RYTM,"Setmelanotide  POMC Heterozygous Deficiency Obesity, Alstrom Syndrome, POMC Epigenetic Disorders",Phase 2,"06/18/2018  Initial data released June 18, 2018: Alstrom Syndrome - Phase 2 proof of concept achieved. Phase 3 trial planned; POMC Heterozygous Deficiency Obesity - 3/4 patients discontinued; POMC Epigenetic Disorders - positive data from one patient released."
OBSV,OBE2109  Endometriosis,Phase 2b,"06/18/2018  Phase 2b trial met endpoints - June 18, 2018."
SLDB,SGT-001  Duchenne Muscular Dystrophy,Phase 1/2,"06/18/2018  Clinical hold announced March 14, 2018. Hold released June 18, 2018."
CBIO,CB 2679d/ ISU304  Hemophilia B,Phase 1/2,"06/18/2018  Cohort 6 patients (2) safety concerns - presence of neutralizing antibodies - noted June 18, 2018."
TGTX,TG-1101 (ublituximab)  Relapsing forms of Multiple Sclerosis (RMS),Phase 2a,"06/18/2018  Phase 2a updated data released at EAN June 18, 2018. Annualized Relapse Rate (ARR) of 0.07."
PTCT,RG7916 - FIREFISH  Spinal Muscular Atrophy (SMA) Type 1,Phase 2/3,"06/18/2018  Updated positive Phase 1 data released June 16, 2018."
ZIOP,Sleeping beauty  Solid tumors,Phase 1,"06/18/2018  Phase 1 trial placed on clinical hold - June 18, 2018."
SRPT,Microdystrophin gene therapy  Duchenne muscular dystrophy,Phase 1/2,"06/19/2018  Phase 1/2 positive data from three patients presented June 19, 2018."
KZIA,Cantrixil  Ovarian cancer,Phase 1,"06/19/2018  Phase 1 initial data released June 19, 2018. 2/5 SD. One PR."
ANIK,Cingal  Osteoarthritis,Phase 3,"06/19/2018  Phase 3 trial did not meet primary endpoint - June 19, 2018."
ARGX,Efgartigimod (ARGX-113)  Pemphigus vulgaris (PV),Phase 2,"06/20/2018  Phase 2 interim data released June 20, 2018, disease control observed in 4/6 patients."
INCY,Ruxolitinib  Graft versus host disease,PDUFA priority review,"06/21/2018  Phase 2 pivotal data released June 21, 2018. Primary endpoint met. sNDA filing due 3Q 2018."
NVS,Ruxolitinib  Graft versus host disease,PDUFA priority review,"06/21/2018  Phase 2 pivotal data released June 21, 2018. Primary endpoint met. sNDA filing due 3Q 2018."
HRTX,HTX-011  Total knee arthroplasty,Phase 2b,"06/21/2018  Phase 2 data released June 21, 2018. Primary endpoint met."
INCY,INCB50465 (CITADEL-202)  Diffuse large B cell lymphoma,Phase 2,"06/21/2018  Phase 2 trial to be discontinued - noted June 21, 2018."
ZFGN,ZGN-1061  Diabetes,Phase 2,"06/23/2018  Phase 2 trial met all endpoints - noted June 23, 2018."
ARRY,Encorafenib and cetuximab - BEACON CRC  BRAF-Mutant Colorectal Cancer,Phase 3,"06/23/2018  Updated data June 23, 2018 noted one-year overall survival rate for this cohort was 62%. Median OS not yet reached. ORR 48%."
SPHS,Topsalysin (PRX302)  Localized low to intermediate risk prostate cancer,Phase 2,"06/25/2018  Noted patient death after second dose - June 25, 2018."
PFE,IBRANCE - PALOMA-3  Breast cancer,Phase 3,"06/25/2018  Phase 3 overall survival secondary endpoint not met - June 25, 2018. PFS primary endpoint met (announced previously)."
MACK,MM-141 - CARRIE  Cancer - front line pancreatic cancer,Phase 2,"06/25/2018  Phase 2 data released June 25, 2018 - endpoints not met."
LLY,Empagliflozin  Type 1 Diabetes,Phase 3,"06/25/2018  Phase 3 trial met primary endpoint - noted June 25, 2018."
RHHBY,Tecentriq+cb+etoposide - IMpower133  Squamous non-small cell lung cancer (NSCLC),Phase 3,"06/25/2018  Phase 3 data trial met co-primary endpoints of PFS and OS - June 25, 2018."
AKAO,Plazomicin  Complicated urinary tract infections (cUTI),Approved,06/26/2018  FDA approval for cUTI but CRL received for the treatment of bloodstream infection (BSI)
DRRX,Remoxy  Chronic pain,CRL,"06/26/2018  Advisory Committee Meeting June 26, 2018 voted 14-3 against recommending approval."
PTIE,Remoxy  Chronic pain,CRL,"06/26/2018  Advisory Committee Meeting June 26, 2018 voted 14-3 against recommending approval."
SMMT,Ezutromid  Duchenne muscular dystrophy,Phase 2,"06/27/2018  Phase 2 top-line data released June 27, 2018. Primary endpoint not met."
ARRY,Binimetinib - COLUMBUS  BRAF mutant melanoma cancer,Approved,"06/27/2018  Approval announced June 27, 2018."
AQXP,AQX-1125 LEADERSHIP  Bladder pain syndrome/interstitial cystitis (BPS/IC),Phase 3,"06/27/2018  Phase 3 data released June 27, 2018. Primary endpoint not met."
GBT,GBT440 - HOPE  Sickle cell disease in adults,Phase 3,"06/27/2018  Phase 3 Part A data released June 27, 2018. Primary endpoint met. Met with FDA to discuss potential accelerated approval."
AMGN,ABP 710  REMICADE biosimilar - rheumatoid arthritis,Phase 3,"06/27/2018  Phase 3 data released June 27, 2018 confirmed non-inferiority compared to infliximab, could not rule out superiority."
CARA,IV CR845  Acute pain,Phase 3,"06/27/2018  Phase 3 data released June 27, 2018. Company noted primary endpoint but data mixed."
AZN,Lynparza - SOLO 1  First-line ovarian cancer following platinum-based chemotherapy,PDUFA priority review,"06/27/2018  Phase 3 data released June 27, 2018. PFS endpoint met."
MRK,Lynparza - SOLO 1  First-line ovarian cancer following platinum-based chemotherapy,PDUFA priority review,"06/27/2018  Phase 3 data released June 27, 2018. PFS endpoint met."
LLY,Ixekizumab  Axial Spondyloarthritis,Phase 3,"06/28/2018  Phase 3 trial met primary endpoint - noted June 28, 2018."
GLPG,GLPG2737 - PELICAN  Adult CF patients who are homozygous for the Class II F508del mutation,Phase 2,"06/28/2018  Phase 2 top-line data lower than expectations released June 28, 2018."
GEMP,Gemcabene - INDIGO-1  Severe Hypertriglyceridemia (SHTG),Phase 2b,"06/28/2018  Phase 2b primary endpoint met - June 28, 2018."
ASNS,ASN100  Staphylococcus aureus,Phase 2,"06/28/2018  Phase 2 trial to be discontinued due to futility - June 28, 2018."
XLRN,Luspatercept - MEDALIST  Myelodysplastic syndromes (MDS) cancer,Phase 3,"06/28/2018  Phase 3 trial met primary endpoint - June 28, 2018."
CELG,Luspatercept - MEDALIST  Myelodysplastic syndromes (MDS) cancer,Phase 3,"06/28/2018  Phase 3 trial met primary endpoint - June 28, 2018."
DERM,Glycopyrronium tosylate  Primary axillary hyperhidrosis,Approved,"06/29/2018  Approval announced June 29, 2018."
RHHBY,Tecentriq plus nab-paclitaxe - IMpassion 130  First-line triple negative breast cancer (TNBC),Phase 3,07/01/2018  https://www.roche.com/media/releases/med-cor-2018-07-02.htm
ALKS,Aripiprazole Lauroxil NanoCrystal Dispersion (ALNCD)  Schizophrenia,Approved,"07/02/2018  FDA approval announced July 2, 2018."
TTNP,Ropinirole implant  Parkinson's disease,Phase 1/2,"07/02/2018  DSMB recommended trial to continue - July 2, 2018 but further enrollment has been postponed due to lack of resources."
CTIC,Pacritinib - PAC203  Myelofibrosis,Phase 2,"07/02/2018  Phase 2 interim analysis noted July 2, 2018 that trial should continue."
ZYNE,ZYN001  Healthy volunteers,Phase 1,07/05/2018  Phase 1 trial failed to meet target blood levels. Company to focus on ZYN002.
RGLS,RGLS4326 Autosomal dominant polycystic kidney disease (ADPKD),Phase 1,07/05/2018  Phase 1 trial has been paused due to unexpected levels observations in mouse toxicity trial.
BIIB,BAN2401 (Aβ mAb)  Alzheimer’s disease,Phase 2,"07/05/2018  Phase 2 data released July 5, 2018 noted statistically significant slowing of disease progression on the ADCOMS endpoint after 18 months."
KMPH,KP415  ADHD,Phase 3,"07/09/2018  Top-line data released July 9, 2018 - primary endpoint met."
CTIC,PIXUVRI - PIX306 Trial  B-cell non-Hodgkin lymphoma,Phase 3,07/09/2018  Phase 3 data released July 10. 2018. Primary endpoint not met.
XLRN,Luspatercept - BELIEVE  b -thalassemia,Phase 3,"07/09/2018  Phase 3 data released July 9, 2018. Primary and key secondary endpoints met."
CELG,Luspatercept - BELIEVE  b -thalassemia,Phase 3,"07/09/2018  Phase 3 data released July 9, 2018. Primary and key secondary endpoints met."
SCYX,SCY-078 - oral  Vulvovaginal candidiasis (VVC),Phase 2b,"07/10/2018  Phase 2b data released July 10, 2018."
BMY,CM-142 – Opdivo (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (CRC),Approved,"07/11/2018  Approval announced July 11, 2018."
ABBV,IMBRUVICA (ibrutinib)  Diffuse large B-cell lymphoma (DLBCL),Phase 3,"07/11/2018  Phase 3 trial did not meet primary endpoint - noted July 11, 2018."
JNJ,IMBRUVICA (ibrutinib)  Diffuse large B-cell lymphoma (DLBCL),Phase 3,"07/11/2018  Phase 3 trial did not meet primary endpoint - noted July 11, 2018."
ZGNX,ZX008 - Study 1504  Dravet syndrom,Phase 3,"07/12/2018  Phase 3 data released July 12, 2018. Primary endpoint met."
SIGA,TPOXX  Smallpox,Approved,"07/13/2018  FDA approval announced July 13, 2018."
PFE,XTANDI (PROSPER)  Non-metastatic high risk hormone-sensitive prostate cancer,Approved,"07/13/2018  FDA approval announced July 13, 2018."
ADXS,Axalimogene filolisbac + durvalumab  Recurrent or refractory HPV-associated cervical cancer and head & neck cancer,Phase 1/2,"07/13/2018  Clinical hold announced March 2018 released July 13, 2018."
JNJ,INVOKANA - CREDENCE  Diabetic Kidney Disease,Phase 3,"07/16/2018  Phase 3 trial stopped early due to positive efficacy - July 16, 2018."
RCUS,AB928  Healthy volunteers,Phase 1,"07/17/2018  Phase 1 data released July 17, 2018. Safe and well tolerated."
PULM,Pulmazole (PUR1900)  Allergic bronchopulmonary aspergillosis in patients with asthma.,Phase 1,"07/17/2018  Phase 1 Part 3 data released July 17, 2018 - safe and well tolerated"
JNJ,D/C/F/TAF  HIV,Approved,"07/18/2018  FDA Approval announced July 17, 2018."
LLY,Tanezumab  Osteoarthritis,Phase 3,"07/18/2018  Phase 3 data released July 18, 2018 - co-primary endpoints met."
PFE,Tanezumab  Osteoarthritis,Phase 3,"07/18/2018  Phase 3 data released July 18, 2018 - co-primary endpoints met."
CBIO,Marzeptacog alfa  Hemophilia,Phase 2/3,"07/18/2018  Phase 2 interim data released July 18, 2018. Phase 2 portion of trial to be completed by end of 2018."
MRSN,XMT1522  HER2 - breast cancer,Phase 1,"07/19/2018  Phase 1 partial clinical hold due to patient death announced July 19, 2018."
AGN,ABICIPAR  Age-related macular degeneration (AMD),Phase 3,"07/19/2018  Phase 3 data released July 19, 2018. Primary endpoint met."
LLY,Tradjenta (linagliptin) - CARMELINA CV outcomes  Type 2 Diabetes,Phase 3,"07/19/2018  Phase 3 trial met primary endpoint - July 19, 2018."
RHHBY,TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) - IMpower132  Squamous non-small cell lung cancer (NSCLC),Phase 3,"07/19/2018  Phase 3 data released July 19, 2018. PFS endpoint met, OS endpoint not yet met - final OS data due 2019."
AGIO,Ivosidenib  IDH1m Relapsed/Refractory AML - cancer,Approved,"07/20/2018  FDA Approval announced July 20, 2018."
RETA,Bardoxolone - PHOENIX  Chronic Kidney Disease,Phase 2,"07/23/2018  Phase 2 full data released July 23, 2018. Primary endpoint met."
XLRN,ACE-083  Charcot-Marie-Tooth disease (CMT),Phase 2,"07/23/2018  Phase 2 preliminary data presented July 23, 2018"
GSK,Tafenoquine  Malaria,Approved,"07/23/2018  FDA Approval announced July 23, 2018."
BGNE,Tislelizumab - BGB-A317  Relapsed or refractory classical Hodgkin lymphoma (cHL),Phase 2,"07/23/2018  Phase 2 pivotal preliminary data released July 23, 2018. ORR 73%, CR 50%."
CELG,REVLIMID - AUGMENT Relapsed or Refractory Follicular Lymphoma,Phase 3,"07/23/2018  Phase 3 data released July 23, 2018. Primary endpoint met. Regulatory filing due 1Q 2019."
NBIX,Elagolix Endometriosis,Approved,"07/24/2018  FDA approval announced July 24, 2018."
ABBV,Elagolix Endometriosis,Approved,"07/24/2018  FDA approval announced July 24, 2018."
MRK,Keytruda KN-048  Head and Neck Cancer,Phase 3,"07/25/2018  Phase 3 trial met OS primary endpoint - July 25, 2018. PFS endpoint not yet reached."
BIIB,BAN2401 (Aβ mAb)  Alzheimer’s disease,Phase 2,"07/25/2018  Phase 2 mixed data released July 25, 2018. High dose exhibited statistical improvement. Low doses missed."
CRMD,Neutrolin - LOCK-IT 100  Hemodialysis patients with central venous catheters,Phase 3,"07/25/2018  Phase 3 interim analysis July 25, 2018 by DSMB recommended trial to be stopped early as sufficient efficacy has been demonstrated."
TORC,RTB101 and Everolimus  Respiratory Tract Infections,Phase 2b,"07/25/2018  Phase 2b data released July 25, 2018. Once daily treatment met primary endpoint. Low dose, twice daily and combo failed."
GSK,Mepolizumab  Chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype,CRL,"07/25/2018  Advisory Committee July 25, 2018 voted 3-16 against recommending approval. PDUFA date September 7, 2018."
ATNX,KX-01 (KX2-391) Ointment  Actinic keratosis,Phase 3,"07/26/2018  Phase 3 data released July 26, 2018. Primary endpoint met."
ARRY,Selumetinib - ASTRA  Thyroid cancer,Phase 3,"07/26/2018  Phase 3 trial did not meet primary endpoint - noted July 26, 2018."
AZN,Selumetinib - ASTRA  Thyroid cancer,Phase 3,"07/26/2018  Phase 3 trial did not meet primary endpoint - noted July 26, 2018."
INSY,Buprenorphine  Moderate to severe postoperative pain after bunionectomy,CRL,"07/27/2018  CRL issued July 27, 2018."
TNXP,TNX-102 SL (Tonmya)  Post-traumatic stress disorder (PTSD),Phase 3,"07/27/2018  Phase 3 trial halted due to insufficient efficacy - July 27, 2018."
DRRX,RBP-7000  Schizophrenia,Approved,"07/27/2018  FDA Approval announced July 27, 2018."
SNNA,SNA-001 Acne,Phase 3,"07/30/2018  Phase 3 data released July 30, 2018 did not meet primary endpoint."
RDHL,RHB-104 MAP US  Crohn’s disease,Phase 3,"07/30/2018  Phase 3 data released July 30, 2018. Primary endpoint met but further trial required."
PGNX,Azedra  Pheochromocytoma,Approved,"07/30/2018  FDA approval announced July 30, 2018."
TBPH,TD-9855  nOH,Phase 2a,"08/01/2018  Phase 2a data released August 1, 2018 with Phase 3 trial to commence late 2018 or early 2019."
SBPH,Inarigivir - ACHIEVE  Hepatitis B (HBV),Phase 2a,"08/02/2018  Phase 2 data from third cohort met primary endpoint - August 2, 2018."
EPZM,Tazemetostat  Follicular lymphoma,Phase 2,"08/02/2018  Phase 2 trial terminated due to lack of efficacy - August 8, 2018."
OVID,OV101 (STARS)  Adults with Angelman syndrome,Phase 2,"08/06/2018  Phase 2 data released August 6, 2018. Primary endpoint met but twice-a-day group failed to score significantly better than placebo."
PTGX,PTG-100  Ulcerative colitis,Phase 2b,"08/06/2018  Phase 2b trial discontinued following interim analysis - March 26, 2018. However, company noted August 6, 2018 that human error by CRO contributed to this decision. Will meet with FDA 2H to discuss future development."
DRRX,Remoxy  Chronic pain,CRL,"08/06/2018  CRL issued September 26, 2016. NDA refiled but additional CRL issued August 6, 2018."
PTIE,Remoxy  Chronic pain,CRL,"08/06/2018  CRL issued September 26, 2016. NDA refiled but additional CRL issued August 6, 2018."
BLPH,INOpulse delivery device  Pulmonary Arterial Hypertension (PAH),Phase 3,"08/07/2018  Phase 3 trial stopped due to futility - August 7, 2018."
AMPE,Ampion  Osteoarthritis of the Knee,Phase 3,"08/07/2018  Noted August 7, 2018 that further trials required before filing BLA."
ONCE,SPK-8011  Hemophilia A,Phase 1/2,"08/07/2018  Phase 1/2 data updated data released August 7, 2018. 5/7 patients showed positive FVIII levels, but two patients showed low levels below 5%."
RGNX,RGX-501  Homozygous familial hypercholesterolemia (HoFH),Phase 1/2,"08/08/2018  Phase 1/2 interim data released August 8, 2018. Four SAEs + no improvement in LDL levels of low dose cohort. Further data due 4Q 2018."
UTHR,Orenitram Pulmonary arterial hypertension (PAH),Phase 3,"08/08/2018  Phase 3 data released August 8, 2018. Primary endpoint met."
SBBP,COR-003 (levoketoconazole) - SONICS  Endogenous Cushing’s syndrome,Phase 3,"08/08/2018  Phase 3 data released August 8, 2018. Primary endpoint met."
PRTK,Omadacycline  Acute bacterial skin and skin structure infections (ABSSSI),Approved,"08/08/2018  PDUFA date under priority review estimated October 4, 2018. Advisory Committee Meeting August 8, 2018 voted 14-4 in support of approval."
ALNY,Patisiran Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR,Approved,"08/10/2018  FDA Approval announced August 10, 2018."
SNY,Patisiran Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR,Approved,"08/10/2018  FDA Approval announced August 10, 2018."
GEMP,Gemcabene  Pediatric Non-Alcoholic Fatty Liver Disease (NAFLD),Phase 2,"08/10/2018  Phase 2 trial terminated - noted August 10, 2018."
TXMD,Segesterone Acetate/ Ethinyl Estradiol  Contraception,Approved,"08/10/2018  FDA Approval announced August 10, 2018."
FOLD,Migalastat  Fabry Disease,Approved,"08/10/2018  FDA Approval announced August 10, 2018."
REGN,EYLEA  Wet AMD,Approved,"08/13/2018  CRL issued August 13, 2018 - ongoing labeling discussions."
AGN,ESMYA (ulipristal acetate)  Uterine Fibroids,CRL,"08/14/2018  CRL issued August 21, 2018."
REGN,Fasinumab  Moderate-to-severe osteoarthritis pain of the hip or knee,Phase 3,"08/16/2018  Phase 3 trial met co-primary endpoints - August 16, 2018. Low dose arms only."
TEVA,Fasinumab  Moderate-to-severe osteoarthritis pain of the hip or knee,Phase 3,"08/16/2018  Phase 3 trial met co-primary endpoints - August 16, 2018. Low dose arms only."
BMY,CM-32 - Opdivo+chemo  Small cell lung cancer (SCLC),Approved,"08/17/2018  FDA approval announced August 17, 2018."
LLY,(MK-3475-189/KEYNOTE-189)  First Line Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC),Approved,"08/20/2018  FDA approval announced August 20, 2018."
MRK,(MK-3475-189/KEYNOTE-189)  First Line Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC),Approved,"08/20/2018  FDA approval announced August 20, 2018."
ESPR,Bempedoic Acid/ Ezetimibe (1002FDC-053)  Hypercholesterolemia,Phase 3,"08/20/2018  Phase 3 data released August 27, 2018."
MNK,Stannsoporfin  Jaundice,CRL,"08/22/2018  CRL issued August 22, 2018."
KALA,INVELTYS  Post‑operative inflammation and pain following cataract surgery,Approved,"08/23/2018  FDA approval announced August 23, 2018."
NVS,BYL719 + fulvestrant  HR + Metastatic breast cancer (MBC),Phase 3,"08/23/2018  Phase 3 trial met primary endpoint - August 23, 2018 with data to be presented at an upcoming medical congress."
ZLAB,Fugan (ZL-3101)  Eczema,Phase 2a,"08/24/2018  Phase 2 top-line data released August 24, 2018. Primary endpoint not met."
BHC,IDP-121 Acne,Approved,"08/24/2018  FDA Approval announced August 24, 2018."
PFE,Tafamidis  TTR amyloid cardiomyopathy,Phase 3,"08/27/2018  Phase 3 positive data released August 27, 2018."
SNNA,SNA-125  Psoriasis,Phase 1/2,"08/27/2018  Phase 1/2 data released August 27, 2018."
ABBV,IMBRUVICA (ibrutinib)  Waldenström’s Macroglobulinemia,Approved,"08/27/2018  FDA approval announced August 27, 2018."
JNJ,IMBRUVICA (ibrutinib)  Waldenström’s Macroglobulinemia,Approved,"08/27/2018  FDA approval announced August 27, 2018."
IONS,Volanesorsen - APPROACH  Familial chylomicronemia syndrome (FCS),CRL,"08/27/2018  CRL issued August 27, 2018."
AKCA,Volanesorsen - APPROACH  Familial chylomicronemia syndrome (FCS),CRL,"08/27/2018  CRL issued August 27, 2018."
TTPH,Eravacycline (TP-434) - IGNITE4  cIAI (complicated intra-abdominal infections),Approved,"08/27/2018  FDA approval announced August 27, 2018."
MRK,Doravirine (MK-1439)  HIV,Approved,"08/30/2018  FDA Approval announced August 30, 2018."
PFE,Domagrozumab  Duchenne muscular dystrophy (DMD),Phase 2,08/30/2018  Phase 2 development terminated due to lack of efficacy.
AZN,Anifrolumab  Lupus,Phase 3,"08/31/2018  Phase 3 TULIP 1 data released August 31, 2018. Primary endpoint not met."
AQST,Sympazan  Lennox-Gastaut Syndrome,Approved,"08/31/2018  Tentative approval announced August 31, 2018."
BCRX,BCX7353 - ZENITH-1  Angioedema attacks in patients with hereditary angioedema (HAE),Phase 2,"09/04/2018  Phase 2 data from first cohort released September 4, 2018 with further data due 1Q 2019."
EYEG,EGP-437  Non-infectious anterior uveitis,Phase 3,"09/04/2018  Phase 3 data did not demonstrate non-inferiority - September 4, 2018."
SPPI,Poziotinib  Non-small cell lung cancer (NSCLC) with exon 20 insertion mutation in EGFR or HER2,Phase 2,"09/05/2018  Phase 2 abstract noted ORR 58%; PFS 5.6 months. Further data to be presented September 24, 2018."
HSGX,NeoCart  Cartilage defects in the knee,Phase 3,"09/05/2018  Phase 3 data released September 5, 2018. Primary endpoint not met. To discuss with FDA possibility of filing BLA."
SGMO,SB-913 - CHAMPIONS  MPS Type 2,Phase 1/2,"09/05/2018  Phase 1/2 initial mixed data released September 5, 2018. Further data due February at the 2019 WORLDSymposium."
PRQR,QR-010 Leber's Congenital Amaurosis (LCA) - Genetic blindness,Phase 1/2,"09/05/2018  Phase 1/2 interim positive data presented September 5, 2018. Phase 2/3 pivotal trial to commence 1H 2019."
LLY,Flortaucipir F 18 (Tau imaging agent)  Alzheimer's disease,Phase 3,"09/05/2018  Phase 3 trial met primary endpoints - September 5, 2018."
GLPG,Filgotinib - TORTUGA  Ankylosing spondylitis,Phase 2,"09/05/2018  Phase 2 data released September 6, 2018. Primary endpoint met."
GILD,Filgotinib - TORTUGA  Ankylosing spondylitis,Phase 2,"09/05/2018  Phase 2 data released September 6, 2018. Primary endpoint met."
IOVA,LN-144  Refractory metastatic melanoma,Phase 2,09/06/2018  Phase 2 update noted ORR 40%.
GSK,Mepolizumab  Chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype,CRL,"09/07/2018  CRL issued September 7, 2018."
FOLD,ATB200  Pompe Disease,Phase 1/2,"09/10/2018  Pivotal trial to be initiated 2H 2018, insufficient data to award accelerated approval pathway."
MRK,ZERBAXA(ceftolozane and tazobactam)  Hospital-acquired bacterial pneumonia (HABP),-,"09/11/2018  Phase 3 trial met primary endpoints, demonstrating non-inferiority to meropenem - September 11, 2018."
PFE,BAVENCIO (avelumab) and INLYTA (axitinib)  Renal cell carcinoma (RCC),Phase 3,"09/11/2018  Phase 3 interim analysis September 11, 2018 showed improvement in PFS."
GLPG,Filgotinib - FINCH 2  Rheumatoid arthritis (RA),Phase 3,"09/11/2018  Phase 3 data released September 11, 2018. Endpoints met."
GILD,Filgotinib - FINCH 2  Rheumatoid arthritis (RA),Phase 3,"09/11/2018  Phase 3 data released September 11, 2018. Endpoints met."
INCY,Ruxolitinib Atopic dermatitis,Phase 2b,09/12/2018  Phase 2b primary and key secondary endpoints met.
VTL,"VTI-308  Alcohol-induced liver decompensation, or AILD",Phase 3,"09/12/2018  Phase 3 data released September 11, 2018 - endpoints not met."
PGNX,1404  Help visualize prostate cancer by targeting prostate specific membrane antigen (PSMA),Phase 3,09/12/2018  Phase 3 trial met one of two co-primary endpoints.
AZN,Moxetumomab  Cancer - leukaemia,Approved,"09/13/2018  Approval announced September 13, 2018."
ATOS,Endoxifen  Male breast cancer and Gynecomastia,Phase 1,"09/13/2018  Phase 1 preliminary data September 13, 2018 noted drug met safety and tolerability objectives."
TEVA,Fremanezumab  Migraine,Approved,"09/14/2018  FDA Approval announced September 14, 2018."
ARGX,ARGX-113  Immune thrombocytopenia (ITP),Phase 2,"09/17/2018  Phase 2 released September 17, 2018 - well-tolerated"
ZEAL,Dasiglucagon  Severe hypoglycemia in diabetes,Phase 3,"09/18/2018  Phase 3 data released September 18, 2018. Endpoints met."
VKTX,VK2809  Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease,Phase 2,"09/18/2018  Phase 2 data released September 18, 2018 met primary and secondary endpoints."
GALT,GR-MD-02 and pembrolizumab (KEYTRUDA)  Melanoma,Phase 1b,"09/20/2018  Phase 1b data released September 20, 2019. ORR 50%."
GTXI,Enobosarm Postmenopausal women with stress urinary incontinence (SUI),Phase 2,"09/21/2018  Phase 2 data released September 21, 2018 did not meet primary endpoint."
NITE,NSR-RPGR  X-linked Retinitis Pigmentosa,Phase 2/3,"09/22/2018  Phase 1/2 preliminary data released September 22, 2018."
ALXN,Eculizumab  Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD),Phase 3,"09/24/2018  Phase 3 primary endpoint met - September 24, 2018."
ARNA,Olorinab (APD371)  Pain associated with Crohn's disease,Phase 2,"09/24/2018  Phase 2 data released September 24, 2018."
SNDX,"Entinostat plus Keytruda - ENCORE 601  Recurrent non-small cell lung cancer (NSCLC), colorectal cancer",Phase 1/2,"09/24/2018  Phase 2 updated data to be presented September 24, 2018 did not meet prespecified ORR endpoint."
VSTM,Duvelisib - DUO  Chronic lymphocytic leukemia (CLL)//Small Lymphocytic Lymphoma (SLL)/Follicular Lymphoma,Approved,"09/24/2018  FDA Approval announced September 24, 2018."
AMRN,Vascepa REDUCE-IT outcomes trial  High Triglycerides With Mixed Dyslipidemia,Phase 3,"09/24/2018  Data released September 24, 2018 met primary endpoint."
RXDX,STARTRK-2 entrectinib  Solid tumors - cancer,Phase 2,"09/24/2018  Phase 2 data released September 24, 2018. 77% ORR (STARTRK-2, STARTRK-1 and ALKA trials)."
ANAB,ANB020 - etokimab  Severe adult eosinophilic asthma,Phase 2a,"09/24/2018  Phase 2a data released September 24, 2018."
TGTX,TG-1101 and TGR-1202 - UNITY-CLL study  Chronic Lymphocytic Leukemia (CLL) and non-Hodgkin's Lymphoma (NHL),Phase 3,"09/25/2018  Noted September 25, 2018 that primary analysis will focus on PFS rather than ORR"
FBIO,CK-101  Non-small cell lung cancer (NSCLC) and other solid tumors,Phase 1/2,"09/25/2018  Phase 1/2 preliminary data released September 24, 2018."
CKPT,CK-101  Non-small cell lung cancer (NSCLC) and other solid tumors,Phase 1/2,"09/25/2018  Phase 1/2 preliminary data released September 24, 2018."
LOXO,"LOXO-292  RET-fusion non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and other tumors",Phase 1,"09/25/2018  Phase 1 updated data released September 25, 2018. 68% ORR."
RARX,RA101495 SC  Atypical hemolytic uremic syndrome (aHUS),Phase 1b,"09/26/2018  Phase 1b PK data released September 26, 2018."
ALDX,ADX-102  Dry eye syndrome,Phase 2b,"09/26/2018  Phase 2b data released September 26, 2018."
GERN,Imetelstat - IMbarkStudy  Myelofibrosis,Phase 2,"09/27/2018  Janssen noted September 27, 2018 not to continue collaboration."
JNJ,Imetelstat - IMbarkStudy  Myelofibrosis,Phase 2,"09/27/2018  Janssen noted September 27, 2018 not to continue collaboration."
ADMP,Symjepi - low dose  Anaphylaxis,Approved,"09/27/2018  FDA Approval announced September 27, 2018."
ZEAL,Dasiglucagon  Severe hypoglycemia in diabetes - children,Phase 3,"09/27/2018  Phase 3 trial initiation announced September 27, 2018."
ALNY,Givosiran  Acute hepatic porphyrias,Phase 3,"09/27/2018  Phase 3 positive interim analysis reported September 27, 2018."
NVO,Somapacitan (NN8640) - REAL 3  Adult Growth Hormone Deficiency (AGHD),Phase 3,09/28/2018  Phase 2 AGHD data noted height velocity did not differ significantly compared to Norditropin.
LLY,"Galcanezumab - EVOLVE-1, EVOLVE-2 and REGAIN  Migraine prevention",Approved,"09/28/2018  FDA approval announced September 27, 2018."
REGN,Cemiplimab  Cutaneous squamous cell carcinoma,Approved,"09/28/2018  FDA Approval announced September 28, 2018."
SNY,Cemiplimab  Cutaneous squamous cell carcinoma,Approved,"09/28/2018  FDA Approval announced September 28, 2018."
INSM,ARIKAYCE  Nontuberculous mycobacterial (NTM) lung disease,Approved,"09/28/2018  FDA Approval announced September 28, 2018."
PFE,Dacomitinib  Non-small cell lung cancer (NSCLC),Approved,"09/28/2018  FDA Approval announced September 27, 2018."
BIIB,Raxatrigine - BIIB074 (Nav1.7 inhibitor)  Painful Lumbosacral Radiculopathy (PLSR),Phase 2,09/30/2018  Phase 2 data released September 2018 - primary endpoint not met.
OMER,OMS721  IgA nephropathy,Phase 3,"10/01/2018  Phase 2 data released October 1, 2018 showed only marginal improvement compared with placebo."
ATRS,XYOSTED (testosterone enanthate)  Testosterone deficiency,Approved,"10/01/2018  FDA Approval announced October 1, 2018."
AMGN,KYPROLIS (ARROW)  Multiple Myeloma,Approved,"10/01/2018  FDA approval announced October 1, 2018."
AVRO,AVR-RD-01  Fabry disease,Phase 1/2,"10/01/2018  Phase 2 interim update October 1, 2018."
RNN,RX-3117 in combination with Abraxane  First-line pancreatic cancer,Phase 2a,"10/02/2018  Phase 2 preliminary data noted out of 14 patients; 1CR 3PRs, 8 SD. Full data due 2019."
PRTK,Sarecycline  Severe acne vulgaris,Approved,"10/02/2018  FDA Approval announced October 2, 2018."
AGN,Sarecycline  Severe acne vulgaris,Approved,"10/02/2018  FDA Approval announced October 2, 2018."
LLY,Ultra rapid insulin  Diabetes,Phase 3,"10/02/2018  Phase 3 trial met primary endpoint - noted October 2, 2018."
CLRB,CLR 131  Multiple myeloma,Phase 1,"10/02/2018  Phase 1b data noted OS of 19.4 months - October 2, 2018."
PRTK,Omadacycline  Acute bacterial skin and skin structure infections (ABSSSI),Approved,"10/02/2018  FDA Approval announced October 2, 2018."
PRTK,Omadacycline  Community-acquired bacterial pneumonia (CABP),Approved,"10/02/2018  FDA Approval announced October 2, 2018."
SRPT,Microdystrophin gene therapy  Duchenne muscular dystrophy,Phase 1/2,"10/03/2018  Phase 1/2 updated data released October 3, 2018."
RHHBY,Hemlibra  Hemophilia,Approved,"10/04/2018  FDA Approval announced October 4, 2018."
PGNX,PyL  Prostate cancer,Phase 3,"10/05/2018  Phase 2/3 data noted one of two co-primary endpoints met - October 5, 2018."
IONS,Inotersen (IONIS-TTRRx)  NEURO-TTR - familial amyloid polyneuropathy (FAP).,Approved,"10/05/2018  FDA Approval announced October 5, 2018,"
PTCT,Inotersen (IONIS-TTRRx)  NEURO-TTR - familial amyloid polyneuropathy (FAP).,Approved,"10/05/2018  FDA Approval announced October 5, 2018,"
AKCA,Inotersen (IONIS-TTRRx)  NEURO-TTR - familial amyloid polyneuropathy (FAP).,Approved,"10/05/2018  FDA Approval announced October 5, 2018,"
CYTK,CK-2127107  Limited mobility,Phase 1b,10/05/2018  Phase 1b interim analysis noted lack of efficacy.
CYTK,Reldesemtiv (CK-2127107)  Chronic obstructive pulmonary disease (COPD),Phase 2,"10/05/2018  Phase 2 data did not meet endpoints - October 5, 2018."
MNLO,Serlopitant  Refractory chronic cough,Phase 2,"10/08/2018  Phase 2 data released October 8, 2018. Endpoints not met."
LOXO,"LOXO-292  RET-fusion non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and other tumors",Phase 1,"10/08/2018  Phase 1/2 updated data noted ORR of 59% - October 6, 2018."
BHC,IDP-122 Psoriasis,Approved,"10/08/2018  Tentative FDA Approval announced October 8, 2018. Final approval expected November 2018 pending the expiration of exclusivity for a related product."
XNCR,XmAb5871  Systemic Lupus Erythematosus (SLE),Phase 2,"10/08/2018  Phase 2 top-line data released October 5, 2018. Primary endpoint not met."
CELG,OTEZLA  Scalp Psoriasis,Phase 3,"10/08/2018  Phase 3 primary endpoint met - October 8, 2018."
AFMD,AFM11  Non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL),Phase 1,"10/08/2018  Phase 1 trial placed on clinical hold - October 8, 2018."
MRK,GARDASIL 9  Human Papilloma virus vaccine,Approved,"10/09/2018  Approval announced October 5, 2018."
VRTX,CTX001  Sickle cell disease,Phase 1,"10/10/2018  Phase 1 IND clinical hold released October 10, 2018."
CRSP,CTX001  Sickle cell disease,Phase 1,"10/10/2018  Phase 1 IND clinical hold released October 10, 2018."
IMDZ,CMB305 Soft tissue sarcomas,Phase 3,10/11/2018  Phase 3 trial to be discontinued due to lack of efficacy.
TRVN,Oliceridine (TRV130)  Moderate to severe acute pain,CRL,"10/11/2018  Advisory Committee Meeting October 11, 2018 voted 7-8 against recommending approval."
BMY,CM-331– Opdivo Second-line Small cell lung cancer (SCLC),Phase 3,"10/12/2018  Phase 3 data released October 12, 2018 - primary endpoint not met."
ACRX,DSUVIA (ARX-04)  Moderate-to-severe acute pain following a surgical procedure,Approved,10/12/2018  Advisory Committee Meeting voted 10-3 recommending approval.
KRYS,KB103  Epidermolysis Bullosa,Phase 1/2,10/15/2018  Phase 1/2 interim data on two patients met primary endpoint.
EYPT,YUTIQ  Non-infectious uveitis,Approved,"10/15/2018  FDA approval announced October 15, 2018."
IMGN,Kadcyla (KATHERINE).  HER2-positive breast cancer - residual invasive disease,Phase 3,"10/15/2018  Phase 3 data released October 15, 2018 met primary endpoint."
RHHBY,Kadcyla (KATHERINE).  HER2-positive breast cancer - residual invasive disease,Phase 3,"10/15/2018  Phase 3 data released October 15, 2018 met primary endpoint."
REGN,Dupixent (dupilumab)  Nasal polyps,Phase 3,"10/16/2018  Phase 3 data released October 16, 2018 - primary and secondary endpoints met."
SNY,Dupixent (dupilumab)  Nasal polyps,Phase 3,"10/16/2018  Phase 3 data released October 16, 2018 - primary and secondary endpoints met."
EIGR,Ubenimex - ULTRA Secondary lymphedema,Phase 2,"10/16/2018  Phase 2 data released October 16, 2018 did not meet endpoints."
EIGR,Exendin 9-39  Post-Bariatric Hypoglycemia (PBH),Phase 2,"10/16/2018  Phase 2 data released October 16, 2018 - endpoints met."
PFE,Talazoparib BRCA-mutated breast cancer,Approved,"10/16/2018  FDA Approval announced October 16, 2018."
EIGR,Pegylated Interferon Lambda (LIMT HDV)  Hepatitis delta virus (HDV),Phase 2,"10/17/2018  Phase 2 LIMT positive data released October 17, 2018."
EARS,AM-125  Vertigo,Phase 1,"10/17/2018  Phase 1 data released October 17, 2018 with Phase 2 trials to commence early 2018."
XOMA,ACZ885 (canakinumab) CV risk reduction,CRL,"10/18/2018  CRL announced October 18, 2018."
NVS,ACZ885 (canakinumab) CV risk reduction,CRL,"10/18/2018  CRL announced October 18, 2018."
BLRX,BL-8040 in combination with KEYTRUDA - COMBAT trial  Pancreatic cancer,Phase 2,10/19/2018  Phase 2 top-line data ESMO October 2018 noted 1/29 PR; disease control 35%.
INCY,INC280  Non-small cell lung cancer,Phase 2,"10/19/2018  Phase 2 released October 19, 2018. ORR 72% in treatment-naive patients, 39% in previously treated patients."
NVS,INC280  Non-small cell lung cancer,Phase 2,"10/19/2018  Phase 2 released October 19, 2018. ORR 72% in treatment-naive patients, 39% in previously treated patients."
MACK,MM-121 SHERLOC  Cancer - Heregulin Positive Non-Small Cell Lung Cancer,Phase 2,"10/19/2018  Phase 2 trial discontinued due to futility - noted October 19, 2018."
DCPH,DCC-2618  Gastrointestinal Stromal Tumors (GIST),Phase 1,"10/19/2018  Phase 1 update at ESMO October 2018. ORR 21%, PFS 40 weeks - 2nd/3rd line."
CLVS,Rucaparib - TRITON2  Castrate-resistant prostate cancer (mCRPC),Phase 2,10/19/2018  Phase 2 initial data presented at ESMO - 44% ORR.
REGN,Dupixent (dupilumab)  Asthma,Approved,"10/19/2018  FDA approval announced October 19, 2018."
SNY,Dupixent (dupilumab)  Asthma,Approved,"10/19/2018  FDA approval announced October 19, 2018."
AGEN,AGEN2034 (anti-PD-1)  Cervical cancer,Phase 1/2,10/20/2018  Phase 1 data presented at ESMO October 2018 noted clinical benefit of 3/7 cervical cancer patients.
AGEN,AGEN2034 and AGEN1884  Solid tumors,Phase 1/2,10/20/2018  Phase 1/2 data presented at ESMO October 2018 noted clinical benefit in 7/16 patients.
ADAP,MAGE-A10  Non-Small Cell Lung Cancer (NSCLC),Phase 1,10/20/2018  Phase 1 data at ESMO noted no current response.
ADAP,MAGE-A4  Soild tumors,Phase 1,10/20/2018  Phase 1 data at ESMO noted best response was 4/6 with stable disease.
DVAX,SD-101 + Pembrolizumab  Melanoma and head and neck squamous cell carcinoma (HNSCC),Phase 1/2,10/20/2018  Phase 1/2 update at ESMO 2018 noted ORR 70%.
MRK,MK-1454 - STING  Solid tumors,Phase 1,10/20/2018  Phase 1 data at ESMO October 2018 noted zero responses in monotherapy arm.
TSRO,TSR-042 - GARNET  Solid tumors,Phase 1,10/20/2018  Phase 1 preliminary data at ESMO October 2018 noted ORR 52%.
OMED,Navicixizumab  Ovarian cancer,Phase 1b,10/20/2018  Phase 1b data ESMO October 2018 noted PFS 5.4 months.
NCNA,NUC-1031 (Acelarin)  Front-Line Treatment of Advanced Biliary Tract Cancer,Phase 1b,10/21/2018  Phase 1b data at ESMO October 2018. ORR 50%.
MRTX,Sitravatinib  Non-small cell lung cancer (NSCLC),Phase 1b,10/21/2018  Phase 1b update due at ESMO October 2018. 1/2 PRs for each of melanoma and NSCLC.
LPTX,DKN-01 + KEYTRUDA  Esophagogastric adenocarcinoma,Phase 1/2,10/21/2018  Phase 1/2 data ESMO October 2018. 24% ORR.
INCY,INCB54828 (FIGHT-202)  Cholangiocarcinoma,Phase 2,10/21/2018  Phase 2 interim data at ESMO October 2018. ORR 40%.
GSK,MOR103/GSK3196165  Rheumatoid Arthritis,Phase 2b,"10/21/2018  Phase 2b released October 21, 2018 did not meet primary endpoint."
MOR,MOR103/GSK3196165  Rheumatoid Arthritis,Phase 2b,"10/21/2018  Phase 2b released October 21, 2018 did not meet primary endpoint."
AZN,Lynparza - SOLO 1  First-line ovarian cancer following platinum-based chemotherapy,PDUFA priority review,10/21/2018  Presentation at ESMO 2018 noted HR 0.30. Median PFS not yet met at 41 months; 13.8 months for placebo.
MRK,Lynparza - SOLO 1  First-line ovarian cancer following platinum-based chemotherapy,PDUFA priority review,10/21/2018  Presentation at ESMO 2018 noted HR 0.30. Median PFS not yet met at 41 months; 13.8 months for placebo.
IONS,Durvalumab Plus Danvatirsen  Refractory head and neck cancer,Phase 1/2,10/22/2018  Phase 1b/2 data presented at ESMO 2018. 23% PR/CR.
AZN,Durvalumab Plus Danvatirsen  Refractory head and neck cancer,Phase 1/2,10/22/2018  Phase 1b/2 data presented at ESMO 2018. 23% PR/CR.
EPZM,Tazemetostat  Epithelioid Sarcoma,Phase 2,10/22/2018  Phase 2 data released at ESMO 2018. 21% ORR in treatment naive patients.
CTMX,CX 072  Solid tumors,Phase 1/2,10/22/2018  Phase 1/2 initial data released at ESMO 2018. 8% ORR.
AVEO,Tivozanib + Opdivo  Renal cell cancer (RCC),Phase 2,10/22/2018  Phase 2 data at ESMO 2018 noted 56% ORR.
ABBV,Upadacitinib - U-ACHIEVE  Ulcerative colitis,Phase 2/3,"10/22/2018  Phase 2b data released October 22, 2018 - primary endpoint met. Phase 3 trial initiation announced October 2018."
MRTX,Sitravatinib plus nivolumab  Non-small cell lung cancer (NSCLC),Phase 2,10/22/2018  Phase 2 update due at ESMO 2018 noted 20% ORR (following removal of 5 unconfirmed PRs or CRs that will not be confirmed).
KURA,Tipifarnib  Head and neck squamous cell carcinomas (HNSCC),Phase 2,10/22/2018  Phase 3 pivotal trial to be initiated 2H 2018. Phase 2 updated data ESMO October 2018 noted 6/17 PRs.
SELB,SEL-212  Tophaceous gout,Phase 3,"10/23/2018  Phase 2 data released October 23, 2018 - SUA 66%."
BYSI,Plinabulin + TAC (Trial 106)  Chemotherapy-induced neutropenia (CIN),Phase 2,"10/23/2018  Phase 2 top-line positive data released October 23, 2018."
BIIB,Dapirolizumab pegol (anti-CD40L)  Lupus,Phase 2b,"10/23/2018  Phase 2b data released October 23, 2018 - primary endpoint not met."
CLSN,GEN-1 OVATION 1  Ovarian cancer,Phase 1b,"10/24/2018  Phase 1b PFS data released October 24, 2018 - PFS of 17.1 months in ITT population."
GLPG,GLPG 2451+2222+2737 - FALCON open label  Cystic fibrosis - homozygous F508del patients,Phase 1/2,"10/24/2018  Phase 1b data released October 24, 2018 noted drug was well tolerated."
SNDX,"E2112  HR+, HER2- breast cancer",Phase 3,10/25/2018  Phase 3 PFS date did not meet primary endpoint
FGEN,Roxadustat  Chronic kidney disease,Phase 3,10/25/2018  Phase 3 Japan data noted hepcidin reduction from baseline (p=0.003) compared to epoetin alfa group (p=0.12)
RARE,UX007 (triheptanoin)  Glut1 DS patients with the movement disorder phenotype,Phase 3,"10/26/2018  Phase 3 data released October 26, 2018 - endpoints not met."
JAZZ,Xyrem  Pediatric narcolepsy patients with cataplexy,Approved,"10/26/2018  FDA Approval announced October 26, 2018."
ESPR,Bempedoic acid - CLEAR LDL-C Lowering Program 1002-047  Hypercholesterolemia,Phase 3,"10/28/2018  Phase 3 data released October 28, 2018. 18% LDL-C Lowering, no difference in adverse events vs placebo."
TXMD,TX-001HR: BIJUVA  Moderate to severe vasomotor symptoms (VMS),PDUFA,"10/29/2018  FDA approval announced October 29, 2018."
MLNT,Baxdela  Community-acquired bacterial pneumonia (CABP),Phase 3,"10/29/2018  Phase 3 data released October 29, 2018. Noted endpoints met."
MRK,KEYTRUDA + carboplatin-paclitaxel or nab-paclitaxel KEYNOTE-407  Squamous non-small cell lung cancer (sNSCLC),Approved,"10/30/2018  FDA approval announced October 30, 2018."
EGRX,Fulvestrant  Breast cancer,Phase 3,"10/30/2018  Pivotal trial data released October 30, 2018 did not meet primary endpoints."
JNJ,INVOKANA CANVAS  Type 2 diabetes,Approved,"10/30/2018  FDA Approval announced October 30, 2018."
GSK,Dolutegravir + rilpivirine  Injectable 2DR in HIV,Phase 3,"10/30/2018  Phase 3 data positive data released October 30, 2018."
NVS,Adalimumab  Rheumatoid Arthritis,Approved,"10/31/2018  FDA approval announced October 31, 2018."
BSTC,XIAFLEX  Uterine fibroids,Phase 1,"10/31/2018  Phase 1 data released October 31, 2018 - primary endpoint of safety and tolerability met."
ACAD,Pimavanserin - CLARITY  Adjunctive Treatment in Patients With Major Depressive Disorder,Phase 2,"10/31/2018  Phase 2 data released October 31, 2018 - noted overall primary endpoint met BUT did not benefit placebo in re-randomized stage."
ALKS,ALKS 5461  Major depressive disorder,PDUFA,"11/01/2018  Advisory Committee Meeting November 1, 2018 voted 2-21 against reccommending approval."
ADVM,ADVM-043  Alpha-1 Antitrypsin (A1AT) Deficiency,Phase 1/2,"11/01/2018  Development to be discontinued - noted November 1, 2018."
TRVN,Oliceridine (TRV130)  Moderate to severe acute pain,CRL,"11/02/2018  CRL issued November 2, 2018."
PFE,Lorlatinib  ALK+ NSCLC,Approved,"11/02/2018  FDA approval announced November 2, 2018."
SAGE,Brexanolone - SAGE-547 (202C)  Postpartum Depression - moderate,PDUFA priority review,"11/02/2018  Advisory Committee meeting November 2, 2018 voted 17-1 recommending approval."
ACRX,DSUVIA (ARX-04)  Moderate-to-severe acute pain following a surgical procedure,Approved,"11/02/2018  FDA Approval announced November 2, 2018."
CHRS,CHS-1701  Pegfilgrastim biosimilar,Approved,"11/02/2018  FDA approval announced November 2, 2018."
THERF,Single vial formulation of EGRIFTA  Reduction of abdominal fat in HIV- patients,Approved,"11/05/2018  FDA approval announced November 5, 2018."
CLSD,Suprachoroidal CLS-TA - SAPPHIRE  Macular edema associated with retinal vein occlusion (RVO),Phase 3,"11/05/2018  Phase 3 data released November 5, 2018 did not meet primary endpoint."
AVEO,TIVO-3 - tivozanib Third line treatment of patients with renal cell cancer,Phase 3,"11/05/2018  Phase 3 PFS data met primary endpoint. OS data due August 2019, preliminary analysis noted no difference in OS."
BMY,Empliciti (elotuzumab) - ELOQUENT-3  Relapsed/refractory multiple myeloma,Approved,"11/06/2018  FDA approval announced November 6, 2018."
ONCS,ImmunoPulse IL-12 - PISCES/KEYNOTE-695  Melanoma - cancer,Phase 2b,"11/06/2018  Phase 2b data November 6, 2018 noted 2/9 PRs."
MACK,MM-121 (SHERBOC)  HER2 negative metastatic breast cancer,Phase 2,"11/07/2018  Phase 2 trial termination announced November 7, 2018."
FOMX,FMX103  Papulopustular rosacea,Phase 3,"11/07/2018  Phase 3 top-line data released November 7, 2018. Primary endpoints met."
BSTC,XIAFLEX (collagenase clostridium histolyticum) - RELEASE  Edematous fibrosclerotic panniculopathy (“cellulite”),Phase 3,"11/07/2018  Phase 3 data released November 7, 2018 - primary endpoint met."
ENDP,XIAFLEX (collagenase clostridium histolyticum) - RELEASE  Edematous fibrosclerotic panniculopathy (“cellulite”),Phase 3,"11/07/2018  Phase 3 data released November 7, 2018 - primary endpoint met."
CDXS,CDX-6114  Phenylketonuria (PKU),Phase 1a,"11/08/2018  Phase 1 trial met endpoints - November 8, 2018."
OMED,Anti-TIGIT (OMP-313M32)  Solid tumors,Phase 1/2,"11/09/2018  Data from Phase 1a portion due at SITC November 9, 2018. SD 39%."
MRTX,Mocetinostat and durvalumab  Non-small cell lung cancer (NSCLC),Phase 2,11/09/2018  Phase 2 update at SITC November 2018 - 5/29 partial responses.
LPTX,TRX518 in combination with gemcitabine chemotherapy or KEYTRUDA or Opdivo  Advanced solid tumors,Phase 1,11/09/2018  Phase 1 interim data noted 46.7% ORR.
TSRO,TSR-022 + TSR-042 AMBER  Solid tumors,Phase 1,"11/09/2018  Phase 1 data at SITC Novemeber 2018 - 15% ORR for high dose , 9% ORR for lower dose."
TBPH,Revefenacin  COPD,Approved,"11/09/2018  FDA Approval announced November 9, 2018."
MYL,Revefenacin  COPD,Approved,"11/09/2018  FDA Approval announced November 9, 2018."
NKTR,"NKTR-214 + OPDIVO (nivolumab) - PIVOT-02  Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers",Phase 1/2,11/09/2018  Phase 1/2 data at SITC November 2018 noted ORR 53%.
BMY,"NKTR-214 + OPDIVO (nivolumab) - PIVOT-02  Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers",Phase 1/2,11/09/2018  Phase 1/2 data at SITC November 2018 noted ORR 53%.
MRK,Keytruda - KEYNOTE-224  Hepatocellular carcinoma (HCC),Approved,"11/09/2018  FDA approval announced November 9, 2018."
ADRO,ADU-S100  Solid tumors or lymphomas,Phase 1b,11/09/2018  Initial data due at SITC November 2018 noted 2/40 PRs and 11 with SD.
EIDX,AG10  ATTR-CM,Phase 2,"11/10/2018  Phase 2 data November 10, 2018 noted >90% stabilization of TTR at day 28."
INFI,IPI-549 + Nivolumab  Solid tumors,Phase 1,11/10/2018  Further data due at SITC November 2018 noted 2/44 PRs.
AMRN,Vascepa REDUCE-IT outcomes trial  High Triglycerides With Mixed Dyslipidemia,Phase 3,"11/10/2018  Data presented at AHA November 10, 2018 noted 26% decrease in risk of death/heart attack."
NVS,Entresto - PIONEER  Heart failure,Phase 3,11/11/2018  Phase 3 data noted 46% reduction in serious clinical outcomes endpoint.
CRVS,CPI-444  Solid tumors - cancer,Phase 1b,11/11/2018  Phase 1b data at SITC November 2018 noted 1/33 PRs on monotherapy and 1/35 on combo.
MESO,MPC-150-IM  End-Stage Heart Failure with LVADs,Phase 2b,"11/11/2018  Phase 2b trial did not meet primary endpoint - November 11, 2018."
OPHT,Zimura  Wet age-related macular degeneration (Wet-AMD),Phase 2a,"11/12/2018  Phase 2a top-line data released November 12, 2018 noted that treatment was generally well tolerated."
CNCE,CTP-543  Alopecia areata,Phase 2a,"11/12/2018  Phase 2 top-line data released November 12, 2018 - primary endpoint met."
VKTX,VK2809  Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease,Phase 2,"11/13/2018  Data presented at AASLD November 12, 2018 noted 67% of patients saw >50% liver fat content."
EYEG,Ocular Bandage Gel  Wound healing,Phase 1/2,"11/13/2018  Top-line positive data released November 13, 2018."
ZYME,"ZW25  HER2-expressing Cancers - ovarian, breast, gastric",Phase 1,"11/14/2018  Phase 1 updated data presented November 14, 2018.41% PR rate."
NOVN,SB206  Molluscum contagiosum skin infection,Phase 2,11/14/2018  Phase 2 preliminary data showed statistical significance. Phase 3 planned 1H 2019.
MNK,MNK-812  Pain,PDUFA,"11/14/2018  Advisory Committee Meeting November 14, 2018 voted 10-7 recommending approval. PDUFA date November 16, 2018"
APVO,Otlertuzumab  Relapsed or refractory peripheral T-cell lymphoma,Phase 2,"11/14/2018  Development terminated - noted November 14, 2018."
QURE,AMT-061  Hemophilia B,Phase 2b,"11/15/2018  Phase 2b top-line positive data released November 15, 2018 with 31% FIX level."
BPMC,Avapritnib BLU-285 - NAVIGATOR  PDGFRα driven Gastrointestinal stromal tumors (GIST),Phase 1,"11/15/2018  Phase 1 updated data due released November 15, 2018. 84% ORR in PDGFRα D842V GIST; 20% ORR 4th line GIST."
NVS,Promacta (eltrombopag)  Severe aplastic anemia (SAA),Approved,"11/16/2018  sNDA approval announced November 16, 2018."
ZIOP,Ad-RTS-hIL-12 + veledimex  Glioblastoma Multiforme (GBM),Phase 1,"11/16/2018  Phase 1 updated data presented November 16, 2018. Overall survival 17.8 months."
SGEN,ADCETRIS in combination with chemotherapy - ECHELON-2  Frontline CD30-positive mature T-cell lymphomas - cancer,Approved,"11/16/2018  FDA Approval announced November 16, 2018."
BGNE,Pamiparib (BGB-290)  Glioblastoma (GBM),Phase 1/2,"11/16/2018  Phase 1/2 data presented at SNO November 16, 2018 noted 2/15 partial responses."
AZN,Durvalumab +/- tremelimumab (MYSTIC)  Lung cancer,Phase 3,"11/16/2018  Overall survival data also did not meet primary endpoint - November 16, 2018."
ARQL,ARQ 751  Solid tumors,Phase 1,"11/16/2018  Phase 1 data released November 16, 2018. 9% partial response rate."
AQST,AQST-119  Erectile dysfunction,CRL,"11/16/2018  CRL issued November 16, 2018."
TCON,TRC102 and Temodar  Glioblastoma - cancer,Phase 2,"11/19/2018  Phase 2 primary endpoint not met - November 19, 2018."
EBS,VLA1601  Zika vaccine,Phase 1,"11/19/2018  Phase 1 data released November 19, 2018 - primary endpoint met with favorable safety profile."
